<!DOCTYPE html SYSTEM "about:legacy-compat"><html lang="en" class="win-std-desktop-val"><head>
<META http-equiv="Content-Type" content="text/html">
<title>Source View: https://www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq</title><meta name="robots" content="noindex,nofollow"><meta name="SortSite-IgnoreRule-Page" content="AccHtmlLinkTextReused,AccAdvancedReadingLevel,Section508-m-3,BugHtmlColgroup,BugIeCssMinMaxWidthHeight,ErrSpellingError,SeoBingTitleLength,SeoPage150k,UseGov5.1,UseGov9.2.3,UseGov10.11,UseGov11.7,UseGov14.3,UseGov17.4,UseGunningFog,W3cTitleTooLong"><link rel="icon" href="https://www-powermapper-com.azureedge.net/favicon.ico"><link rel="stylesheet" href="../Report/report-min-20200618.css"><script type="text/javascript" src="../Report/report-min-20210409.js"></script><!--[if lte IE 8]>
            <script>
                document.createElement('header');
                document.createElement('aside');
            </script>
            <![endif]--></head><body class="source"><a class="accessible" href="#content">Skip to Content</a><header><h1>
                        HTML Document
                    </h1><table><tr><th>
                        URL:
                    </th><td><a rel="nofollow" target="_top" href="https://www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq">https://www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq</a></td></tr><tr><th>
                        HTTP Status:
                    </th><td>200 OK</td></tr><tr><th>
                        MIME Type:
                    </th><td>text/html </td></tr><tr><th>
                        Last Modified:
                    </th><td>Wed, 27 Sep 2023 01:53:29 GMT</td></tr><tr><th>
                        Download Time:
                    </th><td>
                                Less than a second
                            </td></tr><tr><th>
                        Cookies:
                    </th><td>
                                None
                            </td></tr><tr><th>
                        Size:
                    </th><td>207 KB
                        </td></tr><tr><th>
                                Depth:
                            </th><td>3 clicks from home page
                            </td></tr><tr><th>
                                Charset:
                            </th><td>utf-8</td></tr><tr><th>
                                Forms:
                            </th><td>2 forms containing 3 controls
                            </td></tr><tr><th>
                        HTTP Headers:
                    </th><td><button class="chevron toggleChevron" data-toggleid="HttpHeaders"><img width="20" height="20" alt="View Headers" id="chevHttpHeaders" src="../Report/chevron-down.svg"></button>&nbsp;<span>18&nbsp;headers</span><div class="links" id="expand-HttpHeaders">Accept-Ranges: bytes<br>Cache-Control: max-age=0, no-cache<br>Connection: keep-alive<br>Content-Language: en<br>Date: Wed, 27 Sep 2023 21:32:56 GMT<br>Pragma: no-cache<br>Server: nginx<br>Strict-Transport-Security: max-age=31536000 ; includeSubDomains ; preload<br>X-AH-Environment: 01live<br>X-Age: 24359<br>X-Cache-Hits: 8<br>X-Content-Type-Options: nosniff<br>X-Drupal-Cache: MISS<br>X-Drupal-Dynamic-Cache: MISS<br>X-Frame-Options: SAMEORIGIN<br>X-Generator: Drupal 9 (https://www.drupal.org)<br>X-Request-ID: v-a7e4d988-5cd8-11ee-9149-37cd42d5471e<br>X-UA-Compatible: IE=edge<br></div></td></tr><tr><th>
                        Links In:
                    </th><td><button class="chevron toggleChevron" data-toggleid="LinksIn"><img width="20" height="20" alt="View Links" id="chevLinksIn" src="../Report/chevron-down.svg"></button>&nbsp;<span>1&nbsp;pages</span><div class="links" id="expand-LinksIn"><a class="viewsource" rel="nofollow" target="_top" href="https://content.montefioreeinstein.org/cancer/types/gastrointestinal/bile-duct-treatment" data-pageid="329" data-line="0" data-col="0">https://content.montefioreeinstein.org/cancer/types/gastrointestinal/bile-duct-treatment</a><br></div></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="middle"><th><img alt="OK" width="20" height="20" src="../Report/bench-better.svg">
                                Issues:
                            </th><td>
                                No issues found
                            </td></tr></table></header><main id="content" class="pre"><p><code>1</code><code>&lt;!DOCTYPE html&gt;</code></p><p><code>2</code><code>          </code></p><p><code>3</code><code>&lt;html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#"&gt;</code></p><p><code>4</code><code>          </code></p><p><code>5</code><code>  &lt;head&gt;</code></p><p><code>6</code><code>          </code></p><p><code>7</code><code>    &lt;meta http-equiv="X-UA-Compatible" content="IE=edge"&gt;</code></p><p><code>8</code><code>          </code></p><p><code>9</code><code>    &lt;meta charset="utf-8" /&gt;</code></p><p><code>10</code><code>&lt;script type="text/javascript"&gt;</code></p><p><code>11</code><code>(window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:false},ajax:{deny_list:["gov-bam.nr-data.net"]}};(window.NREUM||(NREUM={})).loader_config={xpid:"VgIHVV9VCxADUVRRAggBXlY=",licenseKey:"bfc00e1ee3",applicationID:"355359682"};;/*! For license information please see nr-loader-full-1.242.0.min.js.LICENSE.txt */</code></p><p><code>12</code><code>(()=&gt;</code></p><p><code>13</code><code>{"use strict";var e,t,r={234:(e,t,r)=&gt;</code></p><p><code>14</code><code>{r.d(t,{P_:()=&gt;</code></p><p><code>15</code><code>g,Mt:()=&gt;</code></p><p><code>16</code><code>v,C5:()=&gt;</code></p><p><code>17</code><code>s,DL:()=&gt;</code></p><p><code>18</code><code>x,OP:()=&gt;</code></p><p><code>19</code><code>S,lF:()=&gt;</code></p><p><code>20</code><code>C,Yu:()=&gt;</code></p><p><code>21</code><code>A,Dg:()=&gt;</code></p><p><code>22</code><code>m,CX:()=&gt;</code></p><p><code>23</code><code>c,GE:()=&gt;</code></p><p><code>24</code><code>w,sU:()=&gt;</code></p><p><code>25</code><code>j});var n=r(8632),i=r(9567);const a={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},o={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!o[e])throw new Error("Info for ".concat(e," was never set"));return o[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");o[e]=(0,i.D)(t,a),(0,n.Qy)(e,o[e],"info")}const d=e=&gt;</code></p><p><code>26</code><code>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var u=r(7056),l=r(50);const f=()=&gt;</code></p><p><code>27</code><code>{const e={mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{proxy:{assets:void 0,beacon:void 0},privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,block_internal:!0,enabled:!0,harvestTimeSeconds:10,autoStart:!0},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10,autoStart:!0},metrics:{enabled:!0,autoStart:!0},page_action:{enabled:!0,harvestTimeSeconds:30,autoStart:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1,autoStart:!0},session_trace:{enabled:!0,harvestTimeSeconds:10,autoStart:!0},harvest:{tooManyRequestsDelay:60},session_replay:{autoStart:!0,enabled:!1,harvestTimeSeconds:60,sampling_rate:50,error_sampling_rate:50,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){d(t)?e.mask_selector=t+",[data-nr-mask]":null===t?e.mask_selector=t:(0,l.Z)("An invalid session_replay.mask_selector was provided and will not be used",t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){d(t)?e.block_selector+=",".concat(t):""!==t&amp;&amp;(0,l.Z)("An invalid session_replay.block_selector was provided and will not be used",t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&amp;&amp;"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,l.Z)("An invalid session_replay.mask_input_option was provided and will not be used",t)}},spa:{enabled:!0,harvestTimeSeconds:10,autoStart:!0}}},h={},p="All configuration objects require an agent identifier!";function g(e){if(!e)throw new Error(p);if(!h[e])throw new Error("Configuration for ".concat(e," was never set"));return h[e]}function m(e,t){if(!e)throw new Error(p);h[e]=(0,i.D)(t,f()),(0,n.Qy)(e,h[e],"config")}function v(e,t){if(!e)throw new Error(p);var r=g(e);if(r){for(var n=t.split("."),i=0;i&lt;n.length-1;i++)if("object"!=typeof(r=r[n[i]]))return;r=r[n[n.length-1]]}return r}const b={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},y={};function x(e){if(!e)throw new Error("All loader-config objects require an agent identifier!");if(!y[e])throw new Error("LoaderConfig for ".concat(e," was never set"));return y[e]}function w(e,t){if(!e)throw new Error("All loader-config objects require an agent identifier!");y[e]=(0,i.D)(t,b),(0,n.Qy)(e,y[e],"loader_config")}const A=(0,n.mF)().o;var _=r(385),E=r(6818);const T={buildEnv:E.Re,customTransaction:void 0,disabled:!1,distMethod:E.gF,isolatedBacklog:!1,loaderType:void 0,maxBytes:3e4,offset:Math.floor(_._A?.performance?.timeOrigin||_._A?.performance?.timing?.navigationStart||Date.now()),onerror:void 0,origin:""+_._A.location,ptid:void 0,releaseIds:{},session:void 0,xhrWrappable:"function"==typeof _._A.XMLHttpRequest?.prototype?.addEventListener,version:E.q4,denyList:void 0},D={};function S(e){if(!e)throw new Error("All runtime objects require an agent identifier!");if(!D[e])throw new Error("Runtime for ".concat(e," was never set"));return D[e]}function j(e,t){if(!e)throw new Error("All runtime objects require an agent identifier!");D[e]=(0,i.D)(t,T),(0,n.Qy)(e,D[e],"runtime")}function C(e){return function(e){try{const t=s(e);return!!t.licenseKey&amp;&amp;!!t.errorBeacon&amp;&amp;!!t.applicationID}catch(e){return!1}}(e)}},9567:(e,t,r)=&gt;</code></p><p><code>28</code><code>{r.d(t,{D:()=&gt;</code></p><p><code>29</code><code>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),a=0===Object.keys(r).length?e:r;for(let o in a)if(void 0!==e[o])try{"object"==typeof e[o]&amp;&amp;"object"==typeof t[o]?r[o]=i(e[o],t[o]):r[o]=e[o]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=&gt;</code></p><p><code>30</code><code>{r.d(t,{Re:()=&gt;</code></p><p><code>31</code><code>i,gF:()=&gt;</code></p><p><code>32</code><code>a,q4:()=&gt;</code></p><p><code>33</code><code>n});const n="1.242.0",i="PROD",a="CDN"},385:(e,t,r)=&gt;</code></p><p><code>34</code><code>{r.d(t,{FN:()=&gt;</code></p><p><code>35</code><code>s,IF:()=&gt;</code></p><p><code>36</code><code>u,Nk:()=&gt;</code></p><p><code>37</code><code>f,Tt:()=&gt;</code></p><p><code>38</code><code>c,_A:()=&gt;</code></p><p><code>39</code><code>a,cv:()=&gt;</code></p><p><code>40</code><code>h,iS:()=&gt;</code></p><p><code>41</code><code>o,il:()=&gt;</code></p><p><code>42</code><code>n,ux:()=&gt;</code></p><p><code>43</code><code>d,v6:()=&gt;</code></p><p><code>44</code><code>i,w1:()=&gt;</code></p><p><code>45</code><code>l});const n="undefined"!=typeof window&amp;&amp;!!window.document,i="undefined"!=typeof WorkerGlobalScope&amp;&amp;("undefined"!=typeof self&amp;&amp;self instanceof WorkerGlobalScope&amp;&amp;self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&amp;&amp;globalThis instanceof WorkerGlobalScope&amp;&amp;globalThis.navigator instanceof WorkerNavigator),a=n?window:"undefined"!=typeof WorkerGlobalScope&amp;&amp;("undefined"!=typeof self&amp;&amp;self instanceof WorkerGlobalScope&amp;&amp;self||"undefined"!=typeof globalThis&amp;&amp;globalThis instanceof WorkerGlobalScope&amp;&amp;globalThis),o=Boolean("hidden"===a?.document?.visibilityState),s=""+a?.location,c=/iPad|iPhone|iPod/.test(a.navigator?.userAgent),d=c&amp;&amp;"undefined"==typeof SharedWorker,u=(()=&gt;</code></p><p><code>46</code><code>{const e=a.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&amp;&amp;e.length&gt;</code></p><p><code>47</code><code>=2?+e[1]:0})(),l=Boolean(n&amp;&amp;window.document.documentMode),f=!!a.navigator?.sendBeacon,h=Math.floor(a?.performance?.timeOrigin||a?.performance?.timing?.navigationStart||Date.now())},1117:(e,t,r)=&gt;</code></p><p><code>48</code><code>{r.d(t,{w:()=&gt;</code></p><p><code>49</code><code>a});var n=r(50);const i={agentIdentifier:"",ee:void 0};class a{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=&gt;</code></p><p><code>50</code><code>{let[t,r]=e;Object.keys(i).includes(t)&amp;&amp;(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=&gt;</code></p><p><code>51</code><code>{r.d(t,{L:()=&gt;</code></p><p><code>52</code><code>u,R:()=&gt;</code></p><p><code>53</code><code>c});var n=r(8325),i=r(1284),a=r(4322),o=r(3325);const s={};function c(e,t){const r={staged:!1,priority:o.p[t]||0};d(e),s[e].get(t)||s[e].set(t,r)}function d(e){e&amp;&amp;(s[e]||(s[e]=new Map))}function u(){let e=arguments.length&gt;</code></p><p><code>54</code><code>0&amp;&amp;void 0!==arguments[0]?arguments[0]:"",t=arguments.length&gt;</code></p><p><code>55</code><code>1&amp;&amp;void 0!==arguments[1]?arguments[1]:"feature";if(d(e),!e||!s[e].get(t))return o(t);s[e].get(t).staged=!0;const r=[...s[e]];function o(t){const r=e?n.ee.get(e):n.ee,o=a.X.handlers;if(r.backlog&amp;&amp;o){var s=r.backlog[t],c=o[t];if(c){for(var d=0;s&amp;&amp;d&lt;s.length;++d)l(s[d],c);(0,i.D)(c,(function(e,t){(0,i.D)(t,(function(t,r){r[0].on(e,r[1])}))}))}delete o[t],r.backlog[t]=null,r.emit("drain-"+t,[])}}r.every((e=&gt;</code></p><p><code>56</code><code>{let[t,r]=e;return r.staged}))&amp;&amp;(r.sort(((e,t)=&gt;</code></p><p><code>57</code><code>e[1].priority-t[1].priority)),r.forEach((t=&gt;</code></p><p><code>58</code><code>{let[r]=t;s[e].delete(r),o(r)})))}function l(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],a=e[3],o=e[2];i.apply(a,o)}}))}},8325:(e,t,r)=&gt;</code></p><p><code>59</code><code>{r.d(t,{A:()=&gt;</code></p><p><code>60</code><code>c,ee:()=&gt;</code></p><p><code>61</code><code>d});var n=r(8632),i=r(2210),a=r(234);class o{constructor(e){this.contextId=e}}var s=r(3117);const c="nr@context:".concat(s.a),d=function e(t,r){var n={},s={},u={},f=!1;try{f=16===r.length&amp;&amp;(0,a.OP)(r).isolatedBacklog}catch(e){}var h={on:g,addEventListener:g,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i&lt;r.length;i++)r[i]===t&amp;&amp;r.splice(i,1)},emit:function(e,r,n,i,a){!1!==a&amp;&amp;(a=!0);if(d.aborted&amp;&amp;!i)return;t&amp;&amp;a&amp;&amp;t.emit(e,r,n);for(var o=p(n),c=m(e),u=c.length,l=0;l&lt;u;l++)c[l].apply(o,r);var f=b()[s[e]];f&amp;&amp;f.push([h,e,r,o]);return o},get:v,listeners:m,context:p,buffer:function(e,t){const r=b();if(t=t||"feature",h.aborted)return;Object.entries(e||{}).forEach((e=&gt;</code></p><p><code>62</code><code>{let[n,i]=e;s[i]=t,t in r||(r[t]=[])}))},abort:l,aborted:!1,isBuffering:function(e){return!!b()[s[e]]},debugId:r,backlog:f?{}:t&amp;&amp;"object"==typeof t.backlog?t.backlog:{}};return h;function p(e){return e&amp;&amp;e instanceof o?e:e?(0,i.X)(e,c,(()=&gt;</code></p><p><code>63</code><code>new o(c))):new o(c)}function g(e,t){n[e]=m(e).concat(t)}function m(e){return n[e]||[]}function v(t){return u[t]=u[t]||e(h,t)}function b(){return h.backlog}}(void 0,"globalEE"),u=(0,n.fP)();function l(){d.aborted=!0,d.backlog={}}u.ee||(u.ee=d)},5546:(e,t,r)=&gt;</code></p><p><code>64</code><code>{r.d(t,{E:()=&gt;</code></p><p><code>65</code><code>n,p:()=&gt;</code></p><p><code>66</code><code>i});var n=r(8325).ee.get("handle");function i(e,t,r,i,a){a?(a.buffer([e],i),a.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=&gt;</code></p><p><code>67</code><code>{r.d(t,{X:()=&gt;</code></p><p><code>68</code><code>a});var n=r(5546);a.on=o;var i=a.handlers={};function a(e,t,r,a){o(a||n.E,i,e,t,r)}function o(e,t,r,i,a){a||(a="feature"),e||(e=n.E);var o=t[a]=t[a]||{};(o[r]=o[r]||[]).push([e,i])}},3239:(e,t,r)=&gt;</code></p><p><code>69</code><code>{r.d(t,{bP:()=&gt;</code></p><p><code>70</code><code>s,iz:()=&gt;</code></p><p><code>71</code><code>c,m$:()=&gt;</code></p><p><code>72</code><code>o});var n=r(385);let i=!1,a=!1;try{const e={get passive(){return i=!0,!1},get signal(){return a=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function o(e,t){return i||a?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length&gt;</code></p><p><code>73</code><code>2&amp;&amp;void 0!==arguments[2]&amp;&amp;arguments[2],n=arguments.length&gt;</code></p><p><code>74</code><code>3?arguments[3]:void 0;window.addEventListener(e,t,o(r,n))}function c(e,t){let r=arguments.length&gt;</code></p><p><code>75</code><code>2&amp;&amp;void 0!==arguments[2]&amp;&amp;arguments[2],n=arguments.length&gt;</code></p><p><code>76</code><code>3?arguments[3]:void 0;document.addEventListener(e,t,o(r,n))}},3117:(e,t,r)=&gt;</code></p><p><code>77</code><code>{r.d(t,{a:()=&gt;</code></p><p><code>78</code><code>n});const n=(0,r(4402).Rl)()},4402:(e,t,r)=&gt;</code></p><p><code>79</code><code>{r.d(t,{Ht:()=&gt;</code></p><p><code>80</code><code>d,M:()=&gt;</code></p><p><code>81</code><code>c,Rl:()=&gt;</code></p><p><code>82</code><code>o,ky:()=&gt;</code></p><p><code>83</code><code>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function a(e,t){return e?15&amp;e[t]:16*Math.random()|0}function o(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&amp;&amp;e.getRandomValues&amp;&amp;(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=&gt;</code></p><p><code>84</code><code>"x"===e?a(t,++r).toString(16):"y"===e?(3&amp;a()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&amp;&amp;t.getRandomValues&amp;&amp;(r=t.getRandomValues(new Uint8Array(31)));const o=[];for(var s=0;s&lt;e;s++)o.push(a(r,++i).toString(16));return o.join("")}function c(){return s(16)}function d(){return s(32)}},7056:(e,t,r)=&gt;</code></p><p><code>85</code><code>{r.d(t,{Bq:()=&gt;</code></p><p><code>86</code><code>n,Hb:()=&gt;</code></p><p><code>87</code><code>a,oD:()=&gt;</code></p><p><code>88</code><code>i});const n="NRBA",i=144e5,a=18e5},7894:(e,t,r)=&gt;</code></p><p><code>89</code><code>{function n(){return Math.round(performance.now())}r.d(t,{z:()=&gt;</code></p><p><code>90</code><code>n})},7243:(e,t,r)=&gt;</code></p><p><code>91</code><code>{r.d(t,{e:()=&gt;</code></p><p><code>92</code><code>a});var n=r(385),i={};function a(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,a={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return a}a.port=t.port;var o=t.href.split("://");!a.port&amp;&amp;o[1]&amp;&amp;(a.port=o[1].split("/")[0].split("@").pop().split(":")[1]),a.port&amp;&amp;"0"!==a.port||(a.port="https"===o[0]?"443":"80"),a.hostname=t.hostname||r.hostname,a.pathname=t.pathname,a.protocol=o[0],"/"!==a.pathname.charAt(0)&amp;&amp;(a.pathname="/"+a.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&amp;&amp;t.port===r.port;return a.sameOrigin=s&amp;&amp;(!t.hostname||c),"/"===a.pathname&amp;&amp;(i[e]=a),a}},50:(e,t,r)=&gt;</code></p><p><code>93</code><code>{function n(e,t){"function"==typeof console.warn&amp;&amp;(console.warn("New Relic: ".concat(e)),t&amp;&amp;console.warn(t))}r.d(t,{Z:()=&gt;</code></p><p><code>94</code><code>n})},2587:(e,t,r)=&gt;</code></p><p><code>95</code><code>{r.d(t,{N:()=&gt;</code></p><p><code>96</code><code>c,T:()=&gt;</code></p><p><code>97</code><code>d});var n=r(8325),i=r(5546),a=r(3325);const o={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]},s=new Set;function c(e,t){const r=n.ee.get(t);e&amp;&amp;"object"==typeof e&amp;&amp;(s.has(t)||Object.entries(e).forEach((e=&gt;</code></p><p><code>98</code><code>{let[t,n]=e;o[t]?o[t].forEach((e=&gt;</code></p><p><code>99</code><code>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&amp;&amp;(0,i.p)("feat-"+t,[],void 0,void 0,r),d[t]=Boolean(n)})),Object.keys(o).forEach((e=&gt;</code></p><p><code>100</code><code>{void 0===d[e]&amp;&amp;(o[e]?.forEach((t=&gt;</code></p><p><code>101</code><code>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),d[e]=!1)})),s.add(t))}const d={}},2210:(e,t,r)=&gt;</code></p><p><code>102</code><code>{r.d(t,{X:()=&gt;</code></p><p><code>103</code><code>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&amp;&amp;Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=&gt;</code></p><p><code>104</code><code>{r.d(t,{D:()=&gt;</code></p><p><code>105</code><code>n});const n=(e,t)=&gt;</code></p><p><code>106</code><code>Object.entries(e||{}).map((e=&gt;</code></p><p><code>107</code><code>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=&gt;</code></p><p><code>108</code><code>{r.d(t,{P:()=&gt;</code></p><p><code>109</code><code>a});var n=r(8325);const i=()=&gt;</code></p><p><code>110</code><code>{const e=new WeakSet;return(t,r)=&gt;</code></p><p><code>111</code><code>{if("object"==typeof r&amp;&amp;null!==r){if(e.has(r))return;e.add(r)}return r}};function a(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=&gt;</code></p><p><code>112</code><code>{r.d(t,{K:()=&gt;</code></p><p><code>113</code><code>o,b:()=&gt;</code></p><p><code>114</code><code>a});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function a(e,t){if(i())return e();(0,n.bP)("load",e,t)}function o(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=&gt;</code></p><p><code>115</code><code>{r.d(t,{EZ:()=&gt;</code></p><p><code>116</code><code>d,Qy:()=&gt;</code></p><p><code>117</code><code>c,ce:()=&gt;</code></p><p><code>118</code><code>a,fP:()=&gt;</code></p><p><code>119</code><code>o,gG:()=&gt;</code></p><p><code>120</code><code>u,mF:()=&gt;</code></p><p><code>121</code><code>s});var n=r(7894),i=r(385);const a={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function o(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&amp;&amp;(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=o();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=o();const a=i.initializedAgents||{},s=a[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...a,[e]:{...s,[r]:t}},i}function d(e,t){o()[e]=t}function u(){return function(){let e=o();const t=e.info||{};e.info={beacon:a.beacon,errorBeacon:a.errorBeacon,...t}}(),function(){let e=o();const t=e.init||{};e.init={...t}}(),s(),function(){let e=o();const t=e.loader_config||{};e.loader_config={...t}}(),o()}},7956:(e,t,r)=&gt;</code></p><p><code>122</code><code>{r.d(t,{N:()=&gt;</code></p><p><code>123</code><code>i});var n=r(3239);function i(e){let t=arguments.length&gt;</code></p><p><code>124</code><code>1&amp;&amp;void 0!==arguments[1]&amp;&amp;arguments[1],r=arguments.length&gt;</code></p><p><code>125</code><code>2?arguments[2]:void 0,i=arguments.length&gt;</code></p><p><code>126</code><code>3?arguments[3]:void 0;(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"===document.visibilityState&amp;&amp;e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=&gt;</code></p><p><code>127</code><code>{r.d(t,{em:()=&gt;</code></p><p><code>128</code><code>b,u5:()=&gt;</code></p><p><code>129</code><code>S,QU:()=&gt;</code></p><p><code>130</code><code>P,Kf:()=&gt;</code></p><p><code>131</code><code>I});var n=r(8325),i=r(3117);const a="nr@original:".concat(i.a);var o=Object.prototype.hasOwnProperty,s=!1;function c(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,a){n||(n="");const o="-"===n.charAt(0);for(let s=0;s&lt;t.length;s++){const c=t[s],d=e[c];u(d)||(e[c]=r(d,o?c+n:n,i,c,a))}},r.flag=a,r;function r(t,r,n,s,c){return u(t)?t:(r||(r=""),nrWrapper[a]=t,function(e,t,r){if(Object.defineProperty&amp;&amp;Object.keys)try{return Object.keys(e).forEach((function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})})),t}catch(e){d([e],r)}for(var n in e)o.call(e,n)&amp;&amp;(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var a,o,u,l;try{o=this,a=[...arguments],u="function"==typeof n?n(a,o):n||{}}catch(t){d([t,"",[a,o,s],u],e)}i(r+"start",[a,o,s],u,c);try{return l=t.apply(o,a)}catch(e){throw i(r+"err",[a,o,e],u,c),e}finally{i(r+"end",[a,o,l],u,c)}}}function i(r,n,i,a){if(!s||t){var o=s;s=!0;try{e.emit(r,n,i,t,a)}catch(t){d([t,r,n,i],e)}s=o}}}function d(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function u(e){return!(e&amp;&amp;e instanceof Function&amp;&amp;e.apply&amp;&amp;!e[a])}var l=r(2210),f=r(385);const h={},p=f._A.XMLHttpRequest,g="addEventListener",m="removeEventListener",v="nr@wrapped:".concat(n.A);function b(e){var t=function(e){return(e||n.ee).get("events")}(e);if(h[t.debugId]++)return t;h[t.debugId]=1;var r=c(t,!0);function i(e){r.inPlace(e,[g,m],"-",a)}function a(e,t){return e[1]}return"getPrototypeOf"in Object&amp;&amp;(f.il&amp;&amp;y(document,i),y(f._A,i),y(p.prototype,i)),t.on(g+"-start",(function(e,t){var n=e[1];if(null!==n&amp;&amp;("function"==typeof n||"object"==typeof n)){var i=(0,l.X)(n,v,(function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n}));this.wrapped=e[1]=i}})),t.on(m+"-start",(function(e){e[1]=this.wrapped||e[1]})),t}function y(e,t){let r=e;for(;"object"==typeof r&amp;&amp;!Object.prototype.hasOwnProperty.call(r,g);)r=Object.getPrototypeOf(r);for(var n=arguments.length,i=new Array(n&gt;</code></p><p><code>132</code><code>2?n-2:0),a=2;a&lt;n;a++)i[a-2]=arguments[a];r&amp;&amp;t(r,...i)}var x="fetch-",w=x+"body-",A=["arrayBuffer","blob","json","text","formData"],_=f._A.Request,E=f._A.Response,T="prototype";const D={};function S(e){const t=function(e){return(e||n.ee).get("fetch")}(e);if(!(_&amp;&amp;E&amp;&amp;f._A.fetch))return t;if(D[t.debugId]++)return t;function r(e,r,i){var a=e[r];"function"==typeof a&amp;&amp;(e[r]=function(){var e,r=[...arguments],o={};t.emit(i+"before-start",[r],o),o[n.A]&amp;&amp;o[n.A].dt&amp;&amp;(e=o[n.A].dt);var s=a.apply(this,r);return t.emit(i+"start",[r,e],s),s.then((function(e){return t.emit(i+"end",[null,e],s),e}),(function(e){throw t.emit(i+"end",[e],s),e}))})}return D[t.debugId]=1,A.forEach((e=&gt;</code></p><p><code>133</code><code>{r(_[T],e,w),r(E[T],e,w)})),r(f._A,"fetch",x),t.on(x+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&amp;&amp;(n.rxSize=i),t.emit(x+"done",[null,r],n)}else t.emit(x+"done",[e],n)})),t}const j={},C=["pushState","replaceState"];function P(e){const t=function(e){return(e||n.ee).get("history")}(e);return!f.il||j[t.debugId]++||(j[t.debugId]=1,c(t).inPlace(window.history,C,"-")),t}var O=r(3239);var R=r(50);const k={},N=["open","send"];function I(e){var t=e||n.ee;const r=function(e){return(e||n.ee).get("xhr")}(t);if(k[r.debugId]++)return r;k[r.debugId]=1,b(t);var i=c(r),a=f._A.XMLHttpRequest,o=f._A.MutationObserver,s=f._A.Promise,d=f._A.setInterval,u="readystatechange",l=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],h=[],p=f._A.XMLHttpRequest=function(e){const t=new a(e),n=r.context(t);try{r.emit("new-xhr",[t],n),t.addEventListener(u,(o=n,function(){var e=this;e.readyState&gt;</code></p><p><code>134</code><code>3&amp;&amp;!o.resolved&amp;&amp;(o.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,l,"fn-",w)}),(0,O.m$)(!1))}catch(e){(0,R.Z)("An error occurred while intercepting XHR",e);try{r.emit("internal-error",[e])}catch(e){}}var o;return t};function g(e,t){i.inPlace(t,["onreadystatechange"],"fn-",w)}if(function(e,t){for(var r in e)t[r]=e[r]}(a,p),p.prototype=a.prototype,i.inPlace(p.prototype,N,"-xhr-",w),r.on("send-xhr-start",(function(e,t){g(e,t),function(e){h.push(e),o&amp;&amp;(m?m.then(x):d?d(x):(v=-v,y.data=v))}(t)})),r.on("open-xhr-start",g),o){var m=s&amp;&amp;s.resolve();if(!d&amp;&amp;!s){var v=1,y=document.createTextNode(v);new o(x).observe(y,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&amp;&amp;e[0].type===u||x()}));function x(){for(var e=0;e&lt;h.length;e++)g(0,h[e]);h.length&amp;&amp;(h=[])}function w(e,t){return t}return r}},7825:(e,t,r)=&gt;</code></p><p><code>135</code><code>{r.d(t,{t:()=&gt;</code></p><p><code>136</code><code>n});const n=r(3325).D.ajax},6660:(e,t,r)=&gt;</code></p><p><code>137</code><code>{r.d(t,{t:()=&gt;</code></p><p><code>138</code><code>n});const n=r(3325).D.jserrors},3081:(e,t,r)=&gt;</code></p><p><code>139</code><code>{r.d(t,{gF:()=&gt;</code></p><p><code>140</code><code>a,mY:()=&gt;</code></p><p><code>141</code><code>i,t9:()=&gt;</code></p><p><code>142</code><code>n,vz:()=&gt;</code></p><p><code>143</code><code>s,xS:()=&gt;</code></p><p><code>144</code><code>o});const n=r(3325).D.metrics,i="sm",a="cm",o="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=&gt;</code></p><p><code>145</code><code>{r.d(t,{t:()=&gt;</code></p><p><code>146</code><code>n});const n=r(3325).D.pageAction},7633:(e,t,r)=&gt;</code></p><p><code>147</code><code>{r.d(t,{t:()=&gt;</code></p><p><code>148</code><code>n});const n=r(3325).D.pageViewEvent},9251:(e,t,r)=&gt;</code></p><p><code>149</code><code>{r.d(t,{t:()=&gt;</code></p><p><code>150</code><code>n});const n=r(3325).D.pageViewTiming},7144:(e,t,r)=&gt;</code></p><p><code>151</code><code>{r.d(t,{t:()=&gt;</code></p><p><code>152</code><code>n});const n=r(3325).D.sessionReplay},3614:(e,t,r)=&gt;</code></p><p><code>153</code><code>{r.d(t,{BST_RESOURCE:()=&gt;</code></p><p><code>154</code><code>i,END:()=&gt;</code></p><p><code>155</code><code>s,FEATURE_NAME:()=&gt;</code></p><p><code>156</code><code>n,FN_END:()=&gt;</code></p><p><code>157</code><code>d,FN_START:()=&gt;</code></p><p><code>158</code><code>c,PUSH_STATE:()=&gt;</code></p><p><code>159</code><code>u,RESOURCE:()=&gt;</code></p><p><code>160</code><code>a,START:()=&gt;</code></p><p><code>161</code><code>o});const n=r(3325).D.sessionTrace,i="bstResource",a="resource",o="-start",s="-end",c="fn"+o,d="fn"+s,u="pushState"},5938:(e,t,r)=&gt;</code></p><p><code>162</code><code>{r.d(t,{W:()=&gt;</code></p><p><code>163</code><code>a});var n=r(234),i=r(8325);class a{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},7530:(e,t,r)=&gt;</code></p><p><code>164</code><code>{r.d(t,{j:()=&gt;</code></p><p><code>165</code><code>b});var n=r(3325),i=r(234),a=r(5546),o=r(8325),s=r(7894),c=r(8e3),d=r(3960),u=r(385),l=r(50),f=r(3081),h=r(8632);function p(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId","setApplicationVersion","start"].forEach((t=&gt;</code></p><p><code>166</code><code>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i&lt;r;i++)n[i]=arguments[i];return function(t){for(var r=arguments.length,n=new Array(r&gt;</code></p><p><code>167</code><code>1?r-1:0),i=1;i&lt;r;i++)n[i-1]=arguments[i];let a=[];return Object.values(e.initializedAgents).forEach((e=&gt;</code></p><p><code>168</code><code>{e.exposed&amp;&amp;e.api[t]&amp;&amp;a.push(e.api[t](...n))})),a.length&gt;</code></p><p><code>169</code><code>1?a:a[0]}(t,...n)}}))}var g=r(2587);const m=e=&gt;</code></p><p><code>170</code><code>{r.p=e};let v=!1;function b(e){let t=arguments.length&gt;</code></p><p><code>171</code><code>1&amp;&amp;void 0!==arguments[1]?arguments[1]:{},b=arguments.length&gt;</code></p><p><code>172</code><code>2?arguments[2]:void 0,y=arguments.length&gt;</code></p><p><code>173</code><code>3?arguments[3]:void 0,{init:x,info:w,loader_config:A,runtime:_={loaderType:b},exposed:E=!0}=t;const T=(0,h.gG)();w||(x=T.init,w=T.info,A=T.loader_config),(0,i.Dg)(e,x||{}),(0,i.GE)(e,A||{}),w.jsAttributes??={},u.v6&amp;&amp;(w.jsAttributes.isWorker=!0),(0,i.CX)(e,w);const D=(0,i.P_)(e),S=[w.beacon,w.errorBeacon];v||(v=!0,D.proxy.assets&amp;&amp;(m(D.proxy.assets+"/"),S.push(D.proxy.assets)),D.proxy.beacon&amp;&amp;S.push(D.proxy.beacon)),_.denyList=[...D.ajax.deny_list||[],...D.ajax.block_internal?S:[]],(0,i.sU)(e,_),p();const j=function(e,t){t||(0,c.R)(e,"api");const h={};var p=o.ee.get(e),g=p.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,a){const o=(0,i.C5)(e);return null===r?delete o.jsAttributes[t]:(0,i.CX)(e,{...o,jsAttributes:{...o.jsAttributes,[t]:r}}),w(m,n,!0,a||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=&gt;</code></p><p><code>174</code><code>{h[e]=w(m,e,!0,"api")})),h.addPageAction=w(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=w(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&amp;&amp;(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,w(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length&gt;</code></p><p><code>175</code><code>2&amp;&amp;void 0!==arguments[2]&amp;&amp;arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,l.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of &lt;".concat(typeof t,"&gt;</code></p><p><code>176</code><code> was provided."))}else(0,l.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of &lt;".concat(typeof e,"&gt;</code></p><p><code>177</code><code> was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,l.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of &lt;".concat(typeof e,"&gt;</code></p><p><code>178</code><code> was provided."))},h.setApplicationVersion=function(e){if("string"==typeof e||null===e)return b("application.version",e,"setApplicationVersion",!1);(0,l.Z)("Failed to execute setApplicationVersion. Expected &lt;String | null&gt;</code></p><p><code>179</code><code>, but got &lt;".concat(typeof e,"&gt;</code></p><p><code>180</code><code>."))},h.start=e=&gt;</code></p><p><code>181</code><code>{try{const t=e?"defined":"undefined";(0,a.p)(f.xS,["API/start/".concat(t,"/called")],void 0,n.D.metrics,p);const r=Object.values(n.D);if(void 0===e)e=r;else{if((e=Array.isArray(e)&amp;&amp;e.length?e:[e]).some((e=&gt;</code></p><p><code>182</code><code>!r.includes(e))))return(0,l.Z)("Invalid feature name supplied. Acceptable feature names are: ".concat(r));e.includes(n.D.pageViewEvent)||e.push(n.D.pageViewEvent)}e.forEach((e=&gt;</code></p><p><code>183</code><code>{p.emit("".concat(e,"-opt-in"))}))}catch(e){(0,l.Z)("An unexpected issue occurred",e)}},h.interaction=function(){return(new y).get()};var x=y.prototype={createTracer:function(e,t){var r={},i=this,o="function"==typeof t;return(0,a.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,p),function(){if(g.emit((o?"":"no-")+"fn-start",[(0,s.z)(),i,o],r),o)try{return t.apply(this,arguments)}catch(e){throw g.emit("fn-err",[arguments,this,e],r),e}finally{g.emit("fn-end",[(0,s.z)()],r)}}}};function w(e,t,r,i){return function(){return(0,a.p)(f.xS,["API/"+t+"/called"],void 0,n.D.metrics,p),i&amp;&amp;(0,a.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,p),r?void 0:this}}function A(){r.e(63).then(r.bind(r,7438)).then((t=&gt;</code></p><p><code>184</code><code>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=&gt;</code></p><p><code>185</code><code>(0,l.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=&gt;</code></p><p><code>186</code><code>{x[e]=w(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&amp;&amp;(e=new Error(e)),(0,a.p)(f.xS,["API/noticeError/called"],void 0,n.D.metrics,p),(0,a.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,p)},u.il?(0,d.b)((()=&gt;</code></p><p><code>187</code><code>A()),!0):A(),h}(e,y);return(0,h.Qy)(e,j,"api"),(0,h.Qy)(e,E,"exposed"),(0,h.EZ)("activatedFeatures",g.T),j}},3325:(e,t,r)=&gt;</code></p><p><code>188</code><code>{r.d(t,{D:()=&gt;</code></p><p><code>189</code><code>n,p:()=&gt;</code></p><p><code>190</code><code>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var a=n[e]={exports:{}};return r[e](a,a.exports,i),a.exports}i.m=r,i.d=(e,t)=&gt;</code></p><p><code>191</code><code>{for(var r in t)i.o(t,r)&amp;&amp;!i.o(e,r)&amp;&amp;Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=&gt;</code></p><p><code>192</code><code>Promise.all(Object.keys(i.f).reduce(((t,r)=&gt;</code></p><p><code>193</code><code>(i.f[r](e,t),t)),[])),i.u=e=&gt;</code></p><p><code>194</code><code>({63:"nr-full",110:"nr-full-compressor",379:"nr-full-recorder"}[e]+"-1.242.0.min.js"),i.o=(e,t)=&gt;</code></p><p><code>195</code><code>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.242.0.PROD:",i.l=(r,n,a,o)=&gt;</code></p><p><code>196</code><code>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==a)for(var d=document.getElementsByTagName("script"),u=0;u&lt;d.length;u++){var l=d[u];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+a){s=l;break}}s||(c=!0,(s=document.createElement("script")).charset="utf-8",s.timeout=120,i.nc&amp;&amp;s.setAttribute("nonce",i.nc),s.setAttribute("data-webpack",t+a),s.src=r),e[r]=[n];var f=(t,n)=&gt;</code></p><p><code>197</code><code>{s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&amp;&amp;s.parentNode.removeChild(s),i&amp;&amp;i.forEach((e=&gt;</code></p><p><code>198</code><code>e(n))),t)return t(n)},h=setTimeout(f.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=f.bind(null,s.onerror),s.onload=f.bind(null,s.onload),c&amp;&amp;document.head.appendChild(s)}},i.r=e=&gt;</code></p><p><code>199</code><code>{"undefined"!=typeof Symbol&amp;&amp;Symbol.toStringTag&amp;&amp;Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=&gt;</code></p><p><code>200</code><code>{var e={29:0,789:0};i.f.j=(t,r)=&gt;</code></p><p><code>201</code><code>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var a=new Promise(((r,i)=&gt;</code></p><p><code>202</code><code>n=e[t]=[r,i]));r.push(n[2]=a);var o=i.p+i.u(t),s=new Error;i.l(o,(r=&gt;</code></p><p><code>203</code><code>{if(i.o(e,t)&amp;&amp;(0!==(n=e[t])&amp;&amp;(e[t]=void 0),n)){var a=r&amp;&amp;("load"===r.type?"missing":r.type),o=r&amp;&amp;r.target&amp;&amp;r.target.src;s.message="Loading chunk "+t+" failed.\n("+a+": "+o+")",s.name="ChunkLoadError",s.type=a,s.request=o,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=&gt;</code></p><p><code>204</code><code>{var n,a,[o,s,c]=r,d=0;if(o.some((t=&gt;</code></p><p><code>205</code><code>0!==e[t]))){for(n in s)i.o(s,n)&amp;&amp;(i.m[n]=s[n]);if(c)c(i)}for(t&amp;&amp;t(r);d&lt;o.length;d++)a=o[d],i.o(e,a)&amp;&amp;e[a]&amp;&amp;e[a][0](),e[a]=0},r=self["webpackChunk:NRBA-1.242.0.PROD"]=self["webpackChunk:NRBA-1.242.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=&gt;</code></p><p><code>206</code><code>{var e=i(50);class t{addPageAction(t,r){(0,e.Z)("Call to agent api addPageAction failed. The session trace feature is not currently initialized.")}setPageViewName(t,r){(0,e.Z)("Call to agent api setPageViewName failed. The page view feature is not currently initialized.")}setCustomAttribute(t,r,n){(0,e.Z)("Call to agent api setCustomAttribute failed. The js errors feature is not currently initialized.")}noticeError(t,r){(0,e.Z)("Call to agent api noticeError failed. The js errors feature is not currently initialized.")}setUserId(t){(0,e.Z)("Call to agent api setUserId failed. The js errors feature is not currently initialized.")}setApplicationVersion(t){(0,e.Z)("Call to agent api setApplicationVersion failed. The agent is not currently initialized.")}setErrorHandler(t){(0,e.Z)("Call to agent api setErrorHandler failed. The js errors feature is not currently initialized.")}finished(t){(0,e.Z)("Call to agent api finished failed. The page action feature is not currently initialized.")}addRelease(t,r){(0,e.Z)("Call to agent api addRelease failed. The agent is not currently initialized.")}start(t){(0,e.Z)("Call to agent api addRelease failed. The agent is not currently initialized.")}}var r=i(3325),n=i(234);const a=Object.values(r.D);function o(e){const t={};return a.forEach((r=&gt;</code></p><p><code>207</code><code>{t[r]=function(e,t){return!1!==(0,n.Mt)(t,"".concat(e,".enabled"))}(r,e)})),t}var s=i(7530);var c=i(8e3),d=i(5938),u=i(3960),l=i(385);class f extends d.W{constructor(e,t,r){let i=!(arguments.length&gt;</code></p><p><code>208</code><code>3&amp;&amp;void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=i,this.abortHandler=void 0,this.featAggregate=void 0,this.onAggregateImported=void 0,!1===(0,n.Mt)(this.agentIdentifier,"".concat(this.featureName,".autoStart"))&amp;&amp;(this.auto=!1),this.auto&amp;&amp;(0,c.R)(e,r)}importAggregator(){let t=arguments.length&gt;</code></p><p><code>209</code><code>0&amp;&amp;void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate)return;if(!this.auto)return void this.ee.on("".concat(this.featureName,"-opt-in"),(()=&gt;</code></p><p><code>210</code><code>{(0,c.R)(this.agentIdentifier,this.featureName),this.auto=!0,this.importAggregator()}));const r=l.il&amp;&amp;!0===(0,n.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let a;this.onAggregateImported=new Promise((e=&gt;</code></p><p><code>211</code><code>{a=e}));const o=async()=&gt;</code></p><p><code>212</code><code>{let n;try{if(r){const{setupAgentSession:e}=await i.e(63).then(i.bind(i,3228));n=e(this.agentIdentifier)}}catch(t){(0,e.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",t)}try{if(!this.shouldImportAgg(this.featureName,n))return(0,c.L)(this.agentIdentifier,this.featureName),void a(!1);const{lazyFeatureLoader:e}=await i.e(63).then(i.bind(i,8582)),{Aggregate:r}=await e(this.featureName,"aggregate");this.featAggregate=new r(this.agentIdentifier,this.aggregator,t),a(!0)}catch(t){(0,e.Z)("Downloading and initializing ".concat(this.featureName," failed..."),t),this.abortHandler?.(),(0,c.L)(this.agentIdentifier,this.featureName),a(!1)}};l.il?(0,u.b)((()=&gt;</code></p><p><code>213</code><code>o()),!0):o()}shouldImportAgg(e,t){return e!==r.D.sessionReplay||!!n.Yu.MO&amp;&amp;(!1!==(0,n.Mt)(this.agentIdentifier,"session_trace.enabled")&amp;&amp;(!!t?.isNew||!!t?.state.sessionReplay))}}var h=i(7633);class p extends f{static featureName=h.t;constructor(e,t){let r=!(arguments.length&gt;</code></p><p><code>214</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2];super(e,t,h.t,r),this.importAggregator()}}var g=i(1117),m=i(1284);class v extends g.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var a=this.getBucket(e,t,r,i);return a.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,m.D)(e,(function(e,r){t[e]=b(r,t[e])})),t}(n,a.metrics),a}merge(e,t,r,n,i){var a=this.getBucket(e,t,n,i);if(a.metrics){var o=a.metrics;o.count+=r.count,(0,m.D)(r,(function(e,t){if("count"!==e){var n=o[e],i=r[e];i&amp;&amp;!i.c?o[e]=b(i.t,n):o[e]=function(e,t){if(!t)return e;t.c||(t=y(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,o[e])}}))}else a.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=b(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&amp;&amp;(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&amp;&amp;this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i&lt;e.length;i++)t[r=e[i]]=x(this.aggregatedData[r]),t[r].length&amp;&amp;(n=!0),delete this.aggregatedData[r];return n?t:null}}function b(e,t){return null==e?function(e){e?e.c++:e={c:1};return e}(t):t?(t.c||(t=y(t.t)),t.c+=1,t.t+=e,t.sos+=e*e,e&gt;</code></p><p><code>215</code><code>t.max&amp;&amp;(t.max=e),e&lt;t.min&amp;&amp;(t.min=e),t):{t:e}}function y(e){return{t:e,min:e,max:e,sos:e*e,c:1}}function x(e){return"object"!=typeof e?[]:(0,m.D)(e,w)}function w(e,t){return t}var A=i(8632),_=i(4402),E=i(4351);var T=i(5546),D=i(7956),S=i(3239),j=i(7894),C=i(9251);class P extends f{static featureName=C.t;constructor(e,t){let r=!(arguments.length&gt;</code></p><p><code>216</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2];super(e,t,C.t,r),l.il&amp;&amp;((0,D.N)((()=&gt;</code></p><p><code>217</code><code>(0,T.p)("docHidden",[(0,j.z)()],void 0,C.t,this.ee)),!0),(0,S.bP)("pagehide",(()=&gt;</code></p><p><code>218</code><code>(0,T.p)("winPagehide",[(0,j.z)()],void 0,C.t,this.ee))),this.importAggregator())}}var O=i(3081);class R extends f{static featureName=O.t9;constructor(e,t){let r=!(arguments.length&gt;</code></p><p><code>219</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2];super(e,t,O.t9,r),this.importAggregator()}}var k=i(6660);class N{constructor(e,t,r,n){this.name="UncaughtError",this.message=e,this.sourceURL=t,this.line=r,this.column=n}}class I extends f{static featureName=k.t;#e=new Set;constructor(e,t){let n=!(arguments.length&gt;</code></p><p><code>220</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2];super(e,t,k.t,n);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("fn-err",((e,t,n)=&gt;</code></p><p><code>221</code><code>{this.abortHandler&amp;&amp;!this.#e.has(n)&amp;&amp;(this.#e.add(n),(0,T.p)("err",[this.#t(n),(0,j.z)()],void 0,r.D.jserrors,this.ee))})),this.ee.on("internal-error",(e=&gt;</code></p><p><code>222</code><code>{this.abortHandler&amp;&amp;(0,T.p)("ierr",[this.#t(e),(0,j.z)(),!0],void 0,r.D.jserrors,this.ee)})),l._A.addEventListener("unhandledrejection",(e=&gt;</code></p><p><code>223</code><code>{this.abortHandler&amp;&amp;(0,T.p)("err",[this.#r(e),(0,j.z)(),!1,{unhandledPromiseRejection:1}],void 0,r.D.jserrors,this.ee)}),(0,S.m$)(!1,this.removeOnAbort?.signal)),l._A.addEventListener("error",(e=&gt;</code></p><p><code>224</code><code>{this.abortHandler&amp;&amp;(this.#e.has(e.error)?this.#e.delete(e.error):(0,T.p)("err",[this.#n(e),(0,j.z)()],void 0,r.D.jserrors,this.ee))}),(0,S.m$)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#i,this.importAggregator()}#i(){this.removeOnAbort?.abort(),this.#e.clear(),this.abortHandler=void 0}#t(e){return e instanceof Error?e:void 0!==e?.message?new N(e.message,e.filename||e.sourceURL,e.lineno||e.line,e.colno||e.col):new N("string"==typeof e?e:(0,E.P)(e))}#r(e){let t="Unhandled Promise Rejection: ";if(e?.reason instanceof Error)try{return e.reason.message=t+e.reason.message,e.reason}catch(t){return e.reason}if(void 0===e.reason)return new N(t);const r=this.#t(e.reason);return r.message=t+r.message,r}#n(e){return e.error instanceof Error?e.error:new N(e.message,e.filename,e.lineno,e.colno)}}var z=i(2210);let H=1;const L="nr@id";function M(e){const t=typeof e;return!e||"object"!==t&amp;&amp;"function"!==t?-1:e===l._A?0:(0,z.X)(e,L,(function(){return H++}))}function Z(e){if("string"==typeof e&amp;&amp;e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&amp;&amp;e instanceof ArrayBuffer&amp;&amp;e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&amp;&amp;e instanceof Blob&amp;&amp;e.size)return e.size;if(!("undefined"!=typeof FormData&amp;&amp;e instanceof FormData))try{return(0,E.P)(e).length}catch(e){return}}}var B=i(1214),F=i(7243);class U{constructor(e){this.agentIdentifier=e}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var t=(0,n.DL)(this.agentIdentifier);if(!t)return null;var r=(t.accountID||"").toString()||null,i=(t.agentID||"").toString()||null,a=(t.trustKey||"").toString()||null;if(!r||!i)return null;var o=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),d={spanId:o,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&amp;&amp;this.useTraceContextHeadersForCors())&amp;&amp;(d.traceContextParentHeader=this.generateTraceContextParentHeader(o,s),d.traceContextStateHeader=this.generateTraceContextStateHeader(o,c,r,i,a)),(e.sameOrigin&amp;&amp;!this.excludeNewrelicHeader()||!e.sameOrigin&amp;&amp;this.isAllowedOrigin(e)&amp;&amp;this.useNewrelicHeaderForCors())&amp;&amp;(d.newrelicHeader=this.generateTraceHeader(o,s,c,r,i,a)),d}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,a){if(!("function"==typeof l._A?.btoa))return null;var o={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return a&amp;&amp;n!==a&amp;&amp;(o.d.tk=a),btoa((0,E.P)(o))}shouldGenerateTrace(e){return this.isDtEnabled()&amp;&amp;this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1,r={};if((0,n.Mt)(this.agentIdentifier,"distributed_tracing")&amp;&amp;(r=(0,n.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)t=!0;else if(r.allowed_origins instanceof Array)for(var i=0;i&lt;r.allowed_origins.length;i++){var a=(0,F.e)(r.allowed_origins[i]);if(e.hostname===a.hostname&amp;&amp;e.protocol===a.protocol&amp;&amp;e.port===a.port){t=!0;break}}return t}isDtEnabled(){var e=(0,n.Mt)(this.agentIdentifier,"distributed_tracing");return!!e&amp;&amp;!!e.enabled}excludeNewrelicHeader(){var e=(0,n.Mt)(this.agentIdentifier,"distributed_tracing");return!!e&amp;&amp;!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=(0,n.Mt)(this.agentIdentifier,"distributed_tracing");return!!e&amp;&amp;!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=(0,n.Mt)(this.agentIdentifier,"distributed_tracing");return!!e&amp;&amp;!!e.cors_use_tracecontext_headers}}var q=i(7825),V=["load","error","abort","timeout"],G=V.length,W=n.Yu.REQ,X=n.Yu.XHR;class Q extends f{static featureName=q.t;constructor(e,t){let i=!(arguments.length&gt;</code></p><p><code>225</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2];if(super(e,t,q.t,i),(0,n.OP)(e).xhrWrappable){this.dt=new U(e),this.handler=(e,t,r,n)=&gt;</code></p><p><code>226</code><code>(0,T.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};l._A?.performance?.getEntriesByType("resource").forEach((t=&gt;</code></p><p><code>227</code><code>{if(t.initiatorType in e&amp;&amp;0!==t.responseStatus){const n={status:t.responseStatus},i={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};K(n,t.name),this.handler("xhr",[n,i,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,r.D.ajax)}}))}catch(e){}(0,B.u5)(this.ee),(0,B.Kf)(this.ee),function(e,t,i,a){function o(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=A,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,S.m$)(!1)),l.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,S.m$)(!1))}function s(e){this.params={method:e[0]},K(this,e[1]),this.metrics={}}function c(t,r){var i=(0,n.DL)(e);i.xpid&amp;&amp;this.sameOrigin&amp;&amp;r.setRequestHeader("X-NewRelic-ID",i.xpid);var o=a.generateTracePayload(this.parsedOrigin);if(o){var s=!1;o.newrelicHeader&amp;&amp;(r.setRequestHeader("newrelic",o.newrelicHeader),s=!0),o.traceContextParentHeader&amp;&amp;(r.setRequestHeader("traceparent",o.traceContextParentHeader),o.traceContextStateHeader&amp;&amp;r.setRequestHeader("tracestate",o.traceContextStateHeader),s=!0),s&amp;&amp;(this.dt=o)}}function d(e,r){var n=this.metrics,i=e[0],a=this;if(n&amp;&amp;i){var o=Z(i);o&amp;&amp;(n.txSize=o)}this.startTime=(0,j.z)(),this.listener=function(e){try{"abort"!==e.type||a.loadCaptureCalled||(a.params.aborted=!0),("load"!==e.type||a.called===a.totalCbs&amp;&amp;(a.onloadCalled||"function"!=typeof r.onload)&amp;&amp;"function"==typeof a.end)&amp;&amp;a.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var s=0;s&lt;G;s++)r.addEventListener(V[s],this.listener,(0,S.m$)(!1))}function u(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&amp;&amp;"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function f(e,t){var r=""+M(e)+!!t;this.xhrGuids&amp;&amp;!this.xhrGuids[r]&amp;&amp;(this.xhrGuids[r]=!0,this.totalCbs+=1)}function h(e,t){var r=""+M(e)+!!t;this.xhrGuids&amp;&amp;this.xhrGuids[r]&amp;&amp;(delete this.xhrGuids[r],this.totalCbs-=1)}function p(){this.endTime=(0,j.z)()}function g(e,r){r instanceof X&amp;&amp;"load"===e[0]&amp;&amp;t.emit("xhr-load-added",[e[1],e[2]],r)}function m(e,r){r instanceof X&amp;&amp;"load"===e[0]&amp;&amp;t.emit("xhr-load-removed",[e[1],e[2]],r)}function v(e,t,r){t instanceof X&amp;&amp;("onload"===r&amp;&amp;(this.onload=!0),("load"===(e[0]&amp;&amp;e[0].type)||this.onload)&amp;&amp;(this.xhrCbStart=(0,j.z)()))}function b(e,r){this.xhrCbStart&amp;&amp;t.emit("xhr-cb-time",[(0,j.z)()-this.xhrCbStart,this.onload,r],r)}function y(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&amp;&amp;l.il&amp;&amp;(t=""+l._A.location.href):e[0]&amp;&amp;e[0].url?t=e[0].url:l._A?.URL&amp;&amp;e[0]&amp;&amp;e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&amp;&amp;(t=e[0].toString()),"string"==typeof t&amp;&amp;0!==t.length){t&amp;&amp;(this.parsedOrigin=(0,F.e)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var n=a.generateTracePayload(this.parsedOrigin);if(n&amp;&amp;(n.newrelicHeader||n.traceContextParentHeader))if(e[0]&amp;&amp;e[0].headers)s(e[0].headers,n)&amp;&amp;(this.dt=n);else{var i={};for(var o in r)i[o]=r[o];i.headers=new Headers(r.headers||{}),s(i.headers,n)&amp;&amp;(this.dt=n),e.length&gt;</code></p><p><code>228</code><code>1?e[1]=i:e.push(i)}}function s(e,t){var r=!1;return t.newrelicHeader&amp;&amp;(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&amp;&amp;(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&amp;&amp;e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,j.z)(),this.dt=t,e.length&gt;</code></p><p><code>229</code><code>=1&amp;&amp;(this.target=e[0]),e.length&gt;</code></p><p><code>230</code><code>=2&amp;&amp;(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&amp;&amp;i instanceof W?r=i.url:l._A?.URL&amp;&amp;"object"==typeof i&amp;&amp;i instanceof URL&amp;&amp;(r=i.href),K(this,r);var a=(""+(i&amp;&amp;i instanceof W&amp;&amp;i.method||n.method||"GET")).toUpperCase();this.params.method=a,this.txSize=Z(n.body)||0}function w(e,t){var n;this.endTime=(0,j.z)(),this.params||(this.params={}),this.params.status=t?t.status:0,"string"==typeof this.rxSize&amp;&amp;this.rxSize.length&gt;</code></p><p><code>231</code><code>0&amp;&amp;(n=+this.rxSize);var a={txSize:this.txSize,rxSize:n,duration:(0,j.z)()-this.startTime};i("xhr",[this.params,a,this.startTime,this.endTime,"fetch"],this,r.D.ajax)}function A(e){var t=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var a=0;a&lt;G;a++)e.removeEventListener(V[a],this.listener,!1);t.aborted||(n.duration=(0,j.z)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&amp;&amp;(t.status=0):_(this,e),n.cbTime=this.cbTime,i("xhr",[t,n,this.startTime,this.endTime,"xhr"],this,r.D.ajax))}}function _(e,t){e.params.status=t.status;var r=function(e,t){var r=e.responseType;return"json"===r&amp;&amp;null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?Z(e.response):"text"===r||""===r||void 0===r?Z(e.responseText):void 0}(t,e.lastSize);if(r&amp;&amp;(e.metrics.rxSize=r),e.sameOrigin){var n=t.getResponseHeader("X-NewRelic-App-Data");n&amp;&amp;(e.params.cat=n.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",o),t.on("open-xhr-start",s),t.on("open-xhr-end",c),t.on("send-xhr-start",d),t.on("xhr-cb-time",u),t.on("xhr-load-added",f),t.on("xhr-load-removed",h),t.on("xhr-resolved",p),t.on("addEventListener-end",g),t.on("removeEventListener-end",m),t.on("fn-end",b),t.on("fetch-before-start",y),t.on("fetch-start",x),t.on("fn-start",v),t.on("fetch-done",w)}(e,this.ee,this.handler,this.dt),this.importAggregator()}}}function K(e,t){var r=(0,F.e)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}var Y=i(3614);const{BST_RESOURCE:J,RESOURCE:ee,START:te,END:re,FEATURE_NAME:ne,FN_END:ie,FN_START:ae,PUSH_STATE:oe}=Y;var se=i(7144);class ce extends f{static featureName=se.t;constructor(e,t){let r=!(arguments.length&gt;</code></p><p><code>232</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2];super(e,t,se.t,r),this.importAggregator()}}var de=i(4649);class ue extends f{static featureName=de.t;constructor(e,t){let r=!(arguments.length&gt;</code></p><p><code>233</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2];super(e,t,de.t,r),this.importAggregator()}}new class extends t{constructor(t){let r=arguments.length&gt;</code></p><p><code>234</code><code>1&amp;&amp;void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);super(),l._A?(this.agentIdentifier=r,this.sharedAggregator=new v({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(t.features||[]),this.desiredFeatures.add(p),Object.assign(this,(0,s.j)(this.agentIdentifier,t,t.loaderType||"agent")),this.run()):(0,e.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,n.C5)(this.agentIdentifier),init:(0,n.P_)(this.agentIdentifier),loader_config:(0,n.DL)(this.agentIdentifier),runtime:(0,n.OP)(this.agentIdentifier)}}run(){const t="features";try{const n=o(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((e,t)=&gt;</code></p><p><code>235</code><code>r.p[e.featureName]-r.p[t.featureName])),i.forEach((t=&gt;</code></p><p><code>236</code><code>{if(n[t.featureName]||t.featureName===r.D.pageViewEvent){const i=function(e){switch(e){case r.D.ajax:return[r.D.jserrors];case r.D.sessionTrace:return[r.D.ajax,r.D.pageViewEvent];case r.D.sessionReplay:return[r.D.sessionTrace];case r.D.pageViewTiming:return[r.D.pageViewEvent];default:return[]}}(t.featureName);i.every((e=&gt;</code></p><p><code>237</code><code>n[e]))||(0,e.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,E.P)(i),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,A.Qy)(this.agentIdentifier,this.features,t)}catch(r){(0,e.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",r);for(const e in this.features)this.features[e].abortHandler?.();const n=(0,A.fP)();return delete n.initializedAgents[this.agentIdentifier]?.api,delete n.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,n.ee?.abort(),delete n.ee?.get(this.agentIdentifier),!1}}addToTrace(t){(0,e.Z)("Call to agent api addToTrace failed. The page action feature is not currently initialized.")}setCurrentRouteName(t){(0,e.Z)("Call to agent api setCurrentRouteName failed. The spa feature is not currently initialized.")}interaction(){(0,e.Z)("Call to agent api interaction failed. The spa feature is not currently initialized.")}}({features:[p,P,class extends f{static featureName=ne;constructor(e,t){if(super(e,t,ne,!(arguments.length&gt;</code></p><p><code>238</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2]),!l.il)return;const n=this.ee;let i;(0,B.QU)(n),this.eventsEE=(0,B.em)(n),this.eventsEE.on(ae,(function(e,t){this.bstStart=(0,j.z)()})),this.eventsEE.on(ie,(function(e,t){(0,T.p)("bst",[e[0],t,this.bstStart,(0,j.z)()],void 0,r.D.sessionTrace,n)})),n.on(oe+te,(function(e){this.time=(0,j.z)(),this.startPath=location.pathname+location.hash})),n.on(oe+re,(function(e){(0,T.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,r.D.sessionTrace,n)}));try{i=new PerformanceObserver((e=&gt;</code></p><p><code>239</code><code>{const t=e.getEntries();(0,T.p)(J,[t],void 0,r.D.sessionTrace,n)})),i.observe({type:ee,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},ce,Q,R,ue,I],loaderType:"pro"})})()})();&lt;/script&gt;</code></p><p><code>240</code><code>          </code></p><p><code>241</code><code>&lt;script&gt;</code></p><p><code>242</code><code>window.CDEConfig = {</code></p><p><code>243</code><code>  "exitDisclaimerHref":{</code></p><p><code>244</code><code>    "en":"\/policies\/linking",</code></p><p><code>245</code><code>    "es":"\/espanol\/politicas\/enlaces"</code></p><p><code>246</code><code>  },</code></p><p><code>247</code><code>  "showFloatingDelighters":true,</code></p><p><code>248</code><code>  "environmentConfig":{</code></p><p><code>249</code><code>    </code></p><p><code>250</code><code>  },</code></p><p><code>251</code><code>  "glossaryConfig":{</code></p><p><code>252</code><code>    "apiServer":"https:\/\/webapis.cancer.gov\/glossary\/v1\/"</code></p><p><code>253</code><code>  },</code></p><p><code>254</code><code>  "drugDictionaryConfig":{</code></p><p><code>255</code><code>    "apiServer":"https:\/\/webapis.cancer.gov\/drugdictionary\/v1\/"</code></p><p><code>256</code><code>  },</code></p><p><code>257</code><code>  "ctsConfig":{</code></p><p><code>258</code><code>    "apiServer":"https:\/\/clinicaltrialsapi.cancer.gov\/api\/v2",</code></p><p><code>259</code><code>    "printApiBase":"https:\/\/www.cancer.gov\/CTS.Print",</code></p><p><code>260</code><code>    "zipConversionEndpoint":"\/cts_api\/zip_code_lookup"</code></p><p><code>261</code><code>  },</code></p><p><code>262</code><code>  "r4rConfig":{</code></p><p><code>263</code><code>    "apiServer":"https:\/\/webapis.cancer.gov\/r4r\/v1"</code></p><p><code>264</code><code>  },</code></p><p><code>265</code><code>  "general":{</code></p><p><code>266</code><code>    "apiServer":"https:\/\/webapis.cancer.gov",</code></p><p><code>267</code><code>    "mediaServer":"https:\/\/nci-media.cancer.gov"</code></p><p><code>268</code><code>  },</code></p><p><code>269</code><code>  "sitewideSearchConfig":{</code></p><p><code>270</code><code>    "bestBetsApiServer":"https:\/\/webapis.cancer.gov\/bestbets\/v1\/",</code></p><p><code>271</code><code>    "searchApiServer":"https:\/\/webapis.cancer.gov\/sitewidesearch\/v1\/"</code></p><p><code>272</code><code>  },</code></p><p><code>273</code><code>  "chartData": {</code></p><p><code>274</code><code>    "factBook": {</code></p><p><code>275</code><code>      "baseUrl": "\/about-nci\/budget\/fact-book",</code></p><p><code>276</code><code>      "dataType": "json"</code></p><p><code>277</code><code>    }</code></p><p><code>278</code><code>  }</code></p><p><code>279</code><code>};&lt;/script&gt;</code></p><p><code>280</code><code>          </code></p><p><code>281</code><code>&lt;script id="ncids-nav-info"&gt;</code></p><p><code>282</code><code>window.ncidsNavInfo = { nav: { id: "11924", menu_type: "section-nav"}, item_id: 940470};&lt;/script&gt;</code></p><p><code>283</code><code>          </code></p><p><code>284</code><code>&lt;meta name="description" content="Bile duct cancer (also called cholangiocarcinoma) can occur in the bile ducts in the liver (intrahepatic) or outside the liver (perihilar or distal ). Learn about the types of bile duct cancer, risk factors, clinical features, staging, and treatment for bile duct cancer in this expert-reviewed summary." /&gt;</code></p><p><code>285</code><code>          </code></p><p><code>286</code><code>&lt;link rel="canonical" href="https://www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq" /&gt;</code></p><p><code>287</code><code>          </code></p><p><code>288</code><code>&lt;meta http-equiv="content-language" content="en" /&gt;</code></p><p><code>289</code><code>          </code></p><p><code>290</code><code>&lt;meta property="og:site_name" content="National Cancer Institute" /&gt;</code></p><p><code>291</code><code>          </code></p><p><code>292</code><code>&lt;meta property="og:type" content="Website" /&gt;</code></p><p><code>293</code><code>          </code></p><p><code>294</code><code>&lt;meta property="og:url" content="https://www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq" /&gt;</code></p><p><code>295</code><code>          </code></p><p><code>296</code><code>&lt;meta property="og:title" content="Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)" /&gt;</code></p><p><code>297</code><code>          </code></p><p><code>298</code><code>&lt;meta property="og:description" content="Bile duct cancer (also called cholangiocarcinoma) can occur in the bile ducts in the liver (intrahepatic) or outside the liver (perihilar or distal ). Learn about the types of bile duct cancer, risk factors, clinical features, staging, and treatment for bile duct cancer in this expert-reviewed summary." /&gt;</code></p><p><code>299</code><code>          </code></p><p><code>300</code><code>&lt;meta name="dcterms.subject" content="Cancer Types" /&gt;</code></p><p><code>301</code><code>          </code></p><p><code>302</code><code>&lt;meta name="dcterms.type" content="pdqCancerInfoSummary" /&gt;</code></p><p><code>303</code><code>          </code></p><p><code>304</code><code>&lt;meta name="dcterms.coverage" content="nciglobal,ncienterprise" /&gt;</code></p><p><code>305</code><code>          </code></p><p><code>306</code><code>&lt;meta name="dcterms.audience" content="Health Professionals" /&gt;</code></p><p><code>307</code><code>          </code></p><p><code>308</code><code>&lt;meta name="dcterms.isPartOf" content="Cancer Types Landing Page" /&gt;</code></p><p><code>309</code><code>          </code></p><p><code>310</code><code>&lt;meta name="dcterms.isReferencedBy" content="event1" /&gt;</code></p><p><code>311</code><code>          </code></p><p><code>312</code><code>&lt;meta name="dcterms.issued" content="08/04/2023 - 08:00" /&gt;</code></p><p><code>313</code><code>          </code></p><p><code>314</code><code>&lt;meta name="twitter:card" content="summary" /&gt;</code></p><p><code>315</code><code>          </code></p><p><code>316</code><code>&lt;meta name="Generator" content="Drupal 9 (https://www.drupal.org)" /&gt;</code></p><p><code>317</code><code>          </code></p><p><code>318</code><code>&lt;meta name="MobileOptimized" content="width" /&gt;</code></p><p><code>319</code><code>          </code></p><p><code>320</code><code>&lt;meta name="HandheldFriendly" content="true" /&gt;</code></p><p><code>321</code><code>          </code></p><p><code>322</code><code>&lt;meta name="viewport" content="width=device-width, user-scalable=yes, initial-scale=1, minimum-scale=1" /&gt;</code></p><p><code>323</code><code>          </code></p><p><code>324</code><code>&lt;script id="cgov-adobe-url" type="text/javascript" src="//assets.adobedtm.com/6a4249cd0a2c/949e98979342/launch-5f2a5357bf66.min.js"&gt;</code></p><p><code>325</code><code>&lt;/script&gt;</code></p><p><code>326</code><code>          </code></p><p><code>327</code><code>&lt;link rel="icon" href="/core/misc/favicon.ico" type="image/vnd.microsoft.icon" /&gt;</code></p><p><code>328</code><code>          </code></p><p><code>329</code><code>&lt;link rel="alternate" hreflang="en" href="https://www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq" /&gt;</code></p><p><code>330</code><code>          </code></p><p><code>331</code><code>&lt;link rel="alternate" hreflang="es" href="https://www.cancer.gov/espanol/tipos/higado/pro/tratamiento-vias-biliares-pdq" /&gt;</code></p><p><code>332</code><code>          </code></p><p><code>333</code><code>          </code></p><p><code>334</code><code>    &lt;title&gt;</code></p><p><code>335</code><code>Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®) - NCI&lt;/title&gt;</code></p><p><code>336</code><code>          </code></p><p><code>337</code><code>    &lt;link rel="preconnect" href="https://static.cancer.gov" /&gt;</code></p><p><code>338</code><code>          </code></p><p><code>339</code><code>        &lt;link rel="preconnect" href="https://fonts.googleapis.com"&gt;</code></p><p><code>340</code><code>          </code></p><p><code>341</code><code>    &lt;link rel="preconnect" href="https://fonts.gstatic.com" crossorigin&gt;</code></p><p><code>342</code><code>          </code></p><p><code>343</code><code>    &lt;link href="https://fonts.googleapis.com/css2?family=Open+Sans:ital,wght@0,300;0,400;0,600;0,700;1,300;1,400;1,600;1,700&amp;family=Poppins:ital,wght@0,300;0,400;0,500;0,600;1,300;1,400;1,500;1,600&amp;family=Roboto+Mono:ital,wght@0,300;0,400;0,700;1,300;1,400;1,700&amp;display=swap" rel="stylesheet"&gt;</code></p><p><code>344</code><code>          </code></p><p><code>345</code><code>    &lt;link rel="apple-touch-icon" sizes="180x180" href="/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/apple-touch-icon.png?v=1" /&gt;</code></p><p><code>346</code><code>          </code></p><p><code>347</code><code>    &lt;link rel="icon" type="image/png" href="/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/favicon-32x32.png?v=1" sizes="32x32" /&gt;</code></p><p><code>348</code><code>          </code></p><p><code>349</code><code>    &lt;link rel="icon" type="image/png" href="/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/favicon-16x16.png?v=1" sizes="16x16" /&gt;</code></p><p><code>350</code><code>          </code></p><p><code>351</code><code>    &lt;link rel="mask-icon" href="/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/safari-pinned-tab.svg?v=1" color="#c0143c" /&gt;</code></p><p><code>352</code><code>          </code></p><p><code>353</code><code>    &lt;link rel="shortcut icon" href="/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/favicon.ico?v=1" /&gt;</code></p><p><code>354</code><code>          </code></p><p><code>355</code><code>    &lt;meta name="apple-mobile-web-app-title" content="Cancer.gov" /&gt;</code></p><p><code>356</code><code>          </code></p><p><code>357</code><code>    &lt;meta name="application-name" content="Cancer.gov" /&gt;</code></p><p><code>358</code><code>          </code></p><p><code>359</code><code>    &lt;meta name="msapplication-config" content="/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/browserconfig.xml?v=1" /&gt;</code></p><p><code>360</code><code>          </code></p><p><code>361</code><code>    &lt;link rel="stylesheet" media="all" href="/sites/g/files/xnrzdm211/files/css/css_sl7QUD1H8m-3-HmAxYnsPVDgLlc-msHkQ9qf52aVYeE.css" /&gt;</code></p><p><code>362</code><code>          </code></p><p><code>363</code><code>&lt;link rel="stylesheet" media="all" href="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/css/ncids-common.css?s1d5be" /&gt;</code></p><p><code>364</code><code>          </code></p><p><code>365</code><code>&lt;link rel="stylesheet" media="all" href="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/css/pdq.css?s1d5be" /&gt;</code></p><p><code>366</code><code>          </code></p><p><code>367</code><code>          </code></p><p><code>368</code><code>    </code></p><p><code>369</code><code>  &lt;/head&gt;</code></p><p><code>370</code><code>          </code></p><p><code>371</code><code>  &lt;body class="has-translated-content"&gt;</code></p><p><code>372</code><code>          </code></p><p><code>373</code><code>        &lt;a href="#main-content" class="usa-skipnav"&gt;</code></p><p><code>374</code><code>          </code></p><p><code>375</code><code>      Skip to main content</code></p><p><code>376</code><code>    &lt;/a&gt;</code></p><p><code>377</code><code>          </code></p><p><code>378</code><code>    </code></p><p><code>379</code><code>      &lt;div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas&gt;</code></p><p><code>380</code><code>          </code></p><p><code>381</code><code>    </code></p><p><code>382</code><code>          </code></p><p><code>383</code><code>          </code></p><p><code>384</code><code>  &lt;section id="usa-banner" class="usa-banner usa-banner--nci-banner" aria-label="Official government website"&gt;</code></p><p><code>385</code><code>          </code></p><p><code>386</code><code>  &lt;header class="usa-banner__header"&gt;</code></p><p><code>387</code><code>          </code></p><p><code>388</code><code>    &lt;div class="usa-banner__inner"&gt;</code></p><p><code>389</code><code>          </code></p><p><code>390</code><code>      &lt;div class="usa-banner__header-text"&gt;</code></p><p><code>391</code><code>          </code></p><p><code>392</code><code>        An official website of the United States government</code></p><p><code>393</code><code>      &lt;/div&gt;</code></p><p><code>394</code><code>          </code></p><p><code>395</code><code>            &lt;a href="/espanol/tipos/higado/pro/tratamiento-vias-biliares-pdq" id="lang-toggle" class="usa-button usa-button--nci-small" hreflang="es"&gt;</code></p><p><code>396</code><code>Español&lt;/a&gt;</code></p><p><code>397</code><code>          </code></p><p><code>398</code><code>    &lt;/div&gt;</code></p><p><code>399</code><code>          </code></p><p><code>400</code><code>  &lt;/header&gt;</code></p><p><code>401</code><code>          </code></p><p><code>402</code><code>&lt;/section&gt;</code></p><p><code>403</code><code>          </code></p><p><code>404</code><code>          </code></p><p><code>405</code><code>          </code></p><p><code>406</code><code>          </code></p><p><code>407</code><code>  &lt;header id="nci-header" class="nci-header nci-header--extended" data-base-path="/"&gt;</code></p><p><code>408</code><code>          </code></p><p><code>409</code><code>	&lt;div class="nci-header__navbar"&gt;</code></p><p><code>410</code><code>          </code></p><p><code>411</code><code>		&lt;div class="nci-logo" id="extended-mega-logo"&gt;</code></p><p><code>412</code><code>          </code></p><p><code>413</code><code>			&lt;a href="/" aria-label="National Cancer Institute Home Page"&gt;</code></p><p><code>414</code><code>          </code></p><p><code>415</code><code>				&lt;picture&gt;</code></p><p><code>416</code><code>&lt;source media="(min-width: 1024px)" srcset="/sites/g/files/xnrzdm211/files/ncids_header/logos/Logo_NCI.svg" /&gt;</code></p><p><code>417</code><code>          </code></p><p><code>418</code><code>&lt;img src="/sites/g/files/xnrzdm211/files/ncids_header/logos/Logo_NCI_Mobile.svg" alt="" /&gt;</code></p><p><code>419</code><code>          </code></p><p><code>420</code><code>&lt;/picture&gt;</code></p><p><code>421</code><code>          </code></p><p><code>422</code><code>          </code></p><p><code>423</code><code>			&lt;/a&gt;</code></p><p><code>424</code><code>          </code></p><p><code>425</code><code>		&lt;/div&gt;</code></p><p><code>426</code><code>          </code></p><p><code>427</code><code>          </code></p><p><code>428</code><code>		&lt;div class="nci-header-nav__secondary"&gt;</code></p><p><code>429</code><code>          </code></p><p><code>430</code><code>			&lt;button class="usa-button nci-header-mobilenav__open-btn"&gt;</code></p><p><code>431</code><code>Menu&lt;/button&gt;</code></p><p><code>432</code><code>          </code></p><p><code>433</code><code>          </code></p><p><code>434</code><code>							&lt;form class="nci-header-search" method="get" action="/search/results" role="search"&gt;</code></p><p><code>435</code><code>          </code></p><p><code>436</code><code>					&lt;label class="usa-sr-only" for="nci-header-search__field"&gt;</code></p><p><code>437</code><code>          </code></p><p><code>438</code><code>						Search</code></p><p><code>439</code><code>					&lt;/label&gt;</code></p><p><code>440</code><code>          </code></p><p><code>441</code><code>          </code></p><p><code>442</code><code>																										&lt;input class="usa-input" id="nci-header-search__field" type="search" name="swKeyword"  data-autosuggest-collection="cgov"/&gt;</code></p><p><code>443</code><code>          </code></p><p><code>444</code><code>					&lt;button class="usa-button nci-header-search__search-button" type="submit" aria-label="Search"&gt;</code></p><p><code>445</code><code>          </code></p><p><code>446</code><code>						&lt;span class="nci-header-search__label" aria-hidden="true"&gt;</code></p><p><code>447</code><code>Search&lt;/span&gt;</code></p><p><code>448</code><code>          </code></p><p><code>449</code><code>						&lt;svg class="usa-icon" xmlns="http://www.w3.org/2000/svg" role="img" viewbox="0 0 24 24" aria-hidden="true"&gt;</code></p><p><code>450</code><code>          </code></p><p><code>451</code><code>							&lt;path d="M0 0h24v24H0z" fill="none"/&gt;</code></p><p><code>452</code><code>          </code></p><p><code>453</code><code>							&lt;path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z"/&gt;</code></p><p><code>454</code><code>          </code></p><p><code>455</code><code>						&lt;/svg&gt;</code></p><p><code>456</code><code>          </code></p><p><code>457</code><code>					&lt;/button&gt;</code></p><p><code>458</code><code>          </code></p><p><code>459</code><code>				&lt;/form&gt;</code></p><p><code>460</code><code>          </code></p><p><code>461</code><code>					&lt;/div&gt;</code></p><p><code>462</code><code>          </code></p><p><code>463</code><code>	&lt;/div&gt;</code></p><p><code>464</code><code>          </code></p><p><code>465</code><code>          </code></p><p><code>466</code><code>			&lt;nav aria-label="Primary navigation" class="nci-header-nav"&gt;</code></p><p><code>467</code><code>          </code></p><p><code>468</code><code>			&lt;div class="nci-header-nav__inner"&gt;</code></p><p><code>469</code><code>          </code></p><p><code>470</code><code>				&lt;ul class="nci-header-nav__primary"&gt;</code></p><p><code>471</code><code>          </code></p><p><code>472</code><code>											&lt;li class="nci-header-nav__primary-item"&gt;</code></p><p><code>473</code><code>          </code></p><p><code>474</code><code>																																											&lt;a  href="/about-cancer" class="nci-header-nav__primary-link" data-menu-id="829"&gt;</code></p><p><code>475</code><code>          </code></p><p><code>476</code><code>								&lt;span&gt;</code></p><p><code>477</code><code>About Cancer&lt;/span&gt;</code></p><p><code>478</code><code>          </code></p><p><code>479</code><code>							&lt;/a&gt;</code></p><p><code>480</code><code>          </code></p><p><code>481</code><code>						&lt;/li&gt;</code></p><p><code>482</code><code>          </code></p><p><code>483</code><code>											&lt;li class="nci-header-nav__primary-item"&gt;</code></p><p><code>484</code><code>          </code></p><p><code>485</code><code>																																																										&lt;a  href="/types" class="nci-header-nav__primary-link usa-current" data-menu-id="11868"&gt;</code></p><p><code>486</code><code>          </code></p><p><code>487</code><code>								&lt;span&gt;</code></p><p><code>488</code><code>Cancer Types&lt;/span&gt;</code></p><p><code>489</code><code>          </code></p><p><code>490</code><code>							&lt;/a&gt;</code></p><p><code>491</code><code>          </code></p><p><code>492</code><code>						&lt;/li&gt;</code></p><p><code>493</code><code>          </code></p><p><code>494</code><code>											&lt;li class="nci-header-nav__primary-item"&gt;</code></p><p><code>495</code><code>          </code></p><p><code>496</code><code>																																											&lt;a  href="/research" class="nci-header-nav__primary-link" data-menu-id="12732"&gt;</code></p><p><code>497</code><code>          </code></p><p><code>498</code><code>								&lt;span&gt;</code></p><p><code>499</code><code>Research&lt;/span&gt;</code></p><p><code>500</code><code>          </code></p><p><code>501</code><code>							&lt;/a&gt;</code></p><p><code>502</code><code>          </code></p><p><code>503</code><code>						&lt;/li&gt;</code></p><p><code>504</code><code>          </code></p><p><code>505</code><code>											&lt;li class="nci-header-nav__primary-item"&gt;</code></p><p><code>506</code><code>          </code></p><p><code>507</code><code>																																											&lt;a  href="/grants-training" class="nci-header-nav__primary-link" data-menu-id="914792"&gt;</code></p><p><code>508</code><code>          </code></p><p><code>509</code><code>								&lt;span&gt;</code></p><p><code>510</code><code>Grants &amp;amp; Training&lt;/span&gt;</code></p><p><code>511</code><code>          </code></p><p><code>512</code><code>							&lt;/a&gt;</code></p><p><code>513</code><code>          </code></p><p><code>514</code><code>						&lt;/li&gt;</code></p><p><code>515</code><code>          </code></p><p><code>516</code><code>											&lt;li class="nci-header-nav__primary-item"&gt;</code></p><p><code>517</code><code>          </code></p><p><code>518</code><code>																																											&lt;a  href="/news-events" class="nci-header-nav__primary-link" data-menu-id="12664"&gt;</code></p><p><code>519</code><code>          </code></p><p><code>520</code><code>								&lt;span&gt;</code></p><p><code>521</code><code>News &amp;amp; Events&lt;/span&gt;</code></p><p><code>522</code><code>          </code></p><p><code>523</code><code>							&lt;/a&gt;</code></p><p><code>524</code><code>          </code></p><p><code>525</code><code>						&lt;/li&gt;</code></p><p><code>526</code><code>          </code></p><p><code>527</code><code>											&lt;li class="nci-header-nav__primary-item"&gt;</code></p><p><code>528</code><code>          </code></p><p><code>529</code><code>																																											&lt;a  href="/about-nci" class="nci-header-nav__primary-link" data-menu-id="10952"&gt;</code></p><p><code>530</code><code>          </code></p><p><code>531</code><code>								&lt;span&gt;</code></p><p><code>532</code><code>About NCI&lt;/span&gt;</code></p><p><code>533</code><code>          </code></p><p><code>534</code><code>							&lt;/a&gt;</code></p><p><code>535</code><code>          </code></p><p><code>536</code><code>						&lt;/li&gt;</code></p><p><code>537</code><code>          </code></p><p><code>538</code><code>									&lt;/ul&gt;</code></p><p><code>539</code><code>          </code></p><p><code>540</code><code>			&lt;/div&gt;</code></p><p><code>541</code><code>          </code></p><p><code>542</code><code>		&lt;/nav&gt;</code></p><p><code>543</code><code>          </code></p><p><code>544</code><code>	</code></p><p><code>545</code><code>&lt;/header&gt;</code></p><p><code>546</code><code>          </code></p><p><code>547</code><code>          </code></p><p><code>548</code><code>          </code></p><p><code>549</code><code>          </code></p><p><code>550</code><code>&lt;div class="grid-container"&gt;</code></p><p><code>551</code><code>          </code></p><p><code>552</code><code>  &lt;div class="grid-row flex-no-wrap"&gt;</code></p><p><code>553</code><code>          </code></p><p><code>554</code><code>    &lt;div class="grid-col-10"&gt;</code></p><p><code>555</code><code>          </code></p><p><code>556</code><code>                &lt;nav class="usa-breadcrumb usa-breadcrumb--wrap" aria-label="Breadcrumbs"&gt;</code></p><p><code>557</code><code>          </code></p><p><code>558</code><code>    &lt;ol class="usa-breadcrumb__list"&gt;</code></p><p><code>559</code><code>          </code></p><p><code>560</code><code>              &lt;li class="usa-breadcrumb__list-item"&gt;</code></p><p><code>561</code><code>          </code></p><p><code>562</code><code>          &lt;a href="/" class="usa-breadcrumb__link"&gt;</code></p><p><code>563</code><code>          </code></p><p><code>564</code><code>            &lt;span&gt;</code></p><p><code>565</code><code>Home&lt;/span&gt;</code></p><p><code>566</code><code>          </code></p><p><code>567</code><code>          &lt;/a&gt;</code></p><p><code>568</code><code>          </code></p><p><code>569</code><code>        &lt;/li&gt;</code></p><p><code>570</code><code>          </code></p><p><code>571</code><code>              &lt;li class="usa-breadcrumb__list-item"&gt;</code></p><p><code>572</code><code>          </code></p><p><code>573</code><code>          &lt;a href="/types" class="usa-breadcrumb__link"&gt;</code></p><p><code>574</code><code>          </code></p><p><code>575</code><code>            &lt;span&gt;</code></p><p><code>576</code><code>Cancer Types&lt;/span&gt;</code></p><p><code>577</code><code>          </code></p><p><code>578</code><code>          &lt;/a&gt;</code></p><p><code>579</code><code>          </code></p><p><code>580</code><code>        &lt;/li&gt;</code></p><p><code>581</code><code>          </code></p><p><code>582</code><code>              &lt;li class="usa-breadcrumb__list-item"&gt;</code></p><p><code>583</code><code>          </code></p><p><code>584</code><code>          &lt;a href="/types/liver" class="usa-breadcrumb__link"&gt;</code></p><p><code>585</code><code>          </code></p><p><code>586</code><code>            &lt;span&gt;</code></p><p><code>587</code><code>Liver &amp;amp; Bile Duct Cancer&lt;/span&gt;</code></p><p><code>588</code><code>          </code></p><p><code>589</code><code>          &lt;/a&gt;</code></p><p><code>590</code><code>          </code></p><p><code>591</code><code>        &lt;/li&gt;</code></p><p><code>592</code><code>          </code></p><p><code>593</code><code>              &lt;li class="usa-breadcrumb__list-item"&gt;</code></p><p><code>594</code><code>          </code></p><p><code>595</code><code>          &lt;a href="/types/liver/hp" class="usa-breadcrumb__link"&gt;</code></p><p><code>596</code><code>          </code></p><p><code>597</code><code>            &lt;span&gt;</code></p><p><code>598</code><code>Health Professional&lt;/span&gt;</code></p><p><code>599</code><code>          </code></p><p><code>600</code><code>          &lt;/a&gt;</code></p><p><code>601</code><code>          </code></p><p><code>602</code><code>        &lt;/li&gt;</code></p><p><code>603</code><code>          </code></p><p><code>604</code><code>                    &lt;li class="usa-breadcrumb__list-item usa-current" aria-current="page"&gt;</code></p><p><code>605</code><code>          </code></p><p><code>606</code><code>          &lt;span&gt;</code></p><p><code>607</code><code>Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version&lt;/span&gt;</code></p><p><code>608</code><code>          </code></p><p><code>609</code><code>        &lt;/li&gt;</code></p><p><code>610</code><code>          </code></p><p><code>611</code><code>          &lt;/ol&gt;</code></p><p><code>612</code><code>          </code></p><p><code>613</code><code>  &lt;/nav&gt;</code></p><p><code>614</code><code>          </code></p><p><code>615</code><code>          </code></p><p><code>616</code><code>          </code></p><p><code>617</code><code>    &lt;/div&gt;</code></p><p><code>618</code><code>          </code></p><p><code>619</code><code>    </code></p><p><code>620</code><code>          </code></p><p><code>621</code><code>      </code></p><p><code>622</code><code>          </code></p><p><code>623</code><code>          </code></p><p><code>624</code><code>&lt;section  class="cgdp-page-options cgdp-page-options--top" aria-label="Page options top"&gt;</code></p><p><code>625</code><code>          </code></p><p><code>626</code><code>  &lt;button class="usa-button usa-button--unstyled" onclick="window.print()"&gt;</code></p><p><code>627</code><code>          </code></p><p><code>628</code><code>    &lt;svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"&gt;</code></p><p><code>629</code><code>          </code></p><p><code>630</code><code>      &lt;path d="M0 0h24v24H0z" fill="none"/&gt;</code></p><p><code>631</code><code>          </code></p><p><code>632</code><code>      &lt;path d="M19 8H5c-1.66 0-3 1.34-3 3v6h4v4h12v-4h4v-6c0-1.66-1.34-3-3-3zm-3 11H8v-5h8v5zm3-7c-.55 0-1-.45-1-1s.45-1 1-1 1 .45 1 1-.45 1-1 1zm-1-9H6v4h12V3z"/&gt;</code></p><p><code>633</code><code>          </code></p><p><code>634</code><code>    &lt;/svg&gt;</code></p><p><code>635</code><code>          </code></p><p><code>636</code><code>    &lt;span class="usa-sr-only"&gt;</code></p><p><code>637</code><code>          </code></p><p><code>638</code><code>      Print    &lt;/span&gt;</code></p><p><code>639</code><code>          </code></p><p><code>640</code><code>  &lt;/button&gt;</code></p><p><code>641</code><code>          </code></p><p><code>642</code><code>  &lt;a class="usa-button usa-button--unstyled" href="mailto:?subject=Information from the National Cancer Institute Web Site &amp;body=I found this information on www.cancer.gov and I'd like to share it with you: https://www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq %0D%0A%0D%0A NCI's Web site, www.cancer.gov, provides accurate, up-to-date, comprehensive cancer information from the U.S. government's principal agency for cancer research. If you have questions or need additional information, we invite you to contact NCI's LiveHelp instant messaging service at https://livehelp.cancer.gov, or call the NCI's Contact Center 1-800-4-CANCER (1-800-422-6237) (toll-free from the United States)."&gt;</code></p><p><code>643</code><code>          </code></p><p><code>644</code><code>    &lt;svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"&gt;</code></p><p><code>645</code><code>          </code></p><p><code>646</code><code>        &lt;path d="M0 0h24v24H0z" fill="none"/&gt;</code></p><p><code>647</code><code>          </code></p><p><code>648</code><code>        &lt;path d="M20 4H4c-1.1 0-1.99.9-1.99 2L2 18c0 1.1.9 2 2 2h16c1.1 0 2-.9 2-2V6c0-1.1-.9-2-2-2zm0 14H4V8l8 5 8-5v10zm-8-7L4 6h16l-8 5z"/&gt;</code></p><p><code>649</code><code>          </code></p><p><code>650</code><code>    &lt;/svg&gt;</code></p><p><code>651</code><code>          </code></p><p><code>652</code><code>    &lt;span class="usa-sr-only"&gt;</code></p><p><code>653</code><code>          </code></p><p><code>654</code><code>      Email    &lt;/span&gt;</code></p><p><code>655</code><code>          </code></p><p><code>656</code><code>  &lt;/a&gt;</code></p><p><code>657</code><code>          </code></p><p><code>658</code><code>&lt;/section&gt;</code></p><p><code>659</code><code>          </code></p><p><code>660</code><code>          </code></p><p><code>661</code><code>  &lt;/div&gt;</code></p><p><code>662</code><code>          </code></p><p><code>663</code><code>&lt;/div&gt;</code></p><p><code>664</code><code>          </code></p><p><code>665</code><code>          </code></p><p><code>666</code><code>&lt;div id="page" class="grid-container"&gt;</code></p><p><code>667</code><code>          </code></p><p><code>668</code><code>      &lt;div class="grid-row grid-gap"&gt;</code></p><p><code>669</code><code>          </code></p><p><code>670</code><code>      &lt;!-- SECTION NAVIGATION --&gt;</code></p><p><code>671</code><code>          </code></p><p><code>672</code><code>  &lt;div class="desktop:grid-col-3 nci-no-print"&gt;</code></p><p><code>673</code><code>          </code></p><p><code>674</code><code>    </code></p><p><code>675</code><code>          </code></p><p><code>676</code><code>          </code></p><p><code>677</code><code>          </code></p><p><code>678</code><code>  &lt;nav aria-label="Secondary navigation"&gt;</code></p><p><code>679</code><code>          </code></p><p><code>680</code><code>    &lt;ul class="usa-sidenav usa-sidenav--nci-sidenav"&gt;</code></p><p><code>681</code><code>          </code></p><p><code>682</code><code>             </code></p><p><code>683</code><code>        </code></p><p><code>684</code><code>  &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>685</code><code>          </code></p><p><code>686</code><code>    &lt;a  href="/types/liver" data-menu-id="11924" class="usa-current usa-current--nci-ancestor"&gt;</code></p><p><code>687</code><code>Liver &amp;amp; Bile Duct Cancer&lt;/a&gt;</code></p><p><code>688</code><code>          </code></p><p><code>689</code><code>          &lt;ul class="usa-sidenav__sublist"&gt;</code></p><p><code>690</code><code>          </code></p><p><code>691</code><code>                                    &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>692</code><code>          </code></p><p><code>693</code><code>    &lt;a  href="/types/liver/what-is-liver-cancer" data-menu-id="1152376" class="nci-has-children"&gt;</code></p><p><code>694</code><code>Liver Cancer&lt;/a&gt;</code></p><p><code>695</code><code>          </code></p><p><code>696</code><code>  &lt;/li&gt;</code></p><p><code>697</code><code>          </code></p><p><code>698</code><code>          </code></p><p><code>699</code><code>  </code></p><p><code>700</code><code>                                    &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>701</code><code>          </code></p><p><code>702</code><code>    &lt;a  href="/types/liver/bile-duct-cancer" data-menu-id="1152331" class="nci-has-children"&gt;</code></p><p><code>703</code><code>Bile Duct Cancer (Cholangiocarcinoma)&lt;/a&gt;</code></p><p><code>704</code><code>          </code></p><p><code>705</code><code>  &lt;/li&gt;</code></p><p><code>706</code><code>          </code></p><p><code>707</code><code>          </code></p><p><code>708</code><code>  </code></p><p><code>709</code><code>                                    &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>710</code><code>          </code></p><p><code>711</code><code>    &lt;a  href="/types/liver/childhood-liver-cancer" data-menu-id="1152316" class="nci-has-children"&gt;</code></p><p><code>712</code><code>Childhood Liver Cancer&lt;/a&gt;</code></p><p><code>713</code><code>          </code></p><p><code>714</code><code>  &lt;/li&gt;</code></p><p><code>715</code><code>          </code></p><p><code>716</code><code>          </code></p><p><code>717</code><code>  </code></p><p><code>718</code><code>                         </code></p><p><code>719</code><code>        </code></p><p><code>720</code><code>  &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>721</code><code>          </code></p><p><code>722</code><code>    &lt;a  href="/types/liver/hp" data-menu-id="940470" class="usa-current usa-current--nci-ancestor"&gt;</code></p><p><code>723</code><code>Health Professional&lt;/a&gt;</code></p><p><code>724</code><code>          </code></p><p><code>725</code><code>          &lt;ul class="usa-sidenav__sublist"&gt;</code></p><p><code>726</code><code>          </code></p><p><code>727</code><code>                              &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>728</code><code>          </code></p><p><code>729</code><code>    &lt;a  href="/types/liver/hp/adult-liver-treatment-pdq" data-menu-id="943611"&gt;</code></p><p><code>730</code><code>Adult Liver Cancer Treatment&lt;/a&gt;</code></p><p><code>731</code><code>          </code></p><p><code>732</code><code>  &lt;/li&gt;</code></p><p><code>733</code><code>          </code></p><p><code>734</code><code>          </code></p><p><code>735</code><code>  </code></p><p><code>736</code><code>                         </code></p><p><code>737</code><code>        </code></p><p><code>738</code><code>  &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>739</code><code>          </code></p><p><code>740</code><code>    &lt;a  href="/types/liver/hp/bile-duct-treatment-pdq" data-menu-id="943597" class="usa-current" aria-current="page"&gt;</code></p><p><code>741</code><code>Bile Duct Cancer (Cholangiocarcinoma) Treatment&lt;/a&gt;</code></p><p><code>742</code><code>          </code></p><p><code>743</code><code>    </code></p><p><code>744</code><code>  &lt;/li&gt;</code></p><p><code>745</code><code>          </code></p><p><code>746</code><code>          </code></p><p><code>747</code><code>  </code></p><p><code>748</code><code>                              &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>749</code><code>          </code></p><p><code>750</code><code>    &lt;a  href="/types/liver/hp/child-liver-treatment-pdq" data-menu-id="947290"&gt;</code></p><p><code>751</code><code>Childhood Liver Cancer Treatment&lt;/a&gt;</code></p><p><code>752</code><code>          </code></p><p><code>753</code><code>  &lt;/li&gt;</code></p><p><code>754</code><code>          </code></p><p><code>755</code><code>          </code></p><p><code>756</code><code>  </code></p><p><code>757</code><code>                              &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>758</code><code>          </code></p><p><code>759</code><code>    &lt;a  href="/types/liver/hp/liver-prevention-pdq" data-menu-id="948884"&gt;</code></p><p><code>760</code><code>Liver Cancer Prevention&lt;/a&gt;</code></p><p><code>761</code><code>          </code></p><p><code>762</code><code>  &lt;/li&gt;</code></p><p><code>763</code><code>          </code></p><p><code>764</code><code>          </code></p><p><code>765</code><code>  </code></p><p><code>766</code><code>                              &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>767</code><code>          </code></p><p><code>768</code><code>    &lt;a  href="/types/liver/hp/liver-screening-pdq" data-menu-id="948820"&gt;</code></p><p><code>769</code><code>Liver Cancer Screening&lt;/a&gt;</code></p><p><code>770</code><code>          </code></p><p><code>771</code><code>  &lt;/li&gt;</code></p><p><code>772</code><code>          </code></p><p><code>773</code><code>          </code></p><p><code>774</code><code>  </code></p><p><code>775</code><code>              &lt;/ul&gt;</code></p><p><code>776</code><code>          </code></p><p><code>777</code><code>    </code></p><p><code>778</code><code>  &lt;/li&gt;</code></p><p><code>779</code><code>          </code></p><p><code>780</code><code>          </code></p><p><code>781</code><code>  </code></p><p><code>782</code><code>                                    &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>783</code><code>          </code></p><p><code>784</code><code>    &lt;a  href="/types/liver/research" data-menu-id="938242" class="nci-has-children"&gt;</code></p><p><code>785</code><code>Research Advances&lt;/a&gt;</code></p><p><code>786</code><code>          </code></p><p><code>787</code><code>  &lt;/li&gt;</code></p><p><code>788</code><code>          </code></p><p><code>789</code><code>          </code></p><p><code>790</code><code>  </code></p><p><code>791</code><code>              &lt;/ul&gt;</code></p><p><code>792</code><code>          </code></p><p><code>793</code><code>    </code></p><p><code>794</code><code>  &lt;/li&gt;</code></p><p><code>795</code><code>          </code></p><p><code>796</code><code>          </code></p><p><code>797</code><code>  </code></p><p><code>798</code><code>    &lt;/ul&gt;</code></p><p><code>799</code><code>          </code></p><p><code>800</code><code>  &lt;/nav&gt;</code></p><p><code>801</code><code>          </code></p><p><code>802</code><code>          </code></p><p><code>803</code><code>  &lt;/div&gt;</code></p><p><code>804</code><code>          </code></p><p><code>805</code><code>          </code></p><p><code>806</code><code>    &lt;div class="cgdpl desktop:grid-col-9"&gt;</code></p><p><code>807</code><code>          </code></p><p><code>808</code><code>            &lt;div id="content" class=""&gt;</code></p><p><code>809</code><code>          </code></p><p><code>810</code><code>        &lt;main class="contentzone has-section-nav" id="main-content"&gt;</code></p><p><code>811</code><code>          </code></p><p><code>812</code><code>            &lt;div data-drupal-messages-fallback class="hidden"&gt;</code></p><p><code>813</code><code>&lt;/div&gt;</code></p><p><code>814</code><code>          </code></p><p><code>815</code><code>&lt;!-- ********************************* BEGIN Page Content ********************************** --&gt;</code></p><p><code>816</code><code>          </code></p><p><code>817</code><code>          </code></p><p><code>818</code><code>&lt;article&gt;</code></p><p><code>819</code><code>          </code></p><p><code>820</code><code>    &lt;div class="resize-content"&gt;</code></p><p><code>821</code><code>          </code></p><p><code>822</code><code>    &lt;h1&gt;</code></p><p><code>823</code><code>Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version&lt;/h1&gt;</code></p><p><code>824</code><code>          </code></p><p><code>825</code><code>    &lt;div id="cgvBody"&gt;</code></p><p><code>826</code><code>          </code></p><p><code>827</code><code>      &lt;div class="summary-sections"&gt;</code></p><p><code>828</code><code>          </code></p><p><code>829</code><code>                &lt;nav class="on-this-page" role="navigation"&gt;</code></p><p><code>830</code><code>          </code></p><p><code>831</code><code>  &lt;h6&gt;</code></p><p><code>832</code><code>On This Page&lt;/h6&gt;</code></p><p><code>833</code><code>          </code></p><p><code>834</code><code>  &lt;ul&gt;</code></p><p><code>835</code><code>          </code></p><p><code>836</code><code>          &lt;li&gt;</code></p><p><code>837</code><code>&lt;a href="#_1"&gt;</code></p><p><code>838</code><code>General Information About Bile Duct Cancer&lt;/a&gt;</code></p><p><code>839</code><code>&lt;/li&gt;</code></p><p><code>840</code><code>          </code></p><p><code>841</code><code>          &lt;li&gt;</code></p><p><code>842</code><code>&lt;a href="#_202"&gt;</code></p><p><code>843</code><code>Cellular Classification of Bile Duct Cancer&lt;/a&gt;</code></p><p><code>844</code><code>&lt;/li&gt;</code></p><p><code>845</code><code>          </code></p><p><code>846</code><code>          &lt;li&gt;</code></p><p><code>847</code><code>&lt;a href="#_25"&gt;</code></p><p><code>848</code><code>Stage Information for Bile Duct Cancer&lt;/a&gt;</code></p><p><code>849</code><code>&lt;/li&gt;</code></p><p><code>850</code><code>          </code></p><p><code>851</code><code>          &lt;li&gt;</code></p><p><code>852</code><code>&lt;a href="#_261"&gt;</code></p><p><code>853</code><code>Treatment Option Overview for Bile Duct Cancer&lt;/a&gt;</code></p><p><code>854</code><code>&lt;/li&gt;</code></p><p><code>855</code><code>          </code></p><p><code>856</code><code>          &lt;li&gt;</code></p><p><code>857</code><code>&lt;a href="#_500"&gt;</code></p><p><code>858</code><code>Treatment of Resectable (Localized) Bile Duct Cancer&lt;/a&gt;</code></p><p><code>859</code><code>&lt;/li&gt;</code></p><p><code>860</code><code>          </code></p><p><code>861</code><code>          &lt;li&gt;</code></p><p><code>862</code><code>&lt;a href="#_501"&gt;</code></p><p><code>863</code><code>Treatment of Unresectable  (Including Metastatic and Recurrent) Bile Duct Cancer&lt;/a&gt;</code></p><p><code>864</code><code>&lt;/li&gt;</code></p><p><code>865</code><code>          </code></p><p><code>866</code><code>          &lt;li&gt;</code></p><p><code>867</code><code>&lt;a href="#_71"&gt;</code></p><p><code>868</code><code>Changes to This Summary (02/24/2023)&lt;/a&gt;</code></p><p><code>869</code><code>&lt;/li&gt;</code></p><p><code>870</code><code>          </code></p><p><code>871</code><code>          &lt;li&gt;</code></p><p><code>872</code><code>&lt;a href="#_AboutThis_1"&gt;</code></p><p><code>873</code><code>About This PDQ Summary&lt;/a&gt;</code></p><p><code>874</code><code>&lt;/li&gt;</code></p><p><code>875</code><code>          </code></p><p><code>876</code><code>      &lt;/ul&gt;</code></p><p><code>877</code><code>          </code></p><p><code>878</code><code>&lt;/nav&gt;</code></p><p><code>879</code><code>          </code></p><p><code>880</code><code>          </code></p><p><code>881</code><code>        &lt;div class="accordion"&gt;</code></p><p><code>882</code><code>          </code></p><p><code>883</code><code>          </code></p><p><code>884</code><code>          </code></p><p><code>885</code><code>    &lt;section id="_1"&gt;</code></p><p><code>886</code><code>          </code></p><p><code>887</code><code>        &lt;h2&gt;</code></p><p><code>888</code><code>General Information About Bile Duct Cancer&lt;/h2&gt;</code></p><p><code>889</code><code>          </code></p><p><code>890</code><code>        &lt;div id="_section_1" class="pdq-sections"&gt;</code></p><p><code>891</code><code>&lt;nav class="in-this-section" role="navigation"&gt;</code></p><p><code>892</code><code>&lt;h6&gt;</code></p><p><code>893</code><code>In This Section&lt;/h6&gt;</code></p><p><code>894</code><code>&lt;ul&gt;</code></p><p><code>895</code><code>&lt;li&gt;</code></p><p><code>896</code><code>&lt;a href="#_4_toc"&gt;</code></p><p><code>897</code><code>Anatomy&lt;ul&gt;</code></p><p><code>898</code><code>&lt;li&gt;</code></p><p><code>899</code><code>&lt;a href="#_349_toc"&gt;</code></p><p><code>900</code><code>Intrahepatic bile duct&lt;/a&gt;</code></p><p><code>901</code><code>&lt;/li&gt;</code></p><p><code>902</code><code>&lt;li&gt;</code></p><p><code>903</code><code>&lt;a href="#_159_toc"&gt;</code></p><p><code>904</code><code>Extrahepatic bile duct&lt;/a&gt;</code></p><p><code>905</code><code>&lt;/li&gt;</code></p><p><code>906</code><code>&lt;/ul&gt;</code></p><p><code>907</code><code>&lt;/a&gt;</code></p><p><code>908</code><code>&lt;/li&gt;</code></p><p><code>909</code><code>&lt;li&gt;</code></p><p><code>910</code><code>&lt;a href="#_91_toc"&gt;</code></p><p><code>911</code><code>Risk Factors&lt;/a&gt;</code></p><p><code>912</code><code>&lt;/li&gt;</code></p><p><code>913</code><code>&lt;li&gt;</code></p><p><code>914</code><code>&lt;a href="#_231_toc"&gt;</code></p><p><code>915</code><code>Clinical Features&lt;/a&gt;</code></p><p><code>916</code><code>&lt;/li&gt;</code></p><p><code>917</code><code>&lt;li&gt;</code></p><p><code>918</code><code>&lt;a href="#_93_toc"&gt;</code></p><p><code>919</code><code>Diagnostic and Staging Evaluation&lt;/a&gt;</code></p><p><code>920</code><code>&lt;/li&gt;</code></p><p><code>921</code><code>&lt;li&gt;</code></p><p><code>922</code><code>&lt;a href="#_7_toc"&gt;</code></p><p><code>923</code><code>Prognosis&lt;/a&gt;</code></p><p><code>924</code><code>&lt;/li&gt;</code></p><p><code>925</code><code>&lt;/ul&gt;</code></p><p><code>926</code><code>&lt;/nav&gt;</code></p><p><code>927</code><code>&lt;p id="_83" tabindex="-1"&gt;</code></p><p><code>928</code><code>Cancer of the bile duct (also called cholangiocarcinoma) is extremely rare. The true incidence of bile duct cancer is unknown because   establishing an accurate diagnosis is difficult.&lt;/p&gt;</code></p><p><code>929</code><code>&lt;p id="_226" tabindex="-1"&gt;</code></p><p><code>930</code><code>Traditionally, bile duct tumors located within the liver were classified with hepatocellular carcinoma as primary liver tumors.[&lt;a href="#cit/section_1.1"&gt;</code></p><p><code>931</code><code>1&lt;/a&gt;</code></p><p><code>932</code><code>]  In contrast, bile duct tumors located outside of the liver were classified with gallbladder cancer as extrahepatic biliary tract tumors.[&lt;a href="#cit/section_1.1"&gt;</code></p><p><code>933</code><code>1&lt;/a&gt;</code></p><p><code>934</code><code>]  The classification of bile duct tumors has changed to include intrahepatic tumors of the bile ducts and extrahepatic tumors (perihilar and distal) of the bile ducts.&lt;/p&gt;</code></p><p><code>935</code><code>&lt;p id="_341" tabindex="-1"&gt;</code></p><p><code>936</code><code>Approximately 50% of cholangiocarcinomas arise in the bile ducts of the perihilar region, 40% in the distal region, and 10% in the intrahepatic region.&lt;/p&gt;</code></p><p><code>937</code><code>&lt;p id="_3" tabindex="-1"&gt;</code></p><p><code>938</code><code>Many bile duct cancers are multifocal. In most patients, the tumor cannot be completely removed by surgery and is incurable. Palliative  measures such as resection, radiation therapy (e.g., brachytherapy or external-beam radiation therapy), or stenting procedures may maintain adequate biliary drainage and allow for improved quality of life. &lt;/p&gt;</code></p><p><code>939</code><code>&lt;section id="_4"&gt;</code></p><p><code>940</code><code>&lt;h3 id="_4_toc"&gt;</code></p><p><code>941</code><code>Anatomy&lt;/h3&gt;</code></p><p><code>942</code><code>&lt;p id="_84" tabindex="-1"&gt;</code></p><p><code>943</code><code>The biliary system consists of a network of ducts that carry bile from the liver to the small bowel and is classified by its anatomical location (Figure &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_253"&gt;</code></p><p><code>944</code><code>1&lt;/a&gt;</code></p><p><code>945</code><code>).  Bile is produced by the liver and is important for fat digestion.&lt;/p&gt;</code></p><p><code>946</code><code>&lt;section id="_349"&gt;</code></p><p><code>947</code><code>&lt;h4 id="_349_toc"&gt;</code></p><p><code>948</code><code>Intrahepatic bile duct&lt;/h4&gt;</code></p><p><code>949</code><code>&lt;p id="_309" tabindex="-1"&gt;</code></p><p><code>950</code><code>The bile ducts located within the liver are called intrahepatic bile ducts.  Tumors of the intrahepatic bile ducts originate in small intrahepatic ductules or large intrahepatic ducts that are  proximal to the bifurcation of the right and left hepatic ducts.  These tumors are also known as intrahepatic cholangiocarcinomas.&lt;/p&gt;</code></p><p><code>951</code><code>&lt;figure id="figure_253" class="image-center-medium"&gt;</code></p><p><code>952</code><code>&lt;a href="https://nci-media.cancer.gov/pdq/media/images/765897.jpg" target="_blank" class="article-image-enlarge"&gt;</code></p><p><code>953</code><code>Enlarge&lt;/a&gt;</code></p><p><code>954</code><code>&lt;img id="_253" alt="Anatomy of the intrahepatic bile ducts; drawing shows the liver and the intrahepatic bile ducts, which include the right and left hepatic ducts. Also shown is the common hepatic duct, gallbladder, cystic duct, common bile duct, pancreas, ampulla of Vater, and small intestine. An inset shows a cross section of a liver lobule with a network of bile ductules leading into a bile duct." title="Anatomy of the intrahepatic bile ducts; drawing shows the liver and the intrahepatic bile ducts, which include the right and left hepatic ducts. Also shown is the common hepatic duct, gallbladder, cystic duct, common bile duct, pancreas, ampulla of Vater, and small intestine. An inset shows a cross section of a liver lobule with a network of bile ductules leading into a bile duct." src="https://nci-media.cancer.gov/pdq/media/images/765897-750.jpg"&gt;</code></p><p><code>955</code><code>&lt;figcaption class="caption-container"&gt;</code></p><p><code>956</code><code>Figure 1.  Anatomy of the intrahepatic bile duct.&lt;/figcaption&gt;</code></p><p><code>957</code><code>&lt;/figure&gt;</code></p><p><code>958</code><code>&lt;/section&gt;</code></p><p><code>959</code><code>&lt;section id="_159"&gt;</code></p><p><code>960</code><code>&lt;h4 id="_159_toc"&gt;</code></p><p><code>961</code><code>Extrahepatic bile duct&lt;/h4&gt;</code></p><p><code>962</code><code>&lt;p id="_229" tabindex="-1"&gt;</code></p><p><code>963</code><code>The bile ducts located outside of the liver are called extrahepatic bile ducts.  They include part of the right and left hepatic ducts that are outside of the liver, the common hepatic duct, and the common bile duct.  The extrahepatic bile ducts can be further divided into the perihilar (hilum) region and distal region.&lt;/p&gt;</code></p><p><code>964</code><code>&lt;figure id="figure_254" class="image-center-medium"&gt;</code></p><p><code>965</code><code>&lt;a href="https://nci-media.cancer.gov/pdq/media/images/659742.jpg" target="_blank" class="article-image-enlarge"&gt;</code></p><p><code>966</code><code>Enlarge&lt;/a&gt;</code></p><p><code>967</code><code>&lt;img id="_254" alt="Anatomy of the extrahepatic bile ducts; drawing shows the extrahepatic bile ducts, including the common hepatic duct (perihilar region) and the common bile duct (distal region). Also shown are the liver, right and left hepatic ducts, gallbladder, cystic duct, pancreas, ampulla of Vater, and small intestine." title="Anatomy of the extrahepatic bile ducts; drawing shows the extrahepatic bile ducts, including the common hepatic duct (perihilar region) and the common bile duct (distal region). Also shown are the liver, right and left hepatic ducts, gallbladder, cystic duct, pancreas, ampulla of Vater, and small intestine." src="https://nci-media.cancer.gov/pdq/media/images/659742-750.jpg"&gt;</code></p><p><code>968</code><code>&lt;figcaption class="caption-container"&gt;</code></p><p><code>969</code><code>Figure 2.  Anatomy of the extrahepatic bile duct.&lt;/figcaption&gt;</code></p><p><code>970</code><code>&lt;/figure&gt;</code></p><p><code>971</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>972</code><code>&lt;ul id="_230"&gt;</code></p><p><code>973</code><code>&lt;li&gt;</code></p><p><code>974</code><code>&lt;strong&gt;</code></p><p><code>975</code><code>Perihilar (hilum) region.&lt;/strong&gt;</code></p><p><code>976</code><code> The hilum is the region where the right and left hepatic ducts exit the liver and join to form the common hepatic duct that is proximal to the origin of the cystic duct.  Tumors of this region are also known as perihilar cholangiocarcinomas or Klatskin tumors.&lt;/li&gt;</code></p><p><code>977</code><code>&lt;li&gt;</code></p><p><code>978</code><code>&lt;strong&gt;</code></p><p><code>979</code><code>Distal region.&lt;/strong&gt;</code></p><p><code>980</code><code> This region includes the common bile duct and inserts into the small intestine.  Tumors of this region are also known as extrahepatic cholangiocarcinomas (Figure &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_254"&gt;</code></p><p><code>981</code><code>2&lt;/a&gt;</code></p><p><code>982</code><code>).&lt;/li&gt;</code></p><p><code>983</code><code>&lt;/ul&gt;</code></p><p><code>984</code><code>&lt;/div&gt;</code></p><p><code>985</code><code>&lt;/section&gt;</code></p><p><code>986</code><code>&lt;/section&gt;</code></p><p><code>987</code><code>&lt;section id="_91"&gt;</code></p><p><code>988</code><code>&lt;h3 id="_91_toc"&gt;</code></p><p><code>989</code><code>Risk Factors&lt;/h3&gt;</code></p><p><code>990</code><code>&lt;p id="_92" tabindex="-1"&gt;</code></p><p><code>991</code><code>Bile duct cancer may occur more frequently in patients with</code></p><p><code>992</code><code>a history of primary sclerosing cholangitis, chronic ulcerative colitis,</code></p><p><code>993</code><code>choledochal cysts, or infections with the liver fluke &lt;em&gt;</code></p><p><code>994</code><code>Clonorchis sinensis&lt;/em&gt;</code></p><p><code>995</code><code>.[&lt;a href="#cit/section_1.2"&gt;</code></p><p><code>996</code><code>2&lt;/a&gt;</code></p><p><code>997</code><code>]  &lt;/p&gt;</code></p><p><code>998</code><code>&lt;/section&gt;</code></p><p><code>999</code><code>&lt;section id="_231"&gt;</code></p><p><code>1000</code><code>&lt;h3 id="_231_toc"&gt;</code></p><p><code>1001</code><code>Clinical Features&lt;/h3&gt;</code></p><p><code>1002</code><code>&lt;p id="_232" tabindex="-1"&gt;</code></p><p><code>1003</code><code>Distal and perihilar bile duct cancers frequently cause biliary tract obstruction, leading to the following symptoms:  &lt;/p&gt;</code></p><p><code>1004</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>1005</code><code>&lt;ul id="_233"&gt;</code></p><p><code>1006</code><code>&lt;li&gt;</code></p><p><code>1007</code><code> Jaundice.&lt;/li&gt;</code></p><p><code>1008</code><code>&lt;li&gt;</code></p><p><code>1009</code><code>Weight loss.&lt;/li&gt;</code></p><p><code>1010</code><code>&lt;li&gt;</code></p><p><code>1011</code><code>Abdominal pain.&lt;/li&gt;</code></p><p><code>1012</code><code>&lt;li&gt;</code></p><p><code>1013</code><code>Fever.&lt;/li&gt;</code></p><p><code>1014</code><code>&lt;li&gt;</code></p><p><code>1015</code><code>Pruritus.&lt;/li&gt;</code></p><p><code>1016</code><code>&lt;/ul&gt;</code></p><p><code>1017</code><code>&lt;/div&gt;</code></p><p><code>1018</code><code>&lt;p id="_234" tabindex="-1"&gt;</code></p><p><code>1019</code><code>Intrahepatic bile duct cancer may be relatively indolent and  difficult to differentiate clinically from metastatic adenocarcinoma deposits in the liver.&lt;/p&gt;</code></p><p><code>1020</code><code>&lt;/section&gt;</code></p><p><code>1021</code><code>&lt;section id="_93"&gt;</code></p><p><code>1022</code><code>&lt;h3 id="_93_toc"&gt;</code></p><p><code>1023</code><code>Diagnostic and Staging Evaluation&lt;/h3&gt;</code></p><p><code>1024</code><code>&lt;p id="_94" tabindex="-1"&gt;</code></p><p><code>1025</code><code>Clinical evaluation is dependent on laboratory and radiographical imaging tests that include the following: &lt;/p&gt;</code></p><p><code>1026</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>1027</code><code>&lt;ul id="_235"&gt;</code></p><p><code>1028</code><code>&lt;li&gt;</code></p><p><code>1029</code><code>	Liver function tests and other laboratory studies.&lt;/li&gt;</code></p><p><code>1030</code><code>&lt;li&gt;</code></p><p><code>1031</code><code>	Abdominal ultrasonography.&lt;/li&gt;</code></p><p><code>1032</code><code>&lt;li&gt;</code></p><p><code>1033</code><code>Computed tomography.&lt;/li&gt;</code></p><p><code>1034</code><code>&lt;li&gt;</code></p><p><code>1035</code><code>Magnetic resonance imaging.&lt;/li&gt;</code></p><p><code>1036</code><code>&lt;li&gt;</code></p><p><code>1037</code><code>Magnetic resonance cholangiopancreatography.&lt;/li&gt;</code></p><p><code>1038</code><code>&lt;/ul&gt;</code></p><p><code>1039</code><code>&lt;/div&gt;</code></p><p><code>1040</code><code>&lt;p id="_257" tabindex="-1"&gt;</code></p><p><code>1041</code><code>These tests demonstrate the extent of the primary tumor and help determine  the presence or absence of distant metastases.&lt;/p&gt;</code></p><p><code>1042</code><code>&lt;p id="_236" tabindex="-1"&gt;</code></p><p><code>1043</code><code>If a patient is medically fit for surgery and the tumor is amenable to surgical resection,  surgical exploration is performed.  Pathological examination of the resected specimen is done to establish definitive pathological staging. &lt;/p&gt;</code></p><p><code>1044</code><code>&lt;/section&gt;</code></p><p><code>1045</code><code>&lt;section id="_7"&gt;</code></p><p><code>1046</code><code>&lt;h3 id="_7_toc"&gt;</code></p><p><code>1047</code><code>Prognosis&lt;/h3&gt;</code></p><p><code>1048</code><code>&lt;p id="_8" tabindex="-1"&gt;</code></p><p><code>1049</code><code>Prognosis depends in part on the tumor&amp;#8217;s anatomical location, which affects resectability.  Because of proximity to major blood vessels and diffuse extension within the liver, a bile duct tumor can be difficult to resect.  Total resection is possible in 25% to 30% of lesions that originate in the distal bile duct; the  resectability rate is lower  for lesions that occur in more proximal sites.[&lt;a href="#cit/section_1.3"&gt;</code></p><p><code>1050</code><code>3&lt;/a&gt;</code></p><p><code>1051</code><code>]  &lt;/p&gt;</code></p><p><code>1052</code><code>&lt;p id="_151" tabindex="-1"&gt;</code></p><p><code>1053</code><code>Complete resection with negative surgical margins offers the only chance of cure for bile duct cancer.  For localized, resectable extrahepatic and intrahepatic tumors,  the presence of involved lymph nodes and perineural invasion are significant adverse prognostic factors.[&lt;a href="#cit/section_1.4"&gt;</code></p><p><code>1054</code><code>4&lt;/a&gt;</code></p><p><code>1055</code><code>-&lt;a href="#cit/section_1.6"&gt;</code></p><p><code>1056</code><code>6&lt;/a&gt;</code></p><p><code>1057</code><code>]&lt;/p&gt;</code></p><p><code>1058</code><code>&lt;p id="_152" tabindex="-1"&gt;</code></p><p><code>1059</code><code>Additionally, among patients with intrahepatic cholangiocarcinomas, worse outcomes have been associated with the following:[&lt;a href="#cit/section_1.7"&gt;</code></p><p><code>1060</code><code>7&lt;/a&gt;</code></p><p><code>1061</code><code>-&lt;a href="#cit/section_1.9"&gt;</code></p><p><code>1062</code><code>9&lt;/a&gt;</code></p><p><code>1063</code><code>]&lt;/p&gt;</code></p><p><code>1064</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>1065</code><code>&lt;ul id="_237"&gt;</code></p><p><code>1066</code><code>&lt;li&gt;</code></p><p><code>1067</code><code>A personal history of primary sclerosing cholangitis.&lt;/li&gt;</code></p><p><code>1068</code><code>&lt;li&gt;</code></p><p><code>1069</code><code>Elevated cancer antigen 19-9 level.&lt;/li&gt;</code></p><p><code>1070</code><code>&lt;li&gt;</code></p><p><code>1071</code><code>Periductal infiltrating tumor growth pattern.&lt;/li&gt;</code></p><p><code>1072</code><code>&lt;li&gt;</code></p><p><code>1073</code><code>Presence of hepatic venous invasion.&lt;/li&gt;</code></p><p><code>1074</code><code>&lt;/ul&gt;</code></p><p><code>1075</code><code>&lt;/div&gt;</code></p><p><code>1076</code><code>&lt;/section&gt;</code></p><p><code>1077</code><code>&lt;h6 do-not-show="toc"&gt;</code></p><p><code>1078</code><code>References&lt;/h6&gt;</code></p><p><code>1079</code><code>&lt;ol&gt;</code></p><p><code>1080</code><code>&lt;li id="section_1.1"&gt;</code></p><p><code>1081</code><code>Siegel R, Ma J, Zou Z, et al.: Cancer statistics, 2014. CA Cancer J Clin 64 (1): 9-29, 2014 Jan-Feb.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=24399786&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=24399786&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1082</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1083</code><code>&lt;/li&gt;</code></p><p><code>1084</code><code>&lt;li id="section_1.2"&gt;</code></p><p><code>1085</code><code>de Groen PC, Gores GJ, LaRusso NF, et al.: Biliary tract cancers. N Engl J Med 341 (18): 1368-78, 1999.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10536130&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10536130&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1086</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1087</code><code>&lt;/li&gt;</code></p><p><code>1088</code><code>&lt;li id="section_1.3"&gt;</code></p><p><code>1089</code><code>Stain SC, Baer HU, Dennison AR, et al.: Current management of hilar cholangiocarcinoma. Surg Gynecol Obstet 175 (6): 579-88, 1992.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=1280374&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=1280374&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1090</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1091</code><code>&lt;/li&gt;</code></p><p><code>1092</code><code>&lt;li id="section_1.4"&gt;</code></p><p><code>1093</code><code>Wakai T, Shirai Y, Moroda T, et al.: Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer 103 (6): 1210-6, 2005.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15685618&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15685618&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1094</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1095</code><code>&lt;/li&gt;</code></p><p><code>1096</code><code>&lt;li id="section_1.5"&gt;</code></p><p><code>1097</code><code>Klempnauer J, Ridder GJ, von Wasielewski R, et al.: Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J Clin Oncol 15 (3): 947-54, 1997.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9060532&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9060532&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1098</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1099</code><code>&lt;/li&gt;</code></p><p><code>1100</code><code>&lt;li id="section_1.6"&gt;</code></p><p><code>1101</code><code>Bhuiya MR, Nimura Y, Kamiya J, et al.: Clinicopathologic studies on perineural invasion of bile duct carcinoma. Ann Surg 215 (4): 344-9, 1992.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=1558415&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=1558415&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1102</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1103</code><code>&lt;/li&gt;</code></p><p><code>1104</code><code>&lt;li id="section_1.7"&gt;</code></p><p><code>1105</code><code>Rosen CB, Nagorney DM, Wiesner RH, et al.: Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 213 (1): 21-5, 1991.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=1845927&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=1845927&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1106</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1107</code><code>&lt;/li&gt;</code></p><p><code>1108</code><code>&lt;li id="section_1.8"&gt;</code></p><p><code>1109</code><code>Shirabe K, Mano Y, Taketomi A, et al.: Clinicopathological prognostic factors after hepatectomy for patients with mass-forming type intrahepatic cholangiocarcinoma: relevance of the lymphatic invasion index. Ann Surg Oncol 17 (7): 1816-22, 2010.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20135355&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20135355&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1110</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1111</code><code>&lt;/li&gt;</code></p><p><code>1112</code><code>&lt;li id="section_1.9"&gt;</code></p><p><code>1113</code><code>Isa T, Kusano T, Shimoji H, et al.: Predictive factors for long-term survival in patients with intrahepatic cholangiocarcinoma. Am J Surg 181 (6): 507-11, 2001.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11513774&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11513774&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1114</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1115</code><code>&lt;/li&gt;</code></p><p><code>1116</code><code>&lt;/ol&gt;</code></p><p><code>1117</code><code>&lt;/div&gt;</code></p><p><code>1118</code><code>          </code></p><p><code>1119</code><code>    &lt;/section&gt;</code></p><p><code>1120</code><code>          </code></p><p><code>1121</code><code>          </code></p><p><code>1122</code><code>          </code></p><p><code>1123</code><code>    &lt;section id="_202"&gt;</code></p><p><code>1124</code><code>          </code></p><p><code>1125</code><code>        &lt;h2&gt;</code></p><p><code>1126</code><code>Cellular Classification of Bile Duct Cancer&lt;/h2&gt;</code></p><p><code>1127</code><code>          </code></p><p><code>1128</code><code>        &lt;div id="_section_202" class="pdq-sections"&gt;</code></p><p><code>1129</code><code>&lt;nav class="in-this-section" role="navigation"&gt;</code></p><p><code>1130</code><code>&lt;h6&gt;</code></p><p><code>1131</code><code>In This Section&lt;/h6&gt;</code></p><p><code>1132</code><code>&lt;ul&gt;</code></p><p><code>1133</code><code>&lt;li&gt;</code></p><p><code>1134</code><code>&lt;a href="#_211_toc"&gt;</code></p><p><code>1135</code><code>Intrahepatic Bile Duct Cancer &lt;/a&gt;</code></p><p><code>1136</code><code>&lt;/li&gt;</code></p><p><code>1137</code><code>&lt;li&gt;</code></p><p><code>1138</code><code>&lt;a href="#_207_toc"&gt;</code></p><p><code>1139</code><code>Perihilar Bile Duct Cancer&lt;/a&gt;</code></p><p><code>1140</code><code>&lt;/li&gt;</code></p><p><code>1141</code><code>&lt;li&gt;</code></p><p><code>1142</code><code>&lt;a href="#_203_toc"&gt;</code></p><p><code>1143</code><code>Distal  Bile Duct Cancer&lt;/a&gt;</code></p><p><code>1144</code><code>&lt;/li&gt;</code></p><p><code>1145</code><code>&lt;/ul&gt;</code></p><p><code>1146</code><code>&lt;/nav&gt;</code></p><p><code>1147</code><code>&lt;section id="_211"&gt;</code></p><p><code>1148</code><code>&lt;h3 id="_211_toc"&gt;</code></p><p><code>1149</code><code>Intrahepatic Bile Duct Cancer &lt;/h3&gt;</code></p><p><code>1150</code><code>&lt;p id="_212" tabindex="-1"&gt;</code></p><p><code>1151</code><code>The most common histopathological types of intrahepatic bile duct tumor include the following:[&lt;a href="#cit/section_2.1"&gt;</code></p><p><code>1152</code><code>1&lt;/a&gt;</code></p><p><code>1153</code><code>]&lt;/p&gt;</code></p><p><code>1154</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>1155</code><code>&lt;ul id="_213"&gt;</code></p><p><code>1156</code><code>&lt;li&gt;</code></p><p><code>1157</code><code>Intrahepatic cholangiocarcinoma.&lt;/li&gt;</code></p><p><code>1158</code><code>&lt;li&gt;</code></p><p><code>1159</code><code>Biliary intraepithelial neoplasia, grade 3 (high-grade dysplasia).&lt;/li&gt;</code></p><p><code>1160</code><code>&lt;li&gt;</code></p><p><code>1161</code><code>Combined hepatocellular-cholangiocarcinoma.&lt;/li&gt;</code></p><p><code>1162</code><code>&lt;li&gt;</code></p><p><code>1163</code><code>Carcinosarcoma.&lt;/li&gt;</code></p><p><code>1164</code><code>&lt;li&gt;</code></p><p><code>1165</code><code>Intraductal papillary neoplasm with an associated invasive carcinoma.&lt;/li&gt;</code></p><p><code>1166</code><code>&lt;li&gt;</code></p><p><code>1167</code><code>Mucinous cystic neoplasm with an associated invasive carcinoma.&lt;/li&gt;</code></p><p><code>1168</code><code>&lt;li&gt;</code></p><p><code>1169</code><code>Neuroendocrine carcinoma.&lt;/li&gt;</code></p><p><code>1170</code><code>&lt;li&gt;</code></p><p><code>1171</code><code>Large cell neuroendocrine carcinoma.&lt;/li&gt;</code></p><p><code>1172</code><code>&lt;li&gt;</code></p><p><code>1173</code><code>Small cell neuroendocrine carcinoma.&lt;/li&gt;</code></p><p><code>1174</code><code>&lt;li&gt;</code></p><p><code>1175</code><code>Intraductal papillary neoplasm with high-grade dysplasia.&lt;/li&gt;</code></p><p><code>1176</code><code>&lt;/ul&gt;</code></p><p><code>1177</code><code>&lt;/div&gt;</code></p><p><code>1178</code><code>&lt;/section&gt;</code></p><p><code>1179</code><code>&lt;section id="_207"&gt;</code></p><p><code>1180</code><code>&lt;h3 id="_207_toc"&gt;</code></p><p><code>1181</code><code>Perihilar Bile Duct Cancer&lt;/h3&gt;</code></p><p><code>1182</code><code>&lt;p id="_208" tabindex="-1"&gt;</code></p><p><code>1183</code><code>Adenocarcinomas are the most common type of perihilar bile duct tumor. The histological types  of perihilar bile duct cancer include the following:[&lt;a href="#cit/section_2.2"&gt;</code></p><p><code>1184</code><code>2&lt;/a&gt;</code></p><p><code>1185</code><code>]&lt;/p&gt;</code></p><p><code>1186</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>1187</code><code>&lt;ul id="_209"&gt;</code></p><p><code>1188</code><code>&lt;li&gt;</code></p><p><code>1189</code><code>Carcinoma &lt;em&gt;</code></p><p><code>1190</code><code>in situ&lt;/em&gt;</code></p><p><code>1191</code><code>.&lt;/li&gt;</code></p><p><code>1192</code><code>&lt;li&gt;</code></p><p><code>1193</code><code>Biliary intraepithelial neoplasia, high grade.&lt;/li&gt;</code></p><p><code>1194</code><code>&lt;li&gt;</code></p><p><code>1195</code><code>Intraductal papillary neoplasm with high-grade dysplasia.&lt;/li&gt;</code></p><p><code>1196</code><code>&lt;li&gt;</code></p><p><code>1197</code><code>Mucinous cystic neoplasm with high-grade intraepithelial neoplasia.&lt;/li&gt;</code></p><p><code>1198</code><code>&lt;li&gt;</code></p><p><code>1199</code><code>Adenocarcinoma.&lt;/li&gt;</code></p><p><code>1200</code><code>&lt;li&gt;</code></p><p><code>1201</code><code>Adenocarcinoma, biliary type.&lt;/li&gt;</code></p><p><code>1202</code><code>&lt;li&gt;</code></p><p><code>1203</code><code>Adenocarcinoma, gastric foveolar type.&lt;/li&gt;</code></p><p><code>1204</code><code>&lt;li&gt;</code></p><p><code>1205</code><code>Adenocarcinoma, intestinal type.</code></p><p><code>1206</code><code>&lt;/li&gt;</code></p><p><code>1207</code><code>&lt;li&gt;</code></p><p><code>1208</code><code>Clear cell adenocarcinoma.&lt;/li&gt;</code></p><p><code>1209</code><code>&lt;li&gt;</code></p><p><code>1210</code><code>Mucinous carcinoma.</code></p><p><code>1211</code><code>&lt;/li&gt;</code></p><p><code>1212</code><code>&lt;li&gt;</code></p><p><code>1213</code><code>Signet-ring cell carcinoma.</code></p><p><code>1214</code><code>&lt;/li&gt;</code></p><p><code>1215</code><code>&lt;li&gt;</code></p><p><code>1216</code><code>Squamous cell carcinoma.&lt;/li&gt;</code></p><p><code>1217</code><code>&lt;li&gt;</code></p><p><code>1218</code><code>Adenosquamous carcinoma.</code></p><p><code>1219</code><code>&lt;/li&gt;</code></p><p><code>1220</code><code>&lt;li&gt;</code></p><p><code>1221</code><code>Undifferentiated carcinoma.&lt;/li&gt;</code></p><p><code>1222</code><code>&lt;li&gt;</code></p><p><code>1223</code><code>High-grade neuroendocrine carcinoma.&lt;/li&gt;</code></p><p><code>1224</code><code>&lt;li&gt;</code></p><p><code>1225</code><code>Small cell neuroendocrine carcinoma.&lt;/li&gt;</code></p><p><code>1226</code><code>&lt;li&gt;</code></p><p><code>1227</code><code>Intraductal papillary neoplasm with an associated invasive carcinoma.&lt;/li&gt;</code></p><p><code>1228</code><code>&lt;li&gt;</code></p><p><code>1229</code><code>Mucinous cystic neoplasm with an associated invasive carcinoma.&lt;/li&gt;</code></p><p><code>1230</code><code>&lt;/ul&gt;</code></p><p><code>1231</code><code>&lt;/div&gt;</code></p><p><code>1232</code><code>&lt;/section&gt;</code></p><p><code>1233</code><code>&lt;section id="_203"&gt;</code></p><p><code>1234</code><code>&lt;h3 id="_203_toc"&gt;</code></p><p><code>1235</code><code>Distal  Bile Duct Cancer&lt;/h3&gt;</code></p><p><code>1236</code><code>&lt;p id="_204" tabindex="-1"&gt;</code></p><p><code>1237</code><code>Adenocarcinomas are the most common type of distal  bile duct tumor. The histological types  of distal  bile duct cancer include the following:[&lt;a href="#cit/section_2.3"&gt;</code></p><p><code>1238</code><code>3&lt;/a&gt;</code></p><p><code>1239</code><code>]&lt;/p&gt;</code></p><p><code>1240</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>1241</code><code>&lt;ul id="_205"&gt;</code></p><p><code>1242</code><code>&lt;li&gt;</code></p><p><code>1243</code><code>Carcinoma &lt;em&gt;</code></p><p><code>1244</code><code>in situ&lt;/em&gt;</code></p><p><code>1245</code><code>.&lt;/li&gt;</code></p><p><code>1246</code><code>&lt;li&gt;</code></p><p><code>1247</code><code>Biliary intraepithelial neoplasia, high grade.&lt;/li&gt;</code></p><p><code>1248</code><code>&lt;li&gt;</code></p><p><code>1249</code><code>Intraductal papillary neoplasm with high-grade intraepithelial neoplasia.&lt;/li&gt;</code></p><p><code>1250</code><code>&lt;li&gt;</code></p><p><code>1251</code><code>Mucinous cystic neoplasm with high-grade intraepithelial neoplasia.&lt;/li&gt;</code></p><p><code>1252</code><code>&lt;li&gt;</code></p><p><code>1253</code><code>Adenocarcinoma.&lt;/li&gt;</code></p><p><code>1254</code><code>&lt;li&gt;</code></p><p><code>1255</code><code>Adenocarcinoma, biliary type.&lt;/li&gt;</code></p><p><code>1256</code><code>&lt;li&gt;</code></p><p><code>1257</code><code>Adenocarcinoma, intestinal type.</code></p><p><code>1258</code><code>&lt;/li&gt;</code></p><p><code>1259</code><code>&lt;li&gt;</code></p><p><code>1260</code><code>Adenocarcinoma, gastric foveolar type.&lt;/li&gt;</code></p><p><code>1261</code><code>&lt;li&gt;</code></p><p><code>1262</code><code>Mucinous adenocarcinoma.&lt;/li&gt;</code></p><p><code>1263</code><code>&lt;li&gt;</code></p><p><code>1264</code><code>Clear cell adenocarcinoma.</code></p><p><code>1265</code><code>&lt;/li&gt;</code></p><p><code>1266</code><code>&lt;li&gt;</code></p><p><code>1267</code><code>Signet-ring cell carcinoma.</code></p><p><code>1268</code><code>&lt;/li&gt;</code></p><p><code>1269</code><code>&lt;li&gt;</code></p><p><code>1270</code><code>Squamous cell carcinoma.&lt;/li&gt;</code></p><p><code>1271</code><code>&lt;li&gt;</code></p><p><code>1272</code><code>Adenosquamous carcinoma.</code></p><p><code>1273</code><code>&lt;/li&gt;</code></p><p><code>1274</code><code>&lt;li&gt;</code></p><p><code>1275</code><code>Undifferentiated carcinoma.&lt;/li&gt;</code></p><p><code>1276</code><code>&lt;li&gt;</code></p><p><code>1277</code><code>High-grade neuroendocrine carcinoma.&lt;/li&gt;</code></p><p><code>1278</code><code>&lt;li&gt;</code></p><p><code>1279</code><code>Small cell neuroendocrine carcinoma.&lt;/li&gt;</code></p><p><code>1280</code><code>&lt;li&gt;</code></p><p><code>1281</code><code>Mixed adenoneuroendocrine carcinoma.&lt;/li&gt;</code></p><p><code>1282</code><code>&lt;li&gt;</code></p><p><code>1283</code><code>Intraductal papillary neoplasm with an associated invasive carcinoma.&lt;/li&gt;</code></p><p><code>1284</code><code>&lt;li&gt;</code></p><p><code>1285</code><code>Mucinous cystic neoplasm with an associated invasive carcinoma.&lt;/li&gt;</code></p><p><code>1286</code><code>&lt;/ul&gt;</code></p><p><code>1287</code><code>&lt;/div&gt;</code></p><p><code>1288</code><code>&lt;/section&gt;</code></p><p><code>1289</code><code>&lt;h6 do-not-show="toc"&gt;</code></p><p><code>1290</code><code>References&lt;/h6&gt;</code></p><p><code>1291</code><code>&lt;ol&gt;</code></p><p><code>1292</code><code>&lt;li id="section_2.1"&gt;</code></p><p><code>1293</code><code>Intrahepatic Bile Ducts. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. Springer; 2017, pp. 295&amp;#8211;302.&lt;/li&gt;</code></p><p><code>1294</code><code>&lt;li id="section_2.2"&gt;</code></p><p><code>1295</code><code>Perihilar bile ducts. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. Springer; 2017, pp. 311&amp;#8211;16.&lt;/li&gt;</code></p><p><code>1296</code><code>&lt;li id="section_2.3"&gt;</code></p><p><code>1297</code><code>Distal bile duct. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. Springer; 2017, pp. 317&amp;#8211;25.&lt;/li&gt;</code></p><p><code>1298</code><code>&lt;/ol&gt;</code></p><p><code>1299</code><code>&lt;/div&gt;</code></p><p><code>1300</code><code>          </code></p><p><code>1301</code><code>    &lt;/section&gt;</code></p><p><code>1302</code><code>          </code></p><p><code>1303</code><code>          </code></p><p><code>1304</code><code>          </code></p><p><code>1305</code><code>    &lt;section id="_25"&gt;</code></p><p><code>1306</code><code>          </code></p><p><code>1307</code><code>        &lt;h2&gt;</code></p><p><code>1308</code><code>Stage Information for Bile Duct Cancer&lt;/h2&gt;</code></p><p><code>1309</code><code>          </code></p><p><code>1310</code><code>        &lt;div id="_section_25" class="pdq-sections"&gt;</code></p><p><code>1311</code><code>&lt;nav class="in-this-section" role="navigation"&gt;</code></p><p><code>1312</code><code>&lt;h6&gt;</code></p><p><code>1313</code><code>In This Section&lt;/h6&gt;</code></p><p><code>1314</code><code>&lt;ul&gt;</code></p><p><code>1315</code><code>&lt;li&gt;</code></p><p><code>1316</code><code>&lt;a href="#_81_toc"&gt;</code></p><p><code>1317</code><code>Staging for Bile Duct Cancer&lt;/a&gt;</code></p><p><code>1318</code><code>&lt;/li&gt;</code></p><p><code>1319</code><code>&lt;li&gt;</code></p><p><code>1320</code><code>&lt;a href="#_26_toc"&gt;</code></p><p><code>1321</code><code>AJCC Staging System for Bile Duct Cancer &lt;ul&gt;</code></p><p><code>1322</code><code>&lt;li&gt;</code></p><p><code>1323</code><code>&lt;a href="#_47_toc"&gt;</code></p><p><code>1324</code><code>AJCC staging system for intrahepatic bile duct cancer&lt;/a&gt;</code></p><p><code>1325</code><code>&lt;/li&gt;</code></p><p><code>1326</code><code>&lt;li&gt;</code></p><p><code>1327</code><code>&lt;a href="#_133_toc"&gt;</code></p><p><code>1328</code><code>AJCC staging system for perihilar bile duct cancer&lt;/a&gt;</code></p><p><code>1329</code><code>&lt;/li&gt;</code></p><p><code>1330</code><code>&lt;li&gt;</code></p><p><code>1331</code><code>&lt;a href="#_34_toc"&gt;</code></p><p><code>1332</code><code>AJCC staging system for distal  bile duct cancer&lt;/a&gt;</code></p><p><code>1333</code><code>&lt;/li&gt;</code></p><p><code>1334</code><code>&lt;/ul&gt;</code></p><p><code>1335</code><code>&lt;/a&gt;</code></p><p><code>1336</code><code>&lt;/li&gt;</code></p><p><code>1337</code><code>&lt;/ul&gt;</code></p><p><code>1338</code><code>&lt;/nav&gt;</code></p><p><code>1339</code><code>&lt;section id="_81"&gt;</code></p><p><code>1340</code><code>&lt;h3 id="_81_toc"&gt;</code></p><p><code>1341</code><code>Staging for Bile Duct Cancer&lt;/h3&gt;</code></p><p><code>1342</code><code>&lt;p id="_82" tabindex="-1"&gt;</code></p><p><code>1343</code><code>Bile duct cancer is classified as resectable (localized) or unresectable, with obvious prognostic importance. The TNM (tumor, node, metastasis) staging system is used for staging bile duct cancer, commonly after surgery and pathological examination of the resected specimen. Evaluation of the extent of disease at laparotomy is an important component of staging.&lt;/p&gt;</code></p><p><code>1344</code><code>&lt;/section&gt;</code></p><p><code>1345</code><code>&lt;section id="_26"&gt;</code></p><p><code>1346</code><code>&lt;h3 id="_26_toc"&gt;</code></p><p><code>1347</code><code>AJCC Staging System for Bile Duct Cancer &lt;/h3&gt;</code></p><p><code>1348</code><code>&lt;section id="_47"&gt;</code></p><p><code>1349</code><code>&lt;h4 id="_47_toc"&gt;</code></p><p><code>1350</code><code>AJCC staging system for intrahepatic bile duct cancer&lt;/h4&gt;</code></p><p><code>1351</code><code>&lt;p id="_50" tabindex="-1"&gt;</code></p><p><code>1352</code><code>The AJCC has designated staging by TNM classification to define intrahepatic bile duct cancer.[&lt;a href="#cit/section_3.1"&gt;</code></p><p><code>1353</code><code>1&lt;/a&gt;</code></p><p><code>1354</code><code>]&lt;/p&gt;</code></p><p><code>1355</code><code>&lt;p id="_55" tabindex="-1"&gt;</code></p><p><code>1356</code><code>Tables &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_353"&gt;</code></p><p><code>1357</code><code>1&lt;/a&gt;</code></p><p><code>1358</code><code>, &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_381"&gt;</code></p><p><code>1359</code><code>2&lt;/a&gt;</code></p><p><code>1360</code><code>, &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_356"&gt;</code></p><p><code>1361</code><code>3&lt;/a&gt;</code></p><p><code>1362</code><code>, &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_379"&gt;</code></p><p><code>1363</code><code>4&lt;/a&gt;</code></p><p><code>1364</code><code>, and &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_359"&gt;</code></p><p><code>1365</code><code>5&lt;/a&gt;</code></p><p><code>1366</code><code> pertain to the intrahepatic bile duct cancer stages.&lt;/p&gt;</code></p><p><code>1367</code><code>&lt;table id="_353" class="table-default expandable-container"&gt;</code></p><p><code>1368</code><code>&lt;caption&gt;</code></p><p><code>1369</code><code>Table 1.  Definitions of TNM Stage 0 Intrahepatic Bile Duct Cancer&lt;span class="sup"&gt;</code></p><p><code>1370</code><code>a&lt;/span&gt;</code></p><p><code>1371</code><code>&lt;/caption&gt;</code></p><p><code>1372</code><code>&lt;colgroup&gt;</code></p><p><code>1373</code><code>&lt;col width="33.33%"&gt;</code></p><p><code>1374</code><code>&lt;col width="33.33%"&gt;</code></p><p><code>1375</code><code>&lt;col width="33.33%"&gt;</code></p><p><code>1376</code><code>&lt;/colgroup&gt;</code></p><p><code>1377</code><code>&lt;THead&gt;</code></p><p><code>1378</code><code>&lt;tr&gt;</code></p><p><code>1379</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1380</code><code>Stage&lt;/th&gt;</code></p><p><code>1381</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1382</code><code>TNM&lt;/th&gt;</code></p><p><code>1383</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1384</code><code>Description&lt;/th&gt;</code></p><p><code>1385</code><code>&lt;/tr&gt;</code></p><p><code>1386</code><code>&lt;/THead&gt;</code></p><p><code>1387</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>1388</code><code>&lt;tr&gt;</code></p><p><code>1389</code><code>&lt;td colspan="3"&gt;</code></p><p><code>1390</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis.&lt;/td&gt;</code></p><p><code>1391</code><code>&lt;/tr&gt;</code></p><p><code>1392</code><code>&lt;tr&gt;</code></p><p><code>1393</code><code>&lt;td colspan="3"&gt;</code></p><p><code>1394</code><code>&lt;span class="sup"&gt;</code></p><p><code>1395</code><code>a&lt;/span&gt;</code></p><p><code>1396</code><code>Reprinted with permission from AJCC: Intrahepatic Bile Duct. In: Amin MB, Edge SB,  Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>1397</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>1398</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 295&amp;#8211;302.&lt;/td&gt;</code></p><p><code>1399</code><code>&lt;/tr&gt;</code></p><p><code>1400</code><code>&lt;/TFoot&gt;</code></p><p><code>1401</code><code>&lt;tbody&gt;</code></p><p><code>1402</code><code>&lt;tr&gt;</code></p><p><code>1403</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1404</code><code>0&lt;/td&gt;</code></p><p><code>1405</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1406</code><code>Tis, N0, M0&lt;/td&gt;</code></p><p><code>1407</code><code>&lt;td&gt;</code></p><p><code>1408</code><code>Tis = Carcinoma &lt;em&gt;</code></p><p><code>1409</code><code>in situ&lt;/em&gt;</code></p><p><code>1410</code><code> (intraductal tumor).&lt;/td&gt;</code></p><p><code>1411</code><code>&lt;/tr&gt;</code></p><p><code>1412</code><code>&lt;tr&gt;</code></p><p><code>1413</code><code>&lt;td&gt;</code></p><p><code>1414</code><code>N0 = No regional lymph node metastasis.&lt;/td&gt;</code></p><p><code>1415</code><code>&lt;/tr&gt;</code></p><p><code>1416</code><code>&lt;tr&gt;</code></p><p><code>1417</code><code>&lt;td&gt;</code></p><p><code>1418</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>1419</code><code>&lt;/tr&gt;</code></p><p><code>1420</code><code>&lt;/tbody&gt;</code></p><p><code>1421</code><code>&lt;/table&gt;</code></p><p><code>1422</code><code>&lt;table id="_381" class="table-default expandable-container"&gt;</code></p><p><code>1423</code><code>&lt;caption&gt;</code></p><p><code>1424</code><code>Table 2.  Definitions of TNM Stage I Intrahepatic Bile Duct Cancer&lt;span class="sup"&gt;</code></p><p><code>1425</code><code>a&lt;/span&gt;</code></p><p><code>1426</code><code>&lt;/caption&gt;</code></p><p><code>1427</code><code>&lt;colgroup&gt;</code></p><p><code>1428</code><code>&lt;col width="11.03%"&gt;</code></p><p><code>1429</code><code>&lt;col width="14.67%"&gt;</code></p><p><code>1430</code><code>&lt;col width="34.76%"&gt;</code></p><p><code>1431</code><code>&lt;col width="39.51%"&gt;</code></p><p><code>1432</code><code>&lt;/colgroup&gt;</code></p><p><code>1433</code><code>&lt;THead&gt;</code></p><p><code>1434</code><code>&lt;tr&gt;</code></p><p><code>1435</code><code>&lt;th colspan="2"&gt;</code></p><p><code>1436</code><code>Stage&lt;/th&gt;</code></p><p><code>1437</code><code>&lt;th&gt;</code></p><p><code>1438</code><code>TNM&lt;/th&gt;</code></p><p><code>1439</code><code>&lt;th&gt;</code></p><p><code>1440</code><code>Description&lt;/th&gt;</code></p><p><code>1441</code><code>&lt;/tr&gt;</code></p><p><code>1442</code><code>&lt;/THead&gt;</code></p><p><code>1443</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>1444</code><code>&lt;tr&gt;</code></p><p><code>1445</code><code>&lt;td colspan="4"&gt;</code></p><p><code>1446</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis.&lt;/td&gt;</code></p><p><code>1447</code><code>&lt;/tr&gt;</code></p><p><code>1448</code><code>&lt;tr&gt;</code></p><p><code>1449</code><code>&lt;td colspan="4"&gt;</code></p><p><code>1450</code><code>&lt;span class="sup"&gt;</code></p><p><code>1451</code><code>a&lt;/span&gt;</code></p><p><code>1452</code><code>Reprinted with permission from AJCC: Intrahepatic Bile Duct. In: Amin MB, Edge SB,  Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>1453</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>1454</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 295&amp;#8211;302.&lt;/td&gt;</code></p><p><code>1455</code><code>&lt;/tr&gt;</code></p><p><code>1456</code><code>&lt;/TFoot&gt;</code></p><p><code>1457</code><code>&lt;tbody&gt;</code></p><p><code>1458</code><code>&lt;tr&gt;</code></p><p><code>1459</code><code>&lt;td rowspan="6"&gt;</code></p><p><code>1460</code><code>I&lt;/td&gt;</code></p><p><code>1461</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1462</code><code>IA&lt;/td&gt;</code></p><p><code>1463</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1464</code><code>T1a, N0, M0&lt;/td&gt;</code></p><p><code>1465</code><code>&lt;td&gt;</code></p><p><code>1466</code><code>T1a = Solitary tumor &amp;#8804;5 cm without vascular invasion.&lt;/td&gt;</code></p><p><code>1467</code><code>&lt;/tr&gt;</code></p><p><code>1468</code><code>&lt;tr&gt;</code></p><p><code>1469</code><code>&lt;td&gt;</code></p><p><code>1470</code><code>N0 = No regional lymph node metastasis.&lt;/td&gt;</code></p><p><code>1471</code><code>&lt;/tr&gt;</code></p><p><code>1472</code><code>&lt;tr&gt;</code></p><p><code>1473</code><code>&lt;td&gt;</code></p><p><code>1474</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>1475</code><code>&lt;/tr&gt;</code></p><p><code>1476</code><code>&lt;tr&gt;</code></p><p><code>1477</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1478</code><code>IB&lt;/td&gt;</code></p><p><code>1479</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1480</code><code>T1b, N0, M0&lt;/td&gt;</code></p><p><code>1481</code><code>&lt;td&gt;</code></p><p><code>1482</code><code>T1b = Solitary tumor &amp;gt;5 cm without vascular invasion.&lt;/td&gt;</code></p><p><code>1483</code><code>&lt;/tr&gt;</code></p><p><code>1484</code><code>&lt;tr&gt;</code></p><p><code>1485</code><code>&lt;td&gt;</code></p><p><code>1486</code><code>N0 = No regional lymph node metastasis.&lt;/td&gt;</code></p><p><code>1487</code><code>&lt;/tr&gt;</code></p><p><code>1488</code><code>&lt;tr&gt;</code></p><p><code>1489</code><code>&lt;td&gt;</code></p><p><code>1490</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>1491</code><code>&lt;/tr&gt;</code></p><p><code>1492</code><code>&lt;/tbody&gt;</code></p><p><code>1493</code><code>&lt;/table&gt;</code></p><p><code>1494</code><code>&lt;table id="_356" class="table-default expandable-container"&gt;</code></p><p><code>1495</code><code>&lt;caption&gt;</code></p><p><code>1496</code><code>Table 3.  Definitions of TNM Stage II Intrahepatic Bile Duct Cancer&lt;span class="sup"&gt;</code></p><p><code>1497</code><code>a&lt;/span&gt;</code></p><p><code>1498</code><code>&lt;/caption&gt;</code></p><p><code>1499</code><code>&lt;colgroup&gt;</code></p><p><code>1500</code><code>&lt;col width="20.04%"&gt;</code></p><p><code>1501</code><code>&lt;col width="21.24%"&gt;</code></p><p><code>1502</code><code>&lt;col width="58.71%"&gt;</code></p><p><code>1503</code><code>&lt;/colgroup&gt;</code></p><p><code>1504</code><code>&lt;THead&gt;</code></p><p><code>1505</code><code>&lt;tr&gt;</code></p><p><code>1506</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1507</code><code>Stage&lt;/th&gt;</code></p><p><code>1508</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1509</code><code>TNM&lt;/th&gt;</code></p><p><code>1510</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1511</code><code>Description&lt;/th&gt;</code></p><p><code>1512</code><code>&lt;/tr&gt;</code></p><p><code>1513</code><code>&lt;/THead&gt;</code></p><p><code>1514</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>1515</code><code>&lt;tr&gt;</code></p><p><code>1516</code><code>&lt;td colspan="3"&gt;</code></p><p><code>1517</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis.&lt;/td&gt;</code></p><p><code>1518</code><code>&lt;/tr&gt;</code></p><p><code>1519</code><code>&lt;tr&gt;</code></p><p><code>1520</code><code>&lt;td colspan="3"&gt;</code></p><p><code>1521</code><code>&lt;span class="sup"&gt;</code></p><p><code>1522</code><code>a&lt;/span&gt;</code></p><p><code>1523</code><code>Reprinted with permission from AJCC: Intrahepatic Bile Duct. In: Amin MB, Edge SB,  Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>1524</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>1525</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 295&amp;#8211;302.&lt;/td&gt;</code></p><p><code>1526</code><code>&lt;/tr&gt;</code></p><p><code>1527</code><code>&lt;/TFoot&gt;</code></p><p><code>1528</code><code>&lt;tbody&gt;</code></p><p><code>1529</code><code>&lt;tr&gt;</code></p><p><code>1530</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1531</code><code>II&lt;/td&gt;</code></p><p><code>1532</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1533</code><code>T2, N0, M0&lt;/td&gt;</code></p><p><code>1534</code><code>&lt;td&gt;</code></p><p><code>1535</code><code>T2 = Solitary tumor with intrahepatic vascular invasion or multiple tumors, with or without vascular invasion.&lt;/td&gt;</code></p><p><code>1536</code><code>&lt;/tr&gt;</code></p><p><code>1537</code><code>&lt;tr&gt;</code></p><p><code>1538</code><code>&lt;td&gt;</code></p><p><code>1539</code><code>N0 = No regional lymph node metastasis.&lt;/td&gt;</code></p><p><code>1540</code><code>&lt;/tr&gt;</code></p><p><code>1541</code><code>&lt;tr&gt;</code></p><p><code>1542</code><code>&lt;td&gt;</code></p><p><code>1543</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>1544</code><code>&lt;/tr&gt;</code></p><p><code>1545</code><code>&lt;/tbody&gt;</code></p><p><code>1546</code><code>&lt;/table&gt;</code></p><p><code>1547</code><code>&lt;table id="_379" class="table-default expandable-container"&gt;</code></p><p><code>1548</code><code>&lt;caption&gt;</code></p><p><code>1549</code><code>Table 4.  Definitions of TNM Stage III Intrahepatic Bile Duct Cancer&lt;span class="sup"&gt;</code></p><p><code>1550</code><code>a&lt;/span&gt;</code></p><p><code>1551</code><code>&lt;/caption&gt;</code></p><p><code>1552</code><code>&lt;colgroup&gt;</code></p><p><code>1553</code><code>&lt;col width="16.23%"&gt;</code></p><p><code>1554</code><code>&lt;col width="26.46%"&gt;</code></p><p><code>1555</code><code>&lt;col width="20.45%"&gt;</code></p><p><code>1556</code><code>&lt;col width="36.85%"&gt;</code></p><p><code>1557</code><code>&lt;/colgroup&gt;</code></p><p><code>1558</code><code>&lt;THead&gt;</code></p><p><code>1559</code><code>&lt;tr&gt;</code></p><p><code>1560</code><code>&lt;th colspan="2"&gt;</code></p><p><code>1561</code><code>Stage&lt;/th&gt;</code></p><p><code>1562</code><code>&lt;th&gt;</code></p><p><code>1563</code><code>TNM&lt;/th&gt;</code></p><p><code>1564</code><code>&lt;th&gt;</code></p><p><code>1565</code><code>Description&lt;/th&gt;</code></p><p><code>1566</code><code>&lt;/tr&gt;</code></p><p><code>1567</code><code>&lt;/THead&gt;</code></p><p><code>1568</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>1569</code><code>&lt;tr&gt;</code></p><p><code>1570</code><code>&lt;td colspan="4"&gt;</code></p><p><code>1571</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis.&lt;/td&gt;</code></p><p><code>1572</code><code>&lt;/tr&gt;</code></p><p><code>1573</code><code>&lt;tr&gt;</code></p><p><code>1574</code><code>&lt;td colspan="4"&gt;</code></p><p><code>1575</code><code>&lt;span class="sup"&gt;</code></p><p><code>1576</code><code>a&lt;/span&gt;</code></p><p><code>1577</code><code>Reprinted with permission from AJCC: Intrahepatic Bile Duct. In: Amin MB, Edge SB,  Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>1578</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>1579</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 295&amp;#8211;302.&lt;/td&gt;</code></p><p><code>1580</code><code>&lt;/tr&gt;</code></p><p><code>1581</code><code>&lt;/TFoot&gt;</code></p><p><code>1582</code><code>&lt;tbody&gt;</code></p><p><code>1583</code><code>&lt;tr&gt;</code></p><p><code>1584</code><code>&lt;td rowspan="17"&gt;</code></p><p><code>1585</code><code>III&lt;/td&gt;</code></p><p><code>1586</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1587</code><code>IIIA&lt;/td&gt;</code></p><p><code>1588</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1589</code><code>T3, N0, M0&lt;/td&gt;</code></p><p><code>1590</code><code>&lt;td&gt;</code></p><p><code>1591</code><code>T3 =Tumor perforating the visceral peritoneum.&lt;/td&gt;</code></p><p><code>1592</code><code>&lt;/tr&gt;</code></p><p><code>1593</code><code>&lt;tr&gt;</code></p><p><code>1594</code><code>&lt;td&gt;</code></p><p><code>1595</code><code>N0 = No regional lymph node metastasis.&lt;/td&gt;</code></p><p><code>1596</code><code>&lt;/tr&gt;</code></p><p><code>1597</code><code>&lt;tr&gt;</code></p><p><code>1598</code><code>&lt;td&gt;</code></p><p><code>1599</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>1600</code><code>&lt;/tr&gt;</code></p><p><code>1601</code><code>&lt;tr&gt;</code></p><p><code>1602</code><code>&lt;td rowspan="14"&gt;</code></p><p><code>1603</code><code>IIIB&lt;/td&gt;</code></p><p><code>1604</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1605</code><code>T4, N0, M0&lt;/td&gt;</code></p><p><code>1606</code><code>&lt;td&gt;</code></p><p><code>1607</code><code>T4 = Tumor involving local extrahepatic structures by direct invasion.&lt;/td&gt;</code></p><p><code>1608</code><code>&lt;/tr&gt;</code></p><p><code>1609</code><code>&lt;tr&gt;</code></p><p><code>1610</code><code>&lt;td&gt;</code></p><p><code>1611</code><code>N0 = No regional lymph node metastasis.&lt;/td&gt;</code></p><p><code>1612</code><code>&lt;/tr&gt;</code></p><p><code>1613</code><code>&lt;tr&gt;</code></p><p><code>1614</code><code>&lt;td&gt;</code></p><p><code>1615</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>1616</code><code>&lt;/tr&gt;</code></p><p><code>1617</code><code>&lt;tr&gt;</code></p><p><code>1618</code><code>&lt;td rowspan="11"&gt;</code></p><p><code>1619</code><code>Any T, N1, M0&lt;/td&gt;</code></p><p><code>1620</code><code>&lt;td&gt;</code></p><p><code>1621</code><code>TX = Primary tumor cannot be assessed.&lt;/td&gt;</code></p><p><code>1622</code><code>&lt;/tr&gt;</code></p><p><code>1623</code><code>&lt;tr&gt;</code></p><p><code>1624</code><code>&lt;td&gt;</code></p><p><code>1625</code><code>T0 = No evidence of primary tumor.&lt;/td&gt;</code></p><p><code>1626</code><code>&lt;/tr&gt;</code></p><p><code>1627</code><code>&lt;tr&gt;</code></p><p><code>1628</code><code>&lt;td&gt;</code></p><p><code>1629</code><code>Tis = Carcinoma&lt;em&gt;</code></p><p><code>1630</code><code> in situ&lt;/em&gt;</code></p><p><code>1631</code><code> (intraductal tumor).&lt;/td&gt;</code></p><p><code>1632</code><code>&lt;/tr&gt;</code></p><p><code>1633</code><code>&lt;tr&gt;</code></p><p><code>1634</code><code>&lt;td&gt;</code></p><p><code>1635</code><code>T1 = Solitary tumor without vascular invasion, &amp;#8804;5 cm or &amp;gt;5 cm.&lt;/td&gt;</code></p><p><code>1636</code><code>&lt;/tr&gt;</code></p><p><code>1637</code><code>&lt;tr&gt;</code></p><p><code>1638</code><code>&lt;td&gt;</code></p><p><code>1639</code><code>&amp;#8211;T1a = Solitary tumor &amp;#8804;5 cm  without vascular invasion.&lt;/td&gt;</code></p><p><code>1640</code><code>&lt;/tr&gt;</code></p><p><code>1641</code><code>&lt;tr&gt;</code></p><p><code>1642</code><code>&lt;td&gt;</code></p><p><code>1643</code><code>&amp;#8211;T1b = Solitary tumor &amp;gt;5 cm without vascular invasion.&lt;/td&gt;</code></p><p><code>1644</code><code>&lt;/tr&gt;</code></p><p><code>1645</code><code>&lt;tr&gt;</code></p><p><code>1646</code><code>&lt;td&gt;</code></p><p><code>1647</code><code>T2 = Solitary tumor with intrahepatic vascular invasion or multiple tumors, with or without vascular invasion.&lt;/td&gt;</code></p><p><code>1648</code><code>&lt;/tr&gt;</code></p><p><code>1649</code><code>&lt;tr&gt;</code></p><p><code>1650</code><code>&lt;td&gt;</code></p><p><code>1651</code><code>T3 = Tumor perforating the visceral peritoneum.&lt;/td&gt;</code></p><p><code>1652</code><code>&lt;/tr&gt;</code></p><p><code>1653</code><code>&lt;tr&gt;</code></p><p><code>1654</code><code>&lt;td&gt;</code></p><p><code>1655</code><code>T4 = Tumor involving local extrahepatic structures by direct invasion.&lt;/td&gt;</code></p><p><code>1656</code><code>&lt;/tr&gt;</code></p><p><code>1657</code><code>&lt;tr&gt;</code></p><p><code>1658</code><code>&lt;td&gt;</code></p><p><code>1659</code><code>N1 =   Regional lymph node metastasis present.&lt;/td&gt;</code></p><p><code>1660</code><code>&lt;/tr&gt;</code></p><p><code>1661</code><code>&lt;tr&gt;</code></p><p><code>1662</code><code>&lt;td&gt;</code></p><p><code>1663</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>1664</code><code>&lt;/tr&gt;</code></p><p><code>1665</code><code>&lt;/tbody&gt;</code></p><p><code>1666</code><code>&lt;/table&gt;</code></p><p><code>1667</code><code>&lt;table id="_359" class="table-default expandable-container"&gt;</code></p><p><code>1668</code><code>&lt;caption&gt;</code></p><p><code>1669</code><code>Table 5.  Definitions of TNM Stage IV Intrahepatic Bile Duct Cancer&lt;span class="sup"&gt;</code></p><p><code>1670</code><code>a&lt;/span&gt;</code></p><p><code>1671</code><code>&lt;/caption&gt;</code></p><p><code>1672</code><code>&lt;colgroup&gt;</code></p><p><code>1673</code><code>&lt;col width="22.01%"&gt;</code></p><p><code>1674</code><code>&lt;col width="20.57%"&gt;</code></p><p><code>1675</code><code>&lt;col width="57.40%"&gt;</code></p><p><code>1676</code><code>&lt;/colgroup&gt;</code></p><p><code>1677</code><code>&lt;THead&gt;</code></p><p><code>1678</code><code>&lt;tr&gt;</code></p><p><code>1679</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1680</code><code>Stage&lt;/th&gt;</code></p><p><code>1681</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1682</code><code>TNM&lt;/th&gt;</code></p><p><code>1683</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1684</code><code>Description&lt;/th&gt;</code></p><p><code>1685</code><code>&lt;/tr&gt;</code></p><p><code>1686</code><code>&lt;/THead&gt;</code></p><p><code>1687</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>1688</code><code>&lt;tr&gt;</code></p><p><code>1689</code><code>&lt;td colspan="3"&gt;</code></p><p><code>1690</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis.&lt;/td&gt;</code></p><p><code>1691</code><code>&lt;/tr&gt;</code></p><p><code>1692</code><code>&lt;tr&gt;</code></p><p><code>1693</code><code>&lt;td colspan="3"&gt;</code></p><p><code>1694</code><code>&lt;span class="sup"&gt;</code></p><p><code>1695</code><code>a&lt;/span&gt;</code></p><p><code>1696</code><code>Reprinted with permission from AJCC: Intrahepatic Bile Duct. In: Amin MB, Edge SB,  Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>1697</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>1698</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 295&amp;#8211;302.&lt;/td&gt;</code></p><p><code>1699</code><code>&lt;/tr&gt;</code></p><p><code>1700</code><code>&lt;/TFoot&gt;</code></p><p><code>1701</code><code>&lt;tbody&gt;</code></p><p><code>1702</code><code>&lt;tr&gt;</code></p><p><code>1703</code><code>&lt;td rowspan="13"&gt;</code></p><p><code>1704</code><code>IV&lt;/td&gt;</code></p><p><code>1705</code><code>&lt;td rowspan="13"&gt;</code></p><p><code>1706</code><code>Any T, Any N, M1&lt;/td&gt;</code></p><p><code>1707</code><code>&lt;td&gt;</code></p><p><code>1708</code><code>TX = Primary tumor cannot be assessed.&lt;/td&gt;</code></p><p><code>1709</code><code>&lt;/tr&gt;</code></p><p><code>1710</code><code>&lt;tr&gt;</code></p><p><code>1711</code><code>&lt;td&gt;</code></p><p><code>1712</code><code>T0 = No evidence of primary tumor.&lt;/td&gt;</code></p><p><code>1713</code><code>&lt;/tr&gt;</code></p><p><code>1714</code><code>&lt;tr&gt;</code></p><p><code>1715</code><code>&lt;td&gt;</code></p><p><code>1716</code><code>Tis = Carcinoma&lt;em&gt;</code></p><p><code>1717</code><code> in situ&lt;/em&gt;</code></p><p><code>1718</code><code> (intraductal tumor).&lt;/td&gt;</code></p><p><code>1719</code><code>&lt;/tr&gt;</code></p><p><code>1720</code><code>&lt;tr&gt;</code></p><p><code>1721</code><code>&lt;td&gt;</code></p><p><code>1722</code><code>T1 = Solitary tumor without vascular invasion, &amp;#8804;5 cm or &amp;gt;5 cm.&lt;/td&gt;</code></p><p><code>1723</code><code>&lt;/tr&gt;</code></p><p><code>1724</code><code>&lt;tr&gt;</code></p><p><code>1725</code><code>&lt;td&gt;</code></p><p><code>1726</code><code>&amp;#8211;T1a = Solitary tumor &amp;#8804;5 cm  without vascular invasion.&lt;/td&gt;</code></p><p><code>1727</code><code>&lt;/tr&gt;</code></p><p><code>1728</code><code>&lt;tr&gt;</code></p><p><code>1729</code><code>&lt;td&gt;</code></p><p><code>1730</code><code>&amp;#8211;T1b = Solitary tumor &amp;gt;5 cm without vascular invasion.&lt;/td&gt;</code></p><p><code>1731</code><code>&lt;/tr&gt;</code></p><p><code>1732</code><code>&lt;tr&gt;</code></p><p><code>1733</code><code>&lt;td&gt;</code></p><p><code>1734</code><code>T2 = Solitary tumor with intrahepatic vascular invasion or multiple tumors, with or without vascular invasion.&lt;/td&gt;</code></p><p><code>1735</code><code>&lt;/tr&gt;</code></p><p><code>1736</code><code>&lt;tr&gt;</code></p><p><code>1737</code><code>&lt;td&gt;</code></p><p><code>1738</code><code>T3 = Tumor perforating the visceral peritoneum.&lt;/td&gt;</code></p><p><code>1739</code><code>&lt;/tr&gt;</code></p><p><code>1740</code><code>&lt;tr&gt;</code></p><p><code>1741</code><code>&lt;td&gt;</code></p><p><code>1742</code><code>T4 = Tumor involving local extrahepatic structures by direct invasion.&lt;/td&gt;</code></p><p><code>1743</code><code>&lt;/tr&gt;</code></p><p><code>1744</code><code>&lt;tr&gt;</code></p><p><code>1745</code><code>&lt;td&gt;</code></p><p><code>1746</code><code>NX = Regional lymph nodes cannot be assessed.&lt;/td&gt;</code></p><p><code>1747</code><code>&lt;/tr&gt;</code></p><p><code>1748</code><code>&lt;tr&gt;</code></p><p><code>1749</code><code>&lt;td&gt;</code></p><p><code>1750</code><code>N0 = No regional lymph node metastasis.&lt;/td&gt;</code></p><p><code>1751</code><code>&lt;/tr&gt;</code></p><p><code>1752</code><code>&lt;tr&gt;</code></p><p><code>1753</code><code>&lt;td&gt;</code></p><p><code>1754</code><code>N1 =   Regional lymph node metastasis present.&lt;/td&gt;</code></p><p><code>1755</code><code>&lt;/tr&gt;</code></p><p><code>1756</code><code>&lt;tr&gt;</code></p><p><code>1757</code><code>&lt;td&gt;</code></p><p><code>1758</code><code>M1 = Distant metastasis present.&lt;/td&gt;</code></p><p><code>1759</code><code>&lt;/tr&gt;</code></p><p><code>1760</code><code>&lt;/tbody&gt;</code></p><p><code>1761</code><code>&lt;/table&gt;</code></p><p><code>1762</code><code>&lt;/section&gt;</code></p><p><code>1763</code><code>&lt;section id="_133"&gt;</code></p><p><code>1764</code><code>&lt;h4 id="_133_toc"&gt;</code></p><p><code>1765</code><code>AJCC staging system for perihilar bile duct cancer&lt;/h4&gt;</code></p><p><code>1766</code><code>&lt;p id="_134" tabindex="-1"&gt;</code></p><p><code>1767</code><code>The AJCC has designated staging by TNM classification to define perihilar bile duct cancer.[&lt;a href="#cit/section_3.2"&gt;</code></p><p><code>1768</code><code>2&lt;/a&gt;</code></p><p><code>1769</code><code>]&lt;/p&gt;</code></p><p><code>1770</code><code>&lt;p id="_154" tabindex="-1"&gt;</code></p><p><code>1771</code><code>Tables &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_360"&gt;</code></p><p><code>1772</code><code>6&lt;/a&gt;</code></p><p><code>1773</code><code>, &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_281"&gt;</code></p><p><code>1774</code><code>7&lt;/a&gt;</code></p><p><code>1775</code><code>, &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_361"&gt;</code></p><p><code>1776</code><code>8&lt;/a&gt;</code></p><p><code>1777</code><code>, &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_380"&gt;</code></p><p><code>1778</code><code>9&lt;/a&gt;</code></p><p><code>1779</code><code>, and &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_364"&gt;</code></p><p><code>1780</code><code>10&lt;/a&gt;</code></p><p><code>1781</code><code>   pertain to the perihilar bile duct cancer stages.&lt;/p&gt;</code></p><p><code>1782</code><code>&lt;table id="_360" class="table-default expandable-container"&gt;</code></p><p><code>1783</code><code>&lt;caption&gt;</code></p><p><code>1784</code><code>Table 6.  Definitions of TNM Stage 0 Perihilar Bile Duct Cancer&lt;span class="sup"&gt;</code></p><p><code>1785</code><code>a&lt;/span&gt;</code></p><p><code>1786</code><code>&lt;/caption&gt;</code></p><p><code>1787</code><code>&lt;colgroup&gt;</code></p><p><code>1788</code><code>&lt;col width="20.04%"&gt;</code></p><p><code>1789</code><code>&lt;col width="20.04%"&gt;</code></p><p><code>1790</code><code>&lt;col width="59.91%"&gt;</code></p><p><code>1791</code><code>&lt;/colgroup&gt;</code></p><p><code>1792</code><code>&lt;THead&gt;</code></p><p><code>1793</code><code>&lt;tr&gt;</code></p><p><code>1794</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1795</code><code>Stage&lt;/th&gt;</code></p><p><code>1796</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1797</code><code>TNM&lt;/th&gt;</code></p><p><code>1798</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1799</code><code>Description&lt;/th&gt;</code></p><p><code>1800</code><code>&lt;/tr&gt;</code></p><p><code>1801</code><code>&lt;/THead&gt;</code></p><p><code>1802</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>1803</code><code>&lt;tr&gt;</code></p><p><code>1804</code><code>&lt;td colspan="3"&gt;</code></p><p><code>1805</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis.&lt;/td&gt;</code></p><p><code>1806</code><code>&lt;/tr&gt;</code></p><p><code>1807</code><code>&lt;tr&gt;</code></p><p><code>1808</code><code>&lt;td colspan="3"&gt;</code></p><p><code>1809</code><code>&lt;span class="sup"&gt;</code></p><p><code>1810</code><code>a&lt;/span&gt;</code></p><p><code>1811</code><code>Reprinted with permission from AJCC: Perihilar Bile Ducts. In: Amin MB, Edge SB,  Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>1812</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>1813</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 311&amp;#8211;6.&lt;/td&gt;</code></p><p><code>1814</code><code>&lt;/tr&gt;</code></p><p><code>1815</code><code>&lt;/TFoot&gt;</code></p><p><code>1816</code><code>&lt;tbody&gt;</code></p><p><code>1817</code><code>&lt;tr&gt;</code></p><p><code>1818</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1819</code><code>0&lt;/td&gt;</code></p><p><code>1820</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1821</code><code>Tis, N0, M0&lt;/td&gt;</code></p><p><code>1822</code><code>&lt;td&gt;</code></p><p><code>1823</code><code>Tis = Carcinoma &lt;em&gt;</code></p><p><code>1824</code><code>in situ&lt;/em&gt;</code></p><p><code>1825</code><code>/high-grade dysplasia.&lt;/td&gt;</code></p><p><code>1826</code><code>&lt;/tr&gt;</code></p><p><code>1827</code><code>&lt;tr&gt;</code></p><p><code>1828</code><code>&lt;td&gt;</code></p><p><code>1829</code><code>N0 = No regional lymph node metastasis.&lt;/td&gt;</code></p><p><code>1830</code><code>&lt;/tr&gt;</code></p><p><code>1831</code><code>&lt;tr&gt;</code></p><p><code>1832</code><code>&lt;td&gt;</code></p><p><code>1833</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>1834</code><code>&lt;/tr&gt;</code></p><p><code>1835</code><code>&lt;/tbody&gt;</code></p><p><code>1836</code><code>&lt;/table&gt;</code></p><p><code>1837</code><code>&lt;table id="_281" class="table-default expandable-container"&gt;</code></p><p><code>1838</code><code>&lt;caption&gt;</code></p><p><code>1839</code><code>Table 7.  Definitions of TNM Stage I Perihilar Bile Duct Cancer&lt;span class="sup"&gt;</code></p><p><code>1840</code><code>a&lt;/span&gt;</code></p><p><code>1841</code><code>&lt;/caption&gt;</code></p><p><code>1842</code><code>&lt;colgroup&gt;</code></p><p><code>1843</code><code>&lt;col width="22.02%"&gt;</code></p><p><code>1844</code><code>&lt;col width="19.84%"&gt;</code></p><p><code>1845</code><code>&lt;col width="58.13%"&gt;</code></p><p><code>1846</code><code>&lt;/colgroup&gt;</code></p><p><code>1847</code><code>&lt;THead&gt;</code></p><p><code>1848</code><code>&lt;tr&gt;</code></p><p><code>1849</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1850</code><code>Stage&lt;/th&gt;</code></p><p><code>1851</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1852</code><code>TNM&lt;/th&gt;</code></p><p><code>1853</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1854</code><code>Description&lt;/th&gt;</code></p><p><code>1855</code><code>&lt;/tr&gt;</code></p><p><code>1856</code><code>&lt;/THead&gt;</code></p><p><code>1857</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>1858</code><code>&lt;tr&gt;</code></p><p><code>1859</code><code>&lt;td colspan="3"&gt;</code></p><p><code>1860</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis.&lt;/td&gt;</code></p><p><code>1861</code><code>&lt;/tr&gt;</code></p><p><code>1862</code><code>&lt;tr&gt;</code></p><p><code>1863</code><code>&lt;td colspan="3"&gt;</code></p><p><code>1864</code><code>&lt;span class="sup"&gt;</code></p><p><code>1865</code><code>a&lt;/span&gt;</code></p><p><code>1866</code><code>Reprinted with permission from AJCC: Perihilar Bile Ducts. In: Amin MB, Edge SB,  Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>1867</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>1868</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 311&amp;#8211;6.&lt;/td&gt;</code></p><p><code>1869</code><code>&lt;/tr&gt;</code></p><p><code>1870</code><code>&lt;/TFoot&gt;</code></p><p><code>1871</code><code>&lt;tbody&gt;</code></p><p><code>1872</code><code>&lt;tr&gt;</code></p><p><code>1873</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1874</code><code>I&lt;/td&gt;</code></p><p><code>1875</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1876</code><code>T1, N0, M0&lt;/td&gt;</code></p><p><code>1877</code><code>&lt;td&gt;</code></p><p><code>1878</code><code>T1 = Tumor confined to the bile duct, with extension up to the muscle layer or fibrous tissue. &lt;/td&gt;</code></p><p><code>1879</code><code>&lt;/tr&gt;</code></p><p><code>1880</code><code>&lt;tr&gt;</code></p><p><code>1881</code><code>&lt;td&gt;</code></p><p><code>1882</code><code>N0 = No regional lymph node metastasis. &lt;/td&gt;</code></p><p><code>1883</code><code>&lt;/tr&gt;</code></p><p><code>1884</code><code>&lt;tr&gt;</code></p><p><code>1885</code><code>&lt;td&gt;</code></p><p><code>1886</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>1887</code><code>&lt;/tr&gt;</code></p><p><code>1888</code><code>&lt;/tbody&gt;</code></p><p><code>1889</code><code>&lt;/table&gt;</code></p><p><code>1890</code><code>&lt;table id="_361" class="table-default expandable-container"&gt;</code></p><p><code>1891</code><code>&lt;caption&gt;</code></p><p><code>1892</code><code>Table 8.  Definitions of TNM Stage II Perihilar Bile Duct Cancer&lt;span class="sup"&gt;</code></p><p><code>1893</code><code>a&lt;/span&gt;</code></p><p><code>1894</code><code>&lt;/caption&gt;</code></p><p><code>1895</code><code>&lt;colgroup&gt;</code></p><p><code>1896</code><code>&lt;col width="18.99%"&gt;</code></p><p><code>1897</code><code>&lt;col width="18.62%"&gt;</code></p><p><code>1898</code><code>&lt;col width="62.38%"&gt;</code></p><p><code>1899</code><code>&lt;/colgroup&gt;</code></p><p><code>1900</code><code>&lt;THead&gt;</code></p><p><code>1901</code><code>&lt;tr&gt;</code></p><p><code>1902</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1903</code><code>Stage &lt;/th&gt;</code></p><p><code>1904</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1905</code><code>TNM&lt;/th&gt;</code></p><p><code>1906</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1907</code><code>Description&lt;/th&gt;</code></p><p><code>1908</code><code>&lt;/tr&gt;</code></p><p><code>1909</code><code>&lt;/THead&gt;</code></p><p><code>1910</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>1911</code><code>&lt;tr&gt;</code></p><p><code>1912</code><code>&lt;td colspan="3"&gt;</code></p><p><code>1913</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis.&lt;/td&gt;</code></p><p><code>1914</code><code>&lt;/tr&gt;</code></p><p><code>1915</code><code>&lt;tr&gt;</code></p><p><code>1916</code><code>&lt;td colspan="3"&gt;</code></p><p><code>1917</code><code>&lt;span class="sup"&gt;</code></p><p><code>1918</code><code>a&lt;/span&gt;</code></p><p><code>1919</code><code>Reprinted with permission from AJCC: Perihilar Bile Ducts. In: Amin MB, Edge SB,  Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>1920</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>1921</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 311&amp;#8211;6.&lt;/td&gt;</code></p><p><code>1922</code><code>&lt;/tr&gt;</code></p><p><code>1923</code><code>&lt;/TFoot&gt;</code></p><p><code>1924</code><code>&lt;tbody&gt;</code></p><p><code>1925</code><code>&lt;tr&gt;</code></p><p><code>1926</code><code>&lt;td rowspan="5"&gt;</code></p><p><code>1927</code><code>II&lt;/td&gt;</code></p><p><code>1928</code><code>&lt;td rowspan="5"&gt;</code></p><p><code>1929</code><code>T2a&amp;#8211;b, N0, M0&lt;/td&gt;</code></p><p><code>1930</code><code>&lt;td&gt;</code></p><p><code>1931</code><code>T2 = Tumor invades beyond the wall of the bile duct to surrounding adipose tissue, or tumor invades adjacent hepatic parenchyma.&lt;/td&gt;</code></p><p><code>1932</code><code>&lt;/tr&gt;</code></p><p><code>1933</code><code>&lt;tr&gt;</code></p><p><code>1934</code><code>&lt;td&gt;</code></p><p><code>1935</code><code>&amp;#8211;T2a = Tumor invades beyond the wall of the bile duct to surrounding adipose tissue.&lt;/td&gt;</code></p><p><code>1936</code><code>&lt;/tr&gt;</code></p><p><code>1937</code><code>&lt;tr&gt;</code></p><p><code>1938</code><code>&lt;td&gt;</code></p><p><code>1939</code><code>&amp;#8211;T2b = Tumor invades adjacent hepatic parenchyma.&lt;/td&gt;</code></p><p><code>1940</code><code>&lt;/tr&gt;</code></p><p><code>1941</code><code>&lt;tr&gt;</code></p><p><code>1942</code><code>&lt;td&gt;</code></p><p><code>1943</code><code>N0 = No regional lymph node metastasis.&lt;/td&gt;</code></p><p><code>1944</code><code>&lt;/tr&gt;</code></p><p><code>1945</code><code>&lt;tr&gt;</code></p><p><code>1946</code><code>&lt;td&gt;</code></p><p><code>1947</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>1948</code><code>&lt;/tr&gt;</code></p><p><code>1949</code><code>&lt;/tbody&gt;</code></p><p><code>1950</code><code>&lt;/table&gt;</code></p><p><code>1951</code><code>&lt;table id="_380" class="table-default expandable-container"&gt;</code></p><p><code>1952</code><code>&lt;caption&gt;</code></p><p><code>1953</code><code>Table 9.  Definitions of TNM Stage III Perihilar Bile Duct Cancer&lt;span class="sup"&gt;</code></p><p><code>1954</code><code>a&lt;/span&gt;</code></p><p><code>1955</code><code>&lt;/caption&gt;</code></p><p><code>1956</code><code>&lt;colgroup&gt;</code></p><p><code>1957</code><code>&lt;col width="6.70%"&gt;</code></p><p><code>1958</code><code>&lt;col width="12.20%"&gt;</code></p><p><code>1959</code><code>&lt;col width="13.95%"&gt;</code></p><p><code>1960</code><code>&lt;col width="67.13%"&gt;</code></p><p><code>1961</code><code>&lt;/colgroup&gt;</code></p><p><code>1962</code><code>&lt;THead&gt;</code></p><p><code>1963</code><code>&lt;tr&gt;</code></p><p><code>1964</code><code>&lt;th colspan="2"&gt;</code></p><p><code>1965</code><code>Stage&lt;/th&gt;</code></p><p><code>1966</code><code>&lt;th&gt;</code></p><p><code>1967</code><code>TNM&lt;/th&gt;</code></p><p><code>1968</code><code>&lt;th&gt;</code></p><p><code>1969</code><code>Description&lt;/th&gt;</code></p><p><code>1970</code><code>&lt;/tr&gt;</code></p><p><code>1971</code><code>&lt;/THead&gt;</code></p><p><code>1972</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>1973</code><code>&lt;tr&gt;</code></p><p><code>1974</code><code>&lt;td colspan="4"&gt;</code></p><p><code>1975</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis.&lt;/td&gt;</code></p><p><code>1976</code><code>&lt;/tr&gt;</code></p><p><code>1977</code><code>&lt;tr&gt;</code></p><p><code>1978</code><code>&lt;td colspan="4"&gt;</code></p><p><code>1979</code><code>&lt;span class="sup"&gt;</code></p><p><code>1980</code><code>a&lt;/span&gt;</code></p><p><code>1981</code><code>Reprinted with permission from AJCC: Perihilar Bile Ducts. In: Amin MB, Edge SB,  Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>1982</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>1983</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 311&amp;#8211;6.&lt;/td&gt;</code></p><p><code>1984</code><code>&lt;/tr&gt;</code></p><p><code>1985</code><code>&lt;/TFoot&gt;</code></p><p><code>1986</code><code>&lt;tbody&gt;</code></p><p><code>1987</code><code>&lt;tr&gt;</code></p><p><code>1988</code><code>&lt;td rowspan="17"&gt;</code></p><p><code>1989</code><code>III&lt;/td&gt;</code></p><p><code>1990</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1991</code><code>IIIA&lt;/td&gt;</code></p><p><code>1992</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1993</code><code>T3, N0, M0 &lt;/td&gt;</code></p><p><code>1994</code><code>&lt;td&gt;</code></p><p><code>1995</code><code>T3 = Tumor invades unilateral branches of the portal vein or hepatic artery. &lt;/td&gt;</code></p><p><code>1996</code><code>&lt;/tr&gt;</code></p><p><code>1997</code><code>&lt;tr&gt;</code></p><p><code>1998</code><code>&lt;td&gt;</code></p><p><code>1999</code><code>N0 = No regional lymph node metastasis. &lt;/td&gt;</code></p><p><code>2000</code><code>&lt;/tr&gt;</code></p><p><code>2001</code><code>&lt;tr&gt;</code></p><p><code>2002</code><code>&lt;td&gt;</code></p><p><code>2003</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>2004</code><code>&lt;/tr&gt;</code></p><p><code>2005</code><code>&lt;tr&gt;</code></p><p><code>2006</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2007</code><code>IIIB&lt;/td&gt;</code></p><p><code>2008</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2009</code><code>T4, N0, M0&lt;/td&gt;</code></p><p><code>2010</code><code>&lt;td&gt;</code></p><p><code>2011</code><code>T4 = Tumor invades the main portal vein or its branches bilaterally, or the common hepatic artery; or unilateral second-order biliary radicals with contralateral portal vein or hepatic artery involvement.&lt;/td&gt;</code></p><p><code>2012</code><code>&lt;/tr&gt;</code></p><p><code>2013</code><code>&lt;tr&gt;</code></p><p><code>2014</code><code>&lt;td&gt;</code></p><p><code>2015</code><code>N0 = No regional lymph node metastasis.&lt;/td&gt;</code></p><p><code>2016</code><code>&lt;/tr&gt;</code></p><p><code>2017</code><code>&lt;tr&gt;</code></p><p><code>2018</code><code>&lt;td&gt;</code></p><p><code>2019</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>2020</code><code>&lt;/tr&gt;</code></p><p><code>2021</code><code>&lt;tr&gt;</code></p><p><code>2022</code><code>&lt;td rowspan="11"&gt;</code></p><p><code>2023</code><code>IIIC&lt;/td&gt;</code></p><p><code>2024</code><code>&lt;td rowspan="11"&gt;</code></p><p><code>2025</code><code>Any T, N1, M0&lt;/td&gt;</code></p><p><code>2026</code><code>&lt;td&gt;</code></p><p><code>2027</code><code>TX = Primary tumor cannot be assessed.&lt;/td&gt;</code></p><p><code>2028</code><code>&lt;/tr&gt;</code></p><p><code>2029</code><code>&lt;tr&gt;</code></p><p><code>2030</code><code>&lt;td&gt;</code></p><p><code>2031</code><code>T0 = No evidence of primary tumor.&lt;/td&gt;</code></p><p><code>2032</code><code>&lt;/tr&gt;</code></p><p><code>2033</code><code>&lt;tr&gt;</code></p><p><code>2034</code><code>&lt;td&gt;</code></p><p><code>2035</code><code>Tis = Carcinoma &lt;em&gt;</code></p><p><code>2036</code><code>in situ&lt;/em&gt;</code></p><p><code>2037</code><code>/high-grade dysplasia.&lt;/td&gt;</code></p><p><code>2038</code><code>&lt;/tr&gt;</code></p><p><code>2039</code><code>&lt;tr&gt;</code></p><p><code>2040</code><code>&lt;td&gt;</code></p><p><code>2041</code><code>T1 = Tumor confined to the bile duct, with extension up to the muscle layer or fibrous tissue.&lt;/td&gt;</code></p><p><code>2042</code><code>&lt;/tr&gt;</code></p><p><code>2043</code><code>&lt;tr&gt;</code></p><p><code>2044</code><code>&lt;td&gt;</code></p><p><code>2045</code><code>T2 = Tumor invades beyond the wall of the bile duct to surrounding adipose tissue, or tumor invades adjacent hepatic parenchyma.&lt;/td&gt;</code></p><p><code>2046</code><code>&lt;/tr&gt;</code></p><p><code>2047</code><code>&lt;tr&gt;</code></p><p><code>2048</code><code>&lt;td&gt;</code></p><p><code>2049</code><code>&amp;#8211;T2a = Tumor invades beyond the wall of the bile duct to surrounding adipose tissue.&lt;/td&gt;</code></p><p><code>2050</code><code>&lt;/tr&gt;</code></p><p><code>2051</code><code>&lt;tr&gt;</code></p><p><code>2052</code><code>&lt;td&gt;</code></p><p><code>2053</code><code>&amp;#8211;T2b = Tumor invades adjacent hepatic parenchyma.&lt;/td&gt;</code></p><p><code>2054</code><code>&lt;/tr&gt;</code></p><p><code>2055</code><code>&lt;tr&gt;</code></p><p><code>2056</code><code>&lt;td&gt;</code></p><p><code>2057</code><code>T3 = Tumor invades unilateral branches of the portal vein or hepatic artery.&lt;/td&gt;</code></p><p><code>2058</code><code>&lt;/tr&gt;</code></p><p><code>2059</code><code>&lt;tr&gt;</code></p><p><code>2060</code><code>&lt;td&gt;</code></p><p><code>2061</code><code>T4 = Tumor invades the main portal vein or its branches bilaterally, or the common hepatic artery; or unilateral second-order biliary radicals with contralateral portal vein or hepatic artery involvement.&lt;/td&gt;</code></p><p><code>2062</code><code>&lt;/tr&gt;</code></p><p><code>2063</code><code>&lt;tr&gt;</code></p><p><code>2064</code><code>&lt;td&gt;</code></p><p><code>2065</code><code>N1 = One to three positive lymph nodes typically involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes.&lt;/td&gt;</code></p><p><code>2066</code><code>&lt;/tr&gt;</code></p><p><code>2067</code><code>&lt;tr&gt;</code></p><p><code>2068</code><code>&lt;td&gt;</code></p><p><code>2069</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>2070</code><code>&lt;/tr&gt;</code></p><p><code>2071</code><code>&lt;/tbody&gt;</code></p><p><code>2072</code><code>&lt;/table&gt;</code></p><p><code>2073</code><code>&lt;table id="_364" class="table-default expandable-container"&gt;</code></p><p><code>2074</code><code>&lt;caption&gt;</code></p><p><code>2075</code><code>Table 10.  Definitions of TNM Stage IV Perihilar Bile Duct Cancer&lt;span class="sup"&gt;</code></p><p><code>2076</code><code>a&lt;/span&gt;</code></p><p><code>2077</code><code>&lt;/caption&gt;</code></p><p><code>2078</code><code>&lt;colgroup&gt;</code></p><p><code>2079</code><code>&lt;col width="12.40%"&gt;</code></p><p><code>2080</code><code>&lt;col width="15.63%"&gt;</code></p><p><code>2081</code><code>&lt;col width="20.96%"&gt;</code></p><p><code>2082</code><code>&lt;col width="50.99%"&gt;</code></p><p><code>2083</code><code>&lt;/colgroup&gt;</code></p><p><code>2084</code><code>&lt;THead&gt;</code></p><p><code>2085</code><code>&lt;tr&gt;</code></p><p><code>2086</code><code>&lt;th colspan="2" align="Center" scope="col"&gt;</code></p><p><code>2087</code><code>Stage&lt;/th&gt;</code></p><p><code>2088</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2089</code><code>TNM&lt;/th&gt;</code></p><p><code>2090</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2091</code><code>Description&lt;/th&gt;</code></p><p><code>2092</code><code>&lt;/tr&gt;</code></p><p><code>2093</code><code>&lt;/THead&gt;</code></p><p><code>2094</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>2095</code><code>&lt;tr&gt;</code></p><p><code>2096</code><code>&lt;td colspan="4"&gt;</code></p><p><code>2097</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis.&lt;/td&gt;</code></p><p><code>2098</code><code>&lt;/tr&gt;</code></p><p><code>2099</code><code>&lt;tr&gt;</code></p><p><code>2100</code><code>&lt;td colspan="4"&gt;</code></p><p><code>2101</code><code>&lt;span class="sup"&gt;</code></p><p><code>2102</code><code>a&lt;/span&gt;</code></p><p><code>2103</code><code>Reprinted with permission from AJCC: Perihilar Bile Ducts. In: Amin MB, Edge SB,  Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>2104</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>2105</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 311&amp;#8211;6.&lt;/td&gt;</code></p><p><code>2106</code><code>&lt;/tr&gt;</code></p><p><code>2107</code><code>&lt;/TFoot&gt;</code></p><p><code>2108</code><code>&lt;tbody&gt;</code></p><p><code>2109</code><code>&lt;tr&gt;</code></p><p><code>2110</code><code>&lt;td rowspan="25"&gt;</code></p><p><code>2111</code><code>IV&lt;/td&gt;</code></p><p><code>2112</code><code>&lt;td rowspan="11"&gt;</code></p><p><code>2113</code><code>IVA&lt;/td&gt;</code></p><p><code>2114</code><code>&lt;td rowspan="11"&gt;</code></p><p><code>2115</code><code>Any T, N2, M0&lt;/td&gt;</code></p><p><code>2116</code><code>&lt;td&gt;</code></p><p><code>2117</code><code>TX = Primary tumor cannot be assessed.&lt;/td&gt;</code></p><p><code>2118</code><code>&lt;/tr&gt;</code></p><p><code>2119</code><code>&lt;tr&gt;</code></p><p><code>2120</code><code>&lt;td&gt;</code></p><p><code>2121</code><code>T0 = No evidence of primary tumor.&lt;/td&gt;</code></p><p><code>2122</code><code>&lt;/tr&gt;</code></p><p><code>2123</code><code>&lt;tr&gt;</code></p><p><code>2124</code><code>&lt;td&gt;</code></p><p><code>2125</code><code>Tis = Carcinoma &lt;em&gt;</code></p><p><code>2126</code><code>in situ&lt;/em&gt;</code></p><p><code>2127</code><code>/high-grade dysplasia.&lt;/td&gt;</code></p><p><code>2128</code><code>&lt;/tr&gt;</code></p><p><code>2129</code><code>&lt;tr&gt;</code></p><p><code>2130</code><code>&lt;td&gt;</code></p><p><code>2131</code><code>T1 = Tumor confined to the bile duct, with extension up to the muscle layer or fibrous tissue.&lt;/td&gt;</code></p><p><code>2132</code><code>&lt;/tr&gt;</code></p><p><code>2133</code><code>&lt;tr&gt;</code></p><p><code>2134</code><code>&lt;td&gt;</code></p><p><code>2135</code><code>T2 = Tumor invades beyond the wall of the bile duct to surrounding adipose tissue, or tumor invades adjacent hepatic parenchyma.&lt;/td&gt;</code></p><p><code>2136</code><code>&lt;/tr&gt;</code></p><p><code>2137</code><code>&lt;tr&gt;</code></p><p><code>2138</code><code>&lt;td&gt;</code></p><p><code>2139</code><code>&amp;#8211;T2a = Tumor invades beyond the wall of the bile duct to surround adipose tissue.&lt;/td&gt;</code></p><p><code>2140</code><code>&lt;/tr&gt;</code></p><p><code>2141</code><code>&lt;tr&gt;</code></p><p><code>2142</code><code>&lt;td&gt;</code></p><p><code>2143</code><code>&amp;#8211;T2b = Tumor invades adjacent hepatic parenchyma.&lt;/td&gt;</code></p><p><code>2144</code><code>&lt;/tr&gt;</code></p><p><code>2145</code><code>&lt;tr&gt;</code></p><p><code>2146</code><code>&lt;td&gt;</code></p><p><code>2147</code><code>T3 = Tumor invades unilateral branches of the portal vein or hepatic artery.&lt;/td&gt;</code></p><p><code>2148</code><code>&lt;/tr&gt;</code></p><p><code>2149</code><code>&lt;tr&gt;</code></p><p><code>2150</code><code>&lt;td&gt;</code></p><p><code>2151</code><code>T4 = Tumor invades the main portal vein or its branches bilaterally, or the common hepatic artery; or unilateral second-order biliary radicals with contralateral portal vein or hepatic artery involvement.&lt;/td&gt;</code></p><p><code>2152</code><code>&lt;/tr&gt;</code></p><p><code>2153</code><code>&lt;tr&gt;</code></p><p><code>2154</code><code>&lt;td&gt;</code></p><p><code>2155</code><code>N2 = Four or more positive lymph nodes from the sites described for N1.&lt;/td&gt;</code></p><p><code>2156</code><code>&lt;/tr&gt;</code></p><p><code>2157</code><code>&lt;tr&gt;</code></p><p><code>2158</code><code>&lt;td&gt;</code></p><p><code>2159</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>2160</code><code>&lt;/tr&gt;</code></p><p><code>2161</code><code>&lt;tr&gt;</code></p><p><code>2162</code><code>&lt;td rowspan="14"&gt;</code></p><p><code>2163</code><code>IVB&lt;/td&gt;</code></p><p><code>2164</code><code>&lt;td rowspan="14"&gt;</code></p><p><code>2165</code><code>Any T, Any N, M1&lt;/td&gt;</code></p><p><code>2166</code><code>&lt;td&gt;</code></p><p><code>2167</code><code>TX = Primary tumor cannot be assessed.&lt;/td&gt;</code></p><p><code>2168</code><code>&lt;/tr&gt;</code></p><p><code>2169</code><code>&lt;tr&gt;</code></p><p><code>2170</code><code>&lt;td&gt;</code></p><p><code>2171</code><code>T0 = No evidence of primary tumor.&lt;/td&gt;</code></p><p><code>2172</code><code>&lt;/tr&gt;</code></p><p><code>2173</code><code>&lt;tr&gt;</code></p><p><code>2174</code><code>&lt;td&gt;</code></p><p><code>2175</code><code>Tis = Carcinoma &lt;em&gt;</code></p><p><code>2176</code><code>in situ&lt;/em&gt;</code></p><p><code>2177</code><code>/high-grade dysplasia.&lt;/td&gt;</code></p><p><code>2178</code><code>&lt;/tr&gt;</code></p><p><code>2179</code><code>&lt;tr&gt;</code></p><p><code>2180</code><code>&lt;td&gt;</code></p><p><code>2181</code><code>T1 = Tumor confined to the bile duct, with extension up to the muscle layer or fibrous tissue.&lt;/td&gt;</code></p><p><code>2182</code><code>&lt;/tr&gt;</code></p><p><code>2183</code><code>&lt;tr&gt;</code></p><p><code>2184</code><code>&lt;td&gt;</code></p><p><code>2185</code><code>T2 = Tumor invades beyond the wall of the bile duct to surrounding adipose tissue, or tumor invades adjacent hepatic parenchyma.&lt;/td&gt;</code></p><p><code>2186</code><code>&lt;/tr&gt;</code></p><p><code>2187</code><code>&lt;tr&gt;</code></p><p><code>2188</code><code>&lt;td&gt;</code></p><p><code>2189</code><code>&amp;#8211;T2a = Tumor invades beyond the wall of the bile duct to surround adipose tissue.&lt;/td&gt;</code></p><p><code>2190</code><code>&lt;/tr&gt;</code></p><p><code>2191</code><code>&lt;tr&gt;</code></p><p><code>2192</code><code>&lt;td&gt;</code></p><p><code>2193</code><code>&amp;#8211;T2b = Tumor invades adjacent hepatic parenchyma.&lt;/td&gt;</code></p><p><code>2194</code><code>&lt;/tr&gt;</code></p><p><code>2195</code><code>&lt;tr&gt;</code></p><p><code>2196</code><code>&lt;td&gt;</code></p><p><code>2197</code><code>T3 = Tumor invades unilateral branches of the portal vein or hepatic artery.&lt;/td&gt;</code></p><p><code>2198</code><code>&lt;/tr&gt;</code></p><p><code>2199</code><code>&lt;tr&gt;</code></p><p><code>2200</code><code>&lt;td&gt;</code></p><p><code>2201</code><code>T4 = Tumor invades the main portal vein or its branches bilaterally, or the common hepatic artery; or unilateral second-order biliary radicals with contralateral portal vein or hepatic artery involvement.&lt;/td&gt;</code></p><p><code>2202</code><code>&lt;/tr&gt;</code></p><p><code>2203</code><code>&lt;tr&gt;</code></p><p><code>2204</code><code>&lt;td&gt;</code></p><p><code>2205</code><code>NX = Regional lymph nodes cannot be assessed.&lt;/td&gt;</code></p><p><code>2206</code><code>&lt;/tr&gt;</code></p><p><code>2207</code><code>&lt;tr&gt;</code></p><p><code>2208</code><code>&lt;td&gt;</code></p><p><code>2209</code><code>N0 = No regional lymph node metastasis.&lt;/td&gt;</code></p><p><code>2210</code><code>&lt;/tr&gt;</code></p><p><code>2211</code><code>&lt;tr&gt;</code></p><p><code>2212</code><code>&lt;td&gt;</code></p><p><code>2213</code><code>N1 = One to three positive lymph nodes typically involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes.&lt;/td&gt;</code></p><p><code>2214</code><code>&lt;/tr&gt;</code></p><p><code>2215</code><code>&lt;tr&gt;</code></p><p><code>2216</code><code>&lt;td&gt;</code></p><p><code>2217</code><code>N2 = Four or more positive lymph nodes from the sites described for N1.&lt;/td&gt;</code></p><p><code>2218</code><code>&lt;/tr&gt;</code></p><p><code>2219</code><code>&lt;tr&gt;</code></p><p><code>2220</code><code>&lt;td&gt;</code></p><p><code>2221</code><code>M1 = Distant metastasis.&lt;/td&gt;</code></p><p><code>2222</code><code>&lt;/tr&gt;</code></p><p><code>2223</code><code>&lt;/tbody&gt;</code></p><p><code>2224</code><code>&lt;/table&gt;</code></p><p><code>2225</code><code>&lt;/section&gt;</code></p><p><code>2226</code><code>&lt;section id="_34"&gt;</code></p><p><code>2227</code><code>&lt;h4 id="_34_toc"&gt;</code></p><p><code>2228</code><code>AJCC staging system for distal  bile duct cancer&lt;/h4&gt;</code></p><p><code>2229</code><code>&lt;p id="_35" tabindex="-1"&gt;</code></p><p><code>2230</code><code>The AJCC has designated staging by TNM classification to define distal bile duct cancer.[&lt;a href="#cit/section_3.3"&gt;</code></p><p><code>2231</code><code>3&lt;/a&gt;</code></p><p><code>2232</code><code>] Stages defined by TNM classification apply to all primary carcinomas arising in the distal  bile duct or in the cystic duct; these stages do not apply to perihilar or intrahepatic cholangiocarcinomas, sarcomas, or carcinoid tumors.&lt;/p&gt;</code></p><p><code>2233</code><code>&lt;p id="_42" tabindex="-1"&gt;</code></p><p><code>2234</code><code>Tables &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_366"&gt;</code></p><p><code>2235</code><code>11&lt;/a&gt;</code></p><p><code>2236</code><code>, &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_367"&gt;</code></p><p><code>2237</code><code>12&lt;/a&gt;</code></p><p><code>2238</code><code>, &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_368"&gt;</code></p><p><code>2239</code><code>13&lt;/a&gt;</code></p><p><code>2240</code><code>, &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_370"&gt;</code></p><p><code>2241</code><code>14&lt;/a&gt;</code></p><p><code>2242</code><code>, and &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_372"&gt;</code></p><p><code>2243</code><code>15&lt;/a&gt;</code></p><p><code>2244</code><code> pertain to the distal  bile duct cancer stages.&lt;/p&gt;</code></p><p><code>2245</code><code>&lt;table id="_366" class="table-default expandable-container"&gt;</code></p><p><code>2246</code><code>&lt;caption&gt;</code></p><p><code>2247</code><code>Table 11.  Definitions of TNM Stage 0 Distal  Bile Duct Cancer&lt;span class="sup"&gt;</code></p><p><code>2248</code><code>a&lt;/span&gt;</code></p><p><code>2249</code><code>&lt;/caption&gt;</code></p><p><code>2250</code><code>&lt;colgroup&gt;</code></p><p><code>2251</code><code>&lt;col width="17.73%"&gt;</code></p><p><code>2252</code><code>&lt;col width="16.42%"&gt;</code></p><p><code>2253</code><code>&lt;col width="65.84%"&gt;</code></p><p><code>2254</code><code>&lt;/colgroup&gt;</code></p><p><code>2255</code><code>&lt;THead&gt;</code></p><p><code>2256</code><code>&lt;tr&gt;</code></p><p><code>2257</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2258</code><code>Stage &lt;/th&gt;</code></p><p><code>2259</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2260</code><code>TNM&lt;/th&gt;</code></p><p><code>2261</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2262</code><code>Definition&lt;/th&gt;</code></p><p><code>2263</code><code>&lt;/tr&gt;</code></p><p><code>2264</code><code>&lt;/THead&gt;</code></p><p><code>2265</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>2266</code><code>&lt;tr&gt;</code></p><p><code>2267</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2268</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis.&lt;/td&gt;</code></p><p><code>2269</code><code>&lt;/tr&gt;</code></p><p><code>2270</code><code>&lt;tr&gt;</code></p><p><code>2271</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2272</code><code>&lt;span class="sup"&gt;</code></p><p><code>2273</code><code>a&lt;/span&gt;</code></p><p><code>2274</code><code>Reprinted with permission from AJCC: Distal Bile Duct. In: Amin MB, Edge SB,  Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>2275</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>2276</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 317&amp;#8211;325.&lt;/td&gt;</code></p><p><code>2277</code><code>&lt;/tr&gt;</code></p><p><code>2278</code><code>&lt;/TFoot&gt;</code></p><p><code>2279</code><code>&lt;tbody&gt;</code></p><p><code>2280</code><code>&lt;tr&gt;</code></p><p><code>2281</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2282</code><code>0&lt;/td&gt;</code></p><p><code>2283</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2284</code><code>Tis, N0, M0&lt;/td&gt;</code></p><p><code>2285</code><code>&lt;td&gt;</code></p><p><code>2286</code><code>Tis = Carcinoma &lt;em&gt;</code></p><p><code>2287</code><code>in situ&lt;/em&gt;</code></p><p><code>2288</code><code>/high-grade dysplasia.&lt;/td&gt;</code></p><p><code>2289</code><code>&lt;/tr&gt;</code></p><p><code>2290</code><code>&lt;tr&gt;</code></p><p><code>2291</code><code>&lt;td&gt;</code></p><p><code>2292</code><code>N0 = No regional lymph node metastasis.&lt;/td&gt;</code></p><p><code>2293</code><code>&lt;/tr&gt;</code></p><p><code>2294</code><code>&lt;tr&gt;</code></p><p><code>2295</code><code>&lt;td&gt;</code></p><p><code>2296</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>2297</code><code>&lt;/tr&gt;</code></p><p><code>2298</code><code>&lt;/tbody&gt;</code></p><p><code>2299</code><code>&lt;/table&gt;</code></p><p><code>2300</code><code>&lt;table id="_367" class="table-default expandable-container"&gt;</code></p><p><code>2301</code><code>&lt;caption&gt;</code></p><p><code>2302</code><code>Table 12.  Definitions of TNM Stage I Distal  Bile Duct Cancer&lt;span class="sup"&gt;</code></p><p><code>2303</code><code>a&lt;/span&gt;</code></p><p><code>2304</code><code>&lt;/caption&gt;</code></p><p><code>2305</code><code>&lt;colgroup&gt;</code></p><p><code>2306</code><code>&lt;col width="19.34%"&gt;</code></p><p><code>2307</code><code>&lt;col width="19.15%"&gt;</code></p><p><code>2308</code><code>&lt;col width="61.49%"&gt;</code></p><p><code>2309</code><code>&lt;/colgroup&gt;</code></p><p><code>2310</code><code>&lt;THead&gt;</code></p><p><code>2311</code><code>&lt;tr&gt;</code></p><p><code>2312</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2313</code><code>Stage &lt;/th&gt;</code></p><p><code>2314</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2315</code><code>TNM&lt;/th&gt;</code></p><p><code>2316</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2317</code><code>Definition&lt;/th&gt;</code></p><p><code>2318</code><code>&lt;/tr&gt;</code></p><p><code>2319</code><code>&lt;/THead&gt;</code></p><p><code>2320</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>2321</code><code>&lt;tr&gt;</code></p><p><code>2322</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2323</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis.&lt;/td&gt;</code></p><p><code>2324</code><code>&lt;/tr&gt;</code></p><p><code>2325</code><code>&lt;tr&gt;</code></p><p><code>2326</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2327</code><code>&lt;span class="sup"&gt;</code></p><p><code>2328</code><code>a&lt;/span&gt;</code></p><p><code>2329</code><code>Reprinted with permission from AJCC: Distal Bile Duct. In: Amin MB, Edge SB,  Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>2330</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>2331</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 317&amp;#8211;325.&lt;/td&gt;</code></p><p><code>2332</code><code>&lt;/tr&gt;</code></p><p><code>2333</code><code>&lt;/TFoot&gt;</code></p><p><code>2334</code><code>&lt;tbody&gt;</code></p><p><code>2335</code><code>&lt;tr&gt;</code></p><p><code>2336</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2337</code><code>I&lt;/td&gt;</code></p><p><code>2338</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2339</code><code>T1, N0, M0&lt;/td&gt;</code></p><p><code>2340</code><code>&lt;td&gt;</code></p><p><code>2341</code><code>T1 = Tumor invades the bile duct wall with a depth &amp;lt;5 mm.&lt;/td&gt;</code></p><p><code>2342</code><code>&lt;/tr&gt;</code></p><p><code>2343</code><code>&lt;tr&gt;</code></p><p><code>2344</code><code>&lt;td&gt;</code></p><p><code>2345</code><code>N0 = No regional lymph node metastasis.&lt;/td&gt;</code></p><p><code>2346</code><code>&lt;/tr&gt;</code></p><p><code>2347</code><code>&lt;tr&gt;</code></p><p><code>2348</code><code>&lt;td&gt;</code></p><p><code>2349</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>2350</code><code>&lt;/tr&gt;</code></p><p><code>2351</code><code>&lt;/tbody&gt;</code></p><p><code>2352</code><code>&lt;/table&gt;</code></p><p><code>2353</code><code>&lt;table id="_368" class="table-default expandable-container"&gt;</code></p><p><code>2354</code><code>&lt;caption&gt;</code></p><p><code>2355</code><code>Table 13.  Definitions of TNM II Distal  Bile Duct Cancer&lt;span class="sup"&gt;</code></p><p><code>2356</code><code>a&lt;/span&gt;</code></p><p><code>2357</code><code>&lt;/caption&gt;</code></p><p><code>2358</code><code>&lt;colgroup&gt;</code></p><p><code>2359</code><code>&lt;col width="15.30%"&gt;</code></p><p><code>2360</code><code>&lt;col width="22.15%"&gt;</code></p><p><code>2361</code><code>&lt;col width="14.57%"&gt;</code></p><p><code>2362</code><code>&lt;col width="47.95%"&gt;</code></p><p><code>2363</code><code>&lt;/colgroup&gt;</code></p><p><code>2364</code><code>&lt;THead&gt;</code></p><p><code>2365</code><code>&lt;tr&gt;</code></p><p><code>2366</code><code>&lt;th colspan="2" align="Center" scope="col"&gt;</code></p><p><code>2367</code><code>Stage&lt;/th&gt;</code></p><p><code>2368</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2369</code><code>TNM&lt;/th&gt;</code></p><p><code>2370</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2371</code><code>Definition&lt;/th&gt;</code></p><p><code>2372</code><code>&lt;/tr&gt;</code></p><p><code>2373</code><code>&lt;/THead&gt;</code></p><p><code>2374</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>2375</code><code>&lt;tr&gt;</code></p><p><code>2376</code><code>&lt;td colspan="4"&gt;</code></p><p><code>2377</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis.&lt;/td&gt;</code></p><p><code>2378</code><code>&lt;/tr&gt;</code></p><p><code>2379</code><code>&lt;tr&gt;</code></p><p><code>2380</code><code>&lt;td colspan="4"&gt;</code></p><p><code>2381</code><code>&lt;span class="sup"&gt;</code></p><p><code>2382</code><code>a&lt;/span&gt;</code></p><p><code>2383</code><code>Reprinted with permission from AJCC: Distal Bile Duct. In: Amin MB, Edge SB,  Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>2384</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>2385</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 317&amp;#8211;325.&lt;/td&gt;</code></p><p><code>2386</code><code>&lt;/tr&gt;</code></p><p><code>2387</code><code>&lt;/TFoot&gt;</code></p><p><code>2388</code><code>&lt;tbody&gt;</code></p><p><code>2389</code><code>&lt;tr&gt;</code></p><p><code>2390</code><code>&lt;td rowspan="15"&gt;</code></p><p><code>2391</code><code>II&lt;/td&gt;</code></p><p><code>2392</code><code>&lt;td rowspan="6"&gt;</code></p><p><code>2393</code><code>IIA&lt;/td&gt;</code></p><p><code>2394</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2395</code><code>T1, N1, M0&lt;/td&gt;</code></p><p><code>2396</code><code>&lt;td&gt;</code></p><p><code>2397</code><code>T1 = Tumor invades the bile duct wall with a depth &amp;lt;5 mm.&lt;/td&gt;</code></p><p><code>2398</code><code>&lt;/tr&gt;</code></p><p><code>2399</code><code>&lt;tr&gt;</code></p><p><code>2400</code><code>&lt;td&gt;</code></p><p><code>2401</code><code>N1 = Metastasis in one to three regional lymph nodes.&lt;/td&gt;</code></p><p><code>2402</code><code>&lt;/tr&gt;</code></p><p><code>2403</code><code>&lt;tr&gt;</code></p><p><code>2404</code><code>&lt;td&gt;</code></p><p><code>2405</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>2406</code><code>&lt;/tr&gt;</code></p><p><code>2407</code><code>&lt;tr&gt;</code></p><p><code>2408</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2409</code><code>T2, N0, M0&lt;/td&gt;</code></p><p><code>2410</code><code>&lt;td&gt;</code></p><p><code>2411</code><code>Tumor invades the bile duct wall with a depth of 5&amp;#8211;12 mm.&lt;/td&gt;</code></p><p><code>2412</code><code>&lt;/tr&gt;</code></p><p><code>2413</code><code>&lt;tr&gt;</code></p><p><code>2414</code><code>&lt;td&gt;</code></p><p><code>2415</code><code>N0 = No regional lymph node metastasis. &lt;/td&gt;</code></p><p><code>2416</code><code>&lt;/tr&gt;</code></p><p><code>2417</code><code>&lt;tr&gt;</code></p><p><code>2418</code><code>&lt;td&gt;</code></p><p><code>2419</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>2420</code><code>&lt;/tr&gt;</code></p><p><code>2421</code><code>&lt;tr&gt;</code></p><p><code>2422</code><code>&lt;td rowspan="9"&gt;</code></p><p><code>2423</code><code>IIB&lt;/td&gt;</code></p><p><code>2424</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2425</code><code>T2, N1, M0&lt;/td&gt;</code></p><p><code>2426</code><code>&lt;td&gt;</code></p><p><code>2427</code><code>T2 = Tumor invades the bile duct wall with a depth of 5&amp;#8211;12 mm.&lt;/td&gt;</code></p><p><code>2428</code><code>&lt;/tr&gt;</code></p><p><code>2429</code><code>&lt;tr&gt;</code></p><p><code>2430</code><code>&lt;td&gt;</code></p><p><code>2431</code><code>N1 = Metastasis in one to three regional lymph nodes.&lt;/td&gt;</code></p><p><code>2432</code><code>&lt;/tr&gt;</code></p><p><code>2433</code><code>&lt;tr&gt;</code></p><p><code>2434</code><code>&lt;td&gt;</code></p><p><code>2435</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>2436</code><code>&lt;/tr&gt;</code></p><p><code>2437</code><code>&lt;tr&gt;</code></p><p><code>2438</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2439</code><code>T3, N0, M0&lt;/td&gt;</code></p><p><code>2440</code><code>&lt;td&gt;</code></p><p><code>2441</code><code>T3 = Tumor invades the bile duct wall with a depth &amp;gt;12 mm.&lt;/td&gt;</code></p><p><code>2442</code><code>&lt;/tr&gt;</code></p><p><code>2443</code><code>&lt;tr&gt;</code></p><p><code>2444</code><code>&lt;td&gt;</code></p><p><code>2445</code><code>N0 = No regional lymph node metastasis.&lt;/td&gt;</code></p><p><code>2446</code><code>&lt;/tr&gt;</code></p><p><code>2447</code><code>&lt;tr&gt;</code></p><p><code>2448</code><code>&lt;td&gt;</code></p><p><code>2449</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>2450</code><code>&lt;/tr&gt;</code></p><p><code>2451</code><code>&lt;tr&gt;</code></p><p><code>2452</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2453</code><code>T3, N1, M0&lt;/td&gt;</code></p><p><code>2454</code><code>&lt;td&gt;</code></p><p><code>2455</code><code>T3 = Tumor invades the bile duct wall with a depth &amp;gt;12 mm.&lt;/td&gt;</code></p><p><code>2456</code><code>&lt;/tr&gt;</code></p><p><code>2457</code><code>&lt;tr&gt;</code></p><p><code>2458</code><code>&lt;td&gt;</code></p><p><code>2459</code><code>N1 = Metastasis in one to three regional lymph nodes.&lt;/td&gt;</code></p><p><code>2460</code><code>&lt;/tr&gt;</code></p><p><code>2461</code><code>&lt;tr&gt;</code></p><p><code>2462</code><code>&lt;td&gt;</code></p><p><code>2463</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>2464</code><code>&lt;/tr&gt;</code></p><p><code>2465</code><code>&lt;/tbody&gt;</code></p><p><code>2466</code><code>&lt;/table&gt;</code></p><p><code>2467</code><code>&lt;table id="_370" class="table-default expandable-container"&gt;</code></p><p><code>2468</code><code>&lt;caption&gt;</code></p><p><code>2469</code><code>Table 14.  Definitions of TNM Stage III Distal  Bile Duct Cancer&lt;/caption&gt;</code></p><p><code>2470</code><code>&lt;colgroup&gt;</code></p><p><code>2471</code><code>&lt;col width="16.15%"&gt;</code></p><p><code>2472</code><code>&lt;col width="16.96%"&gt;</code></p><p><code>2473</code><code>&lt;col width="18.09%"&gt;</code></p><p><code>2474</code><code>&lt;col width="48.78%"&gt;</code></p><p><code>2475</code><code>&lt;/colgroup&gt;</code></p><p><code>2476</code><code>&lt;THead&gt;</code></p><p><code>2477</code><code>&lt;tr&gt;</code></p><p><code>2478</code><code>&lt;th colspan="2" align="Center" scope="col"&gt;</code></p><p><code>2479</code><code>Stage&lt;/th&gt;</code></p><p><code>2480</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2481</code><code>TNM&lt;/th&gt;</code></p><p><code>2482</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2483</code><code>Definition&lt;/th&gt;</code></p><p><code>2484</code><code>&lt;/tr&gt;</code></p><p><code>2485</code><code>&lt;/THead&gt;</code></p><p><code>2486</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>2487</code><code>&lt;tr&gt;</code></p><p><code>2488</code><code>&lt;td colspan="4"&gt;</code></p><p><code>2489</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis.&lt;/td&gt;</code></p><p><code>2490</code><code>&lt;/tr&gt;</code></p><p><code>2491</code><code>&lt;tr&gt;</code></p><p><code>2492</code><code>&lt;td colspan="4"&gt;</code></p><p><code>2493</code><code>&lt;span class="sup"&gt;</code></p><p><code>2494</code><code>a&lt;/span&gt;</code></p><p><code>2495</code><code>Reprinted with permission from AJCC: Distal Bile Duct. In: Amin MB, Edge SB,  Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>2496</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>2497</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 317&amp;#8211;325.&lt;/td&gt;</code></p><p><code>2498</code><code>&lt;/tr&gt;</code></p><p><code>2499</code><code>&lt;/TFoot&gt;</code></p><p><code>2500</code><code>&lt;tbody&gt;</code></p><p><code>2501</code><code>&lt;tr&gt;</code></p><p><code>2502</code><code>&lt;td rowspan="18"&gt;</code></p><p><code>2503</code><code>III&lt;/td&gt;</code></p><p><code>2504</code><code>&lt;td rowspan="9"&gt;</code></p><p><code>2505</code><code>IIIA&lt;/td&gt;</code></p><p><code>2506</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2507</code><code>T1, N2, M0&lt;/td&gt;</code></p><p><code>2508</code><code>&lt;td&gt;</code></p><p><code>2509</code><code>T1 = Tumor invades the bile duct wall with a depth &amp;lt;5 mm.&lt;/td&gt;</code></p><p><code>2510</code><code>&lt;/tr&gt;</code></p><p><code>2511</code><code>&lt;tr&gt;</code></p><p><code>2512</code><code>&lt;td&gt;</code></p><p><code>2513</code><code>N2 = Metastasis in four or more regional lymph nodes.&lt;/td&gt;</code></p><p><code>2514</code><code>&lt;/tr&gt;</code></p><p><code>2515</code><code>&lt;tr&gt;</code></p><p><code>2516</code><code>&lt;td&gt;</code></p><p><code>2517</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>2518</code><code>&lt;/tr&gt;</code></p><p><code>2519</code><code>&lt;tr&gt;</code></p><p><code>2520</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2521</code><code>T2, N2, M0&lt;/td&gt;</code></p><p><code>2522</code><code>&lt;td&gt;</code></p><p><code>2523</code><code>T2 = Tumor invades the bile duct wall with a depth of 5&amp;#8211;12 mm.&lt;/td&gt;</code></p><p><code>2524</code><code>&lt;/tr&gt;</code></p><p><code>2525</code><code>&lt;tr&gt;</code></p><p><code>2526</code><code>&lt;td&gt;</code></p><p><code>2527</code><code>N2 = Metastasis in four or more regional lymph nodes.&lt;/td&gt;</code></p><p><code>2528</code><code>&lt;/tr&gt;</code></p><p><code>2529</code><code>&lt;tr&gt;</code></p><p><code>2530</code><code>&lt;td&gt;</code></p><p><code>2531</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>2532</code><code>&lt;/tr&gt;</code></p><p><code>2533</code><code>&lt;tr&gt;</code></p><p><code>2534</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2535</code><code>T3, N2, M0&lt;/td&gt;</code></p><p><code>2536</code><code>&lt;td&gt;</code></p><p><code>2537</code><code>T3 = Tumor invades the bile duct wall with a depth &amp;gt;12 mm.&lt;/td&gt;</code></p><p><code>2538</code><code>&lt;/tr&gt;</code></p><p><code>2539</code><code>&lt;tr&gt;</code></p><p><code>2540</code><code>&lt;td&gt;</code></p><p><code>2541</code><code>N2 = Metastasis in four or more regional lymph nodes.&lt;/td&gt;</code></p><p><code>2542</code><code>&lt;/tr&gt;</code></p><p><code>2543</code><code>&lt;tr&gt;</code></p><p><code>2544</code><code>&lt;td&gt;</code></p><p><code>2545</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>2546</code><code>&lt;/tr&gt;</code></p><p><code>2547</code><code>&lt;tr&gt;</code></p><p><code>2548</code><code>&lt;td rowspan="9"&gt;</code></p><p><code>2549</code><code>IIIB&lt;/td&gt;</code></p><p><code>2550</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2551</code><code>T4, N0, M0&lt;/td&gt;</code></p><p><code>2552</code><code>&lt;td&gt;</code></p><p><code>2553</code><code>T4 = Tumor involves the celiac axis, superior mesenteric artery, and/or common hepatic artery.&lt;/td&gt;</code></p><p><code>2554</code><code>&lt;/tr&gt;</code></p><p><code>2555</code><code>&lt;tr&gt;</code></p><p><code>2556</code><code>&lt;td&gt;</code></p><p><code>2557</code><code>N0 = No regional lymph node metastasis.&lt;/td&gt;</code></p><p><code>2558</code><code>&lt;/tr&gt;</code></p><p><code>2559</code><code>&lt;tr&gt;</code></p><p><code>2560</code><code>&lt;td&gt;</code></p><p><code>2561</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>2562</code><code>&lt;/tr&gt;</code></p><p><code>2563</code><code>&lt;tr&gt;</code></p><p><code>2564</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2565</code><code>T4, N1, M0 &lt;/td&gt;</code></p><p><code>2566</code><code>&lt;td&gt;</code></p><p><code>2567</code><code>T4 = Tumor involves the celiac axis, superior mesenteric artery, and/or common hepatic artery.&lt;/td&gt;</code></p><p><code>2568</code><code>&lt;/tr&gt;</code></p><p><code>2569</code><code>&lt;tr&gt;</code></p><p><code>2570</code><code>&lt;td&gt;</code></p><p><code>2571</code><code>N1 = Metastasis in one to three regional lymph nodes.&lt;/td&gt;</code></p><p><code>2572</code><code>&lt;/tr&gt;</code></p><p><code>2573</code><code>&lt;tr&gt;</code></p><p><code>2574</code><code>&lt;td&gt;</code></p><p><code>2575</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>2576</code><code>&lt;/tr&gt;</code></p><p><code>2577</code><code>&lt;tr&gt;</code></p><p><code>2578</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2579</code><code>T4, N2, M0&lt;/td&gt;</code></p><p><code>2580</code><code>&lt;td&gt;</code></p><p><code>2581</code><code>T4 = Tumor involves the celiac axis, superior mesenteric artery, and/or common hepatic artery.&lt;/td&gt;</code></p><p><code>2582</code><code>&lt;/tr&gt;</code></p><p><code>2583</code><code>&lt;tr&gt;</code></p><p><code>2584</code><code>&lt;td&gt;</code></p><p><code>2585</code><code>N2 = Metastasis in four or more regional lymph nodes.&lt;/td&gt;</code></p><p><code>2586</code><code>&lt;/tr&gt;</code></p><p><code>2587</code><code>&lt;tr&gt;</code></p><p><code>2588</code><code>&lt;td&gt;</code></p><p><code>2589</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>2590</code><code>&lt;/tr&gt;</code></p><p><code>2591</code><code>&lt;/tbody&gt;</code></p><p><code>2592</code><code>&lt;/table&gt;</code></p><p><code>2593</code><code>&lt;table id="_372" class="table-default expandable-container"&gt;</code></p><p><code>2594</code><code>&lt;caption&gt;</code></p><p><code>2595</code><code>Table 15.  Definitions of TNM Stage IV Distal  Bile Duct Cancer&lt;span class="sup"&gt;</code></p><p><code>2596</code><code>a&lt;/span&gt;</code></p><p><code>2597</code><code>&lt;/caption&gt;</code></p><p><code>2598</code><code>&lt;colgroup&gt;</code></p><p><code>2599</code><code>&lt;col width="16.50%"&gt;</code></p><p><code>2600</code><code>&lt;col width="18.97%"&gt;</code></p><p><code>2601</code><code>&lt;col width="64.52%"&gt;</code></p><p><code>2602</code><code>&lt;/colgroup&gt;</code></p><p><code>2603</code><code>&lt;THead&gt;</code></p><p><code>2604</code><code>&lt;tr&gt;</code></p><p><code>2605</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2606</code><code>Stage&lt;/th&gt;</code></p><p><code>2607</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2608</code><code>TNM&lt;/th&gt;</code></p><p><code>2609</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2610</code><code>Definition&lt;/th&gt;</code></p><p><code>2611</code><code>&lt;/tr&gt;</code></p><p><code>2612</code><code>&lt;/THead&gt;</code></p><p><code>2613</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>2614</code><code>&lt;tr&gt;</code></p><p><code>2615</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2616</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis.&lt;/td&gt;</code></p><p><code>2617</code><code>&lt;/tr&gt;</code></p><p><code>2618</code><code>&lt;tr&gt;</code></p><p><code>2619</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2620</code><code>&lt;span class="sup"&gt;</code></p><p><code>2621</code><code>a&lt;/span&gt;</code></p><p><code>2622</code><code>Reprinted with permission from AJCC: Distal Bile Duct. In: Amin MB, Edge SB,  Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>2623</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>2624</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 317&amp;#8211;325.&lt;/td&gt;</code></p><p><code>2625</code><code>&lt;/tr&gt;</code></p><p><code>2626</code><code>&lt;/TFoot&gt;</code></p><p><code>2627</code><code>&lt;tbody&gt;</code></p><p><code>2628</code><code>&lt;tr&gt;</code></p><p><code>2629</code><code>&lt;td rowspan="11"&gt;</code></p><p><code>2630</code><code>IV&lt;/td&gt;</code></p><p><code>2631</code><code>&lt;td rowspan="11"&gt;</code></p><p><code>2632</code><code>Any T, Any N, M1&lt;/td&gt;</code></p><p><code>2633</code><code>&lt;td&gt;</code></p><p><code>2634</code><code>TX = Primary tumor cannot be assessed.&lt;/td&gt;</code></p><p><code>2635</code><code>&lt;/tr&gt;</code></p><p><code>2636</code><code>&lt;tr&gt;</code></p><p><code>2637</code><code>&lt;td&gt;</code></p><p><code>2638</code><code>TIS = Carcinoma &lt;em&gt;</code></p><p><code>2639</code><code>in situ&lt;/em&gt;</code></p><p><code>2640</code><code>/high-grade dysplasia.&lt;/td&gt;</code></p><p><code>2641</code><code>&lt;/tr&gt;</code></p><p><code>2642</code><code>&lt;tr&gt;</code></p><p><code>2643</code><code>&lt;td&gt;</code></p><p><code>2644</code><code>T1 = Tumor invades the bile duct wall with a depth &amp;lt;5 mm.&lt;/td&gt;</code></p><p><code>2645</code><code>&lt;/tr&gt;</code></p><p><code>2646</code><code>&lt;tr&gt;</code></p><p><code>2647</code><code>&lt;td&gt;</code></p><p><code>2648</code><code>T2 = Tumor invades the bile duct wall with a depth of 5&amp;#8211;12 mm.&lt;/td&gt;</code></p><p><code>2649</code><code>&lt;/tr&gt;</code></p><p><code>2650</code><code>&lt;tr&gt;</code></p><p><code>2651</code><code>&lt;td&gt;</code></p><p><code>2652</code><code>T3 = Tumor invades the bile duct wall with a depth &amp;gt;12 mm.&lt;/td&gt;</code></p><p><code>2653</code><code>&lt;/tr&gt;</code></p><p><code>2654</code><code>&lt;tr&gt;</code></p><p><code>2655</code><code>&lt;td&gt;</code></p><p><code>2656</code><code>T4 = Tumor involves the celiac axis, superior mesenteric artery, and/or common hepatic artery.&lt;/td&gt;</code></p><p><code>2657</code><code>&lt;/tr&gt;</code></p><p><code>2658</code><code>&lt;tr&gt;</code></p><p><code>2659</code><code>&lt;td&gt;</code></p><p><code>2660</code><code>NX = Regional lymph nodes cannot be assessed.&lt;/td&gt;</code></p><p><code>2661</code><code>&lt;/tr&gt;</code></p><p><code>2662</code><code>&lt;tr&gt;</code></p><p><code>2663</code><code>&lt;td&gt;</code></p><p><code>2664</code><code>N0 = No regional lymph node metastasis.&lt;/td&gt;</code></p><p><code>2665</code><code>&lt;/tr&gt;</code></p><p><code>2666</code><code>&lt;tr&gt;</code></p><p><code>2667</code><code>&lt;td&gt;</code></p><p><code>2668</code><code>N1 = Metastasis in one to three regional lymph nodes.&lt;/td&gt;</code></p><p><code>2669</code><code>&lt;/tr&gt;</code></p><p><code>2670</code><code>&lt;tr&gt;</code></p><p><code>2671</code><code>&lt;td&gt;</code></p><p><code>2672</code><code>N2 = Metastasis in four or more regional lymph nodes.&lt;/td&gt;</code></p><p><code>2673</code><code>&lt;/tr&gt;</code></p><p><code>2674</code><code>&lt;tr&gt;</code></p><p><code>2675</code><code>&lt;td&gt;</code></p><p><code>2676</code><code>M1 = Distant metastasis.&lt;/td&gt;</code></p><p><code>2677</code><code>&lt;/tr&gt;</code></p><p><code>2678</code><code>&lt;/tbody&gt;</code></p><p><code>2679</code><code>&lt;/table&gt;</code></p><p><code>2680</code><code>&lt;/section&gt;</code></p><p><code>2681</code><code>&lt;/section&gt;</code></p><p><code>2682</code><code>&lt;h6 do-not-show="toc"&gt;</code></p><p><code>2683</code><code>References&lt;/h6&gt;</code></p><p><code>2684</code><code>&lt;ol&gt;</code></p><p><code>2685</code><code>&lt;li id="section_3.1"&gt;</code></p><p><code>2686</code><code>Intrahepatic Bile Ducts. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. Springer; 2017, pp. 295&amp;#8211;302.&lt;/li&gt;</code></p><p><code>2687</code><code>&lt;li id="section_3.2"&gt;</code></p><p><code>2688</code><code>Perihilar Bile Ducts. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. Springer; 2017, pp. 311&amp;#8211;6.&lt;/li&gt;</code></p><p><code>2689</code><code>&lt;li id="section_3.3"&gt;</code></p><p><code>2690</code><code>Distal bile duct. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. Springer; 2017, pp. 317&amp;#8211;25.&lt;/li&gt;</code></p><p><code>2691</code><code>&lt;/ol&gt;</code></p><p><code>2692</code><code>&lt;/div&gt;</code></p><p><code>2693</code><code>          </code></p><p><code>2694</code><code>    &lt;/section&gt;</code></p><p><code>2695</code><code>          </code></p><p><code>2696</code><code>          </code></p><p><code>2697</code><code>          </code></p><p><code>2698</code><code>    &lt;section id="_261"&gt;</code></p><p><code>2699</code><code>          </code></p><p><code>2700</code><code>        &lt;h2&gt;</code></p><p><code>2701</code><code>Treatment Option Overview for Bile Duct Cancer&lt;/h2&gt;</code></p><p><code>2702</code><code>          </code></p><p><code>2703</code><code>        &lt;div id="_section_261" class="pdq-sections"&gt;</code></p><p><code>2704</code><code>&lt;nav class="in-this-section" role="navigation"&gt;</code></p><p><code>2705</code><code>&lt;h6&gt;</code></p><p><code>2706</code><code>In This Section&lt;/h6&gt;</code></p><p><code>2707</code><code>&lt;ul&gt;</code></p><p><code>2708</code><code>&lt;li&gt;</code></p><p><code>2709</code><code>&lt;a href="#_28_toc"&gt;</code></p><p><code>2710</code><code>Resectable (Localized)  Bile Duct Cancer&lt;/a&gt;</code></p><p><code>2711</code><code>&lt;/li&gt;</code></p><p><code>2712</code><code>&lt;li&gt;</code></p><p><code>2713</code><code>&lt;a href="#_30_toc"&gt;</code></p><p><code>2714</code><code>Unresectable (Including Metastatic and Recurrent)  Bile Duct Cancer&lt;/a&gt;</code></p><p><code>2715</code><code>&lt;/li&gt;</code></p><p><code>2716</code><code>&lt;/ul&gt;</code></p><p><code>2717</code><code>&lt;/nav&gt;</code></p><p><code>2718</code><code>&lt;p id="_271" tabindex="-1"&gt;</code></p><p><code>2719</code><code>The treatment of bile duct cancer depends primarily on whether the cancer can be completely removed by surgery.&lt;/p&gt;</code></p><p><code>2720</code><code>&lt;section id="_28"&gt;</code></p><p><code>2721</code><code>&lt;h3 id="_28_toc"&gt;</code></p><p><code>2722</code><code>Resectable (Localized)  Bile Duct Cancer&lt;/h3&gt;</code></p><p><code>2723</code><code>&lt;p id="_29" tabindex="-1"&gt;</code></p><p><code>2724</code><code>Localized intrahepatic and extrahepatic  bile duct cancer  may be  completely removed by surgery. These tumors represent a very small number of cases  that are usually in the distal common bile duct.  Among patients treated with surgical resection, long-term prognosis varies depending on primary tumor extent, margin status, lymph node involvement, and additional pathological features.[&lt;a href="#cit/section_4.1"&gt;</code></p><p><code>2725</code><code>1&lt;/a&gt;</code></p><p><code>2726</code><code>,&lt;a href="#cit/section_4.2"&gt;</code></p><p><code>2727</code><code>2&lt;/a&gt;</code></p><p><code>2728</code><code>]&lt;/p&gt;</code></p><p><code>2729</code><code>&lt;p id="_238" tabindex="-1"&gt;</code></p><p><code>2730</code><code>Extended resections of hepatic duct bifurcation tumors (Klatskin tumors, also known as hilar tumors) to include adjacent liver, either by lobectomy or removal of portions of segments 4 and 5 of the liver, may be performed. If major hepatic resection is necessary to achieve a complete resection, postoperative hepatic reserve should be evaluated.  For patients with underlying cirrhosis, the Child-Pugh class and the Model for End-Stage Liver Disease score are determined. &lt;/p&gt;</code></p><p><code>2731</code><code>&lt;/section&gt;</code></p><p><code>2732</code><code>&lt;section id="_30"&gt;</code></p><p><code>2733</code><code>&lt;h3 id="_30_toc"&gt;</code></p><p><code>2734</code><code>Unresectable (Including Metastatic and Recurrent)  Bile Duct Cancer&lt;/h3&gt;</code></p><p><code>2735</code><code>&lt;p id="_265" tabindex="-1"&gt;</code></p><p><code>2736</code><code>Most cases of intrahepatic, distal, and perihilar bile duct cancer are unresectable and</code></p><p><code>2737</code><code>cannot be completely removed.  Often the cancer invades directly into the portal vein, the adjacent liver,   along the common bile duct, and to adjacent lymph nodes.  Portal hypertension may result from invasion of the portal vein.  Spread to distant parts of the body is</code></p><p><code>2738</code><code>uncommon, but intra-abdominal metastases, particularly peritoneal metastases, do occur. Transperitoneal and hematogenous hepatic metastases also occur</code></p><p><code>2739</code><code>with bile duct cancer of all sites.  Moreover, most patients who undergo resection will develop recurrent disease within the hepatobiliary system or, less frequently, at distant sites.&lt;/p&gt;</code></p><p><code>2740</code><code>&lt;p id="_432" tabindex="-1"&gt;</code></p><p><code>2741</code><code>In locally advanced disease, phase II trials have evaluated chemoradiotherapy with the goal of improved local control and potential downstaging for surgical resection.[&lt;a href="#cit/section_4.3"&gt;</code></p><p><code>2742</code><code>3&lt;/a&gt;</code></p><p><code>2743</code><code>,&lt;a href="#cit/section_4.4"&gt;</code></p><p><code>2744</code><code>4&lt;/a&gt;</code></p><p><code>2745</code><code>] These approaches have not been compared with standard therapy, and the curative potential is unknown.&lt;/p&gt;</code></p><p><code>2746</code><code>&lt;p id="_239" tabindex="-1"&gt;</code></p><p><code>2747</code><code>For patients with unresectable bile duct cancer, management is directed at palliation.&lt;/p&gt;</code></p><p><code>2748</code><code>&lt;/section&gt;</code></p><p><code>2749</code><code>&lt;p id="_262" tabindex="-1"&gt;</code></p><p><code>2750</code><code>Treatment options for bile duct cancer are described in &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_499"&gt;</code></p><p><code>2751</code><code>Table 16&lt;/a&gt;</code></p><p><code>2752</code><code>. &lt;/p&gt;</code></p><p><code>2753</code><code>&lt;table id="_499" class="table-default expandable-container"&gt;</code></p><p><code>2754</code><code>&lt;caption&gt;</code></p><p><code>2755</code><code>Table 16. Treatment Options for Bile Duct Cancer&lt;/caption&gt;</code></p><p><code>2756</code><code>&lt;colgroup&gt;</code></p><p><code>2757</code><code>&lt;col width="50.00%"&gt;</code></p><p><code>2758</code><code>&lt;col width="50.00%"&gt;</code></p><p><code>2759</code><code>&lt;/colgroup&gt;</code></p><p><code>2760</code><code>&lt;THead&gt;</code></p><p><code>2761</code><code>&lt;tr&gt;</code></p><p><code>2762</code><code>&lt;th&gt;</code></p><p><code>2763</code><code>Staging Criteria&lt;/th&gt;</code></p><p><code>2764</code><code>&lt;th&gt;</code></p><p><code>2765</code><code>Treatment Options&lt;/th&gt;</code></p><p><code>2766</code><code>&lt;/tr&gt;</code></p><p><code>2767</code><code>&lt;/THead&gt;</code></p><p><code>2768</code><code>&lt;tbody&gt;</code></p><p><code>2769</code><code>&lt;tr&gt;</code></p><p><code>2770</code><code>&lt;td rowspan="2"&gt;</code></p><p><code>2771</code><code>Resectable (Localized) Bile Duct Cancer&lt;/td&gt;</code></p><p><code>2772</code><code>&lt;td&gt;</code></p><p><code>2773</code><code>&lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_440"&gt;</code></p><p><code>2774</code><code>Surgery&lt;/a&gt;</code></p><p><code>2775</code><code>&lt;/td&gt;</code></p><p><code>2776</code><code>&lt;/tr&gt;</code></p><p><code>2777</code><code>&lt;tr&gt;</code></p><p><code>2778</code><code>&lt;td&gt;</code></p><p><code>2779</code><code>   &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_476"&gt;</code></p><p><code>2780</code><code>Adjuvant therapy&lt;/a&gt;</code></p><p><code>2781</code><code>&lt;/td&gt;</code></p><p><code>2782</code><code>&lt;/tr&gt;</code></p><p><code>2783</code><code>&lt;tr&gt;</code></p><p><code>2784</code><code>&lt;td rowspan="4"&gt;</code></p><p><code>2785</code><code>Unresectable (Including Metastatic and Recurrent) Bile Duct Cancer &lt;/td&gt;</code></p><p><code>2786</code><code>&lt;td&gt;</code></p><p><code>2787</code><code>&lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_542"&gt;</code></p><p><code>2788</code><code>Palliative therapy&lt;/a&gt;</code></p><p><code>2789</code><code>&lt;/td&gt;</code></p><p><code>2790</code><code>&lt;/tr&gt;</code></p><p><code>2791</code><code>&lt;tr&gt;</code></p><p><code>2792</code><code>&lt;td&gt;</code></p><p><code>2793</code><code>&lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_546"&gt;</code></p><p><code>2794</code><code>Chemotherapy&lt;/a&gt;</code></p><p><code>2795</code><code>&lt;/td&gt;</code></p><p><code>2796</code><code>&lt;/tr&gt;</code></p><p><code>2797</code><code>&lt;tr&gt;</code></p><p><code>2798</code><code>&lt;td&gt;</code></p><p><code>2799</code><code>&lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_558"&gt;</code></p><p><code>2800</code><code>Immunotherapy&lt;/a&gt;</code></p><p><code>2801</code><code>&lt;/td&gt;</code></p><p><code>2802</code><code>&lt;/tr&gt;</code></p><p><code>2803</code><code>&lt;tr&gt;</code></p><p><code>2804</code><code>&lt;td&gt;</code></p><p><code>2805</code><code>&lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_564"&gt;</code></p><p><code>2806</code><code>Targeted therapy&lt;/a&gt;</code></p><p><code>2807</code><code>&lt;/td&gt;</code></p><p><code>2808</code><code>&lt;/tr&gt;</code></p><p><code>2809</code><code>&lt;/tbody&gt;</code></p><p><code>2810</code><code>&lt;/table&gt;</code></p><p><code>2811</code><code>&lt;h6 do-not-show="toc"&gt;</code></p><p><code>2812</code><code>References&lt;/h6&gt;</code></p><p><code>2813</code><code>&lt;ol&gt;</code></p><p><code>2814</code><code>&lt;li id="section_4.1"&gt;</code></p><p><code>2815</code><code>Nagorney DM, Donohue JH, Farnell MB, et al.: Outcomes after curative resections of cholangiocarcinoma. Arch Surg 128 (8): 871-7; discussion 877-9, 1993.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=8393652&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=8393652&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2816</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2817</code><code>&lt;/li&gt;</code></p><p><code>2818</code><code>&lt;li id="section_4.2"&gt;</code></p><p><code>2819</code><code>Washburn WK, Lewis WD, Jenkins RL: Aggressive surgical resection for cholangiocarcinoma. Arch Surg 130 (3): 270-6, 1995.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=7534059&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=7534059&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2820</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2821</code><code>&lt;/li&gt;</code></p><p><code>2822</code><code>&lt;li id="section_4.3"&gt;</code></p><p><code>2823</code><code>Edeline J, Touchefeu Y, Guiu B, et al.: Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol 6 (1): 51-59, 2020.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=31670746&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=31670746&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2824</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2825</code><code>&lt;/li&gt;</code></p><p><code>2826</code><code>&lt;li id="section_4.4"&gt;</code></p><p><code>2827</code><code>Cercek A, Boerner T, Tan BR, et al.: Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol 6 (1): 60-67, 2020.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=31670750&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=31670750&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2828</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2829</code><code>&lt;/li&gt;</code></p><p><code>2830</code><code>&lt;/ol&gt;</code></p><p><code>2831</code><code>&lt;/div&gt;</code></p><p><code>2832</code><code>          </code></p><p><code>2833</code><code>    &lt;/section&gt;</code></p><p><code>2834</code><code>          </code></p><p><code>2835</code><code>          </code></p><p><code>2836</code><code>          </code></p><p><code>2837</code><code>    &lt;section id="_500"&gt;</code></p><p><code>2838</code><code>          </code></p><p><code>2839</code><code>        &lt;h2&gt;</code></p><p><code>2840</code><code>Treatment of Resectable (Localized) Bile Duct Cancer&lt;/h2&gt;</code></p><p><code>2841</code><code>          </code></p><p><code>2842</code><code>        &lt;div id="_section_500" class="pdq-sections"&gt;</code></p><p><code>2843</code><code>&lt;nav class="in-this-section" role="navigation"&gt;</code></p><p><code>2844</code><code>&lt;h6&gt;</code></p><p><code>2845</code><code>In This Section&lt;/h6&gt;</code></p><p><code>2846</code><code>&lt;ul&gt;</code></p><p><code>2847</code><code>&lt;li&gt;</code></p><p><code>2848</code><code>&lt;a href="#_438_toc"&gt;</code></p><p><code>2849</code><code>Treatment Options for Resectable (Localized) Bile Duct Cancer&lt;ul&gt;</code></p><p><code>2850</code><code>&lt;li&gt;</code></p><p><code>2851</code><code>&lt;a href="#_440_toc"&gt;</code></p><p><code>2852</code><code>Surgery&lt;/a&gt;</code></p><p><code>2853</code><code>&lt;/li&gt;</code></p><p><code>2854</code><code>&lt;li&gt;</code></p><p><code>2855</code><code>&lt;a href="#_476_toc"&gt;</code></p><p><code>2856</code><code>Adjuvant therapy&lt;/a&gt;</code></p><p><code>2857</code><code>&lt;/li&gt;</code></p><p><code>2858</code><code>&lt;/ul&gt;</code></p><p><code>2859</code><code>&lt;/a&gt;</code></p><p><code>2860</code><code>&lt;/li&gt;</code></p><p><code>2861</code><code>&lt;li&gt;</code></p><p><code>2862</code><code>&lt;a href="#_TrialSearch_500_sid_5_toc"&gt;</code></p><p><code>2863</code><code>Current Clinical Trials&lt;/a&gt;</code></p><p><code>2864</code><code>&lt;/li&gt;</code></p><p><code>2865</code><code>&lt;/ul&gt;</code></p><p><code>2866</code><code>&lt;/nav&gt;</code></p><p><code>2867</code><code>&lt;section id="_438"&gt;</code></p><p><code>2868</code><code>&lt;h3 id="_438_toc"&gt;</code></p><p><code>2869</code><code>Treatment Options for Resectable (Localized) Bile Duct Cancer&lt;/h3&gt;</code></p><p><code>2870</code><code>&lt;p id="_576" tabindex="-1"&gt;</code></p><p><code>2871</code><code>Treatment options for resectable (localized) bile duct cancer include the following:&lt;/p&gt;</code></p><p><code>2872</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>2873</code><code>&lt;ol id="_465"&gt;</code></p><p><code>2874</code><code>&lt;li&gt;</code></p><p><code>2875</code><code>&lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_440"&gt;</code></p><p><code>2876</code><code>Surgery&lt;/a&gt;</code></p><p><code>2877</code><code>.&lt;/li&gt;</code></p><p><code>2878</code><code>&lt;li&gt;</code></p><p><code>2879</code><code>&lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_476"&gt;</code></p><p><code>2880</code><code>Adjuvant therapy&lt;/a&gt;</code></p><p><code>2881</code><code>.&lt;/li&gt;</code></p><p><code>2882</code><code>&lt;/ol&gt;</code></p><p><code>2883</code><code>&lt;/div&gt;</code></p><p><code>2884</code><code>&lt;section id="_440"&gt;</code></p><p><code>2885</code><code>&lt;h4 id="_440_toc"&gt;</code></p><p><code>2886</code><code>Surgery&lt;/h4&gt;</code></p><p><code>2887</code><code>&lt;section id="_441"&gt;</code></p><p><code>2888</code><code>&lt;h5 id="_441_toc"&gt;</code></p><p><code>2889</code><code>Intrahepatic bile duct cancer&lt;/h5&gt;</code></p><p><code>2890</code><code>&lt;p id="_442" tabindex="-1"&gt;</code></p><p><code>2891</code><code>For intrahepatic bile duct cancers, hepatic resection to achieve negative margins is potentially curative.  If a major liver resection is necessary to achieve negative surgical margins, preoperative portal vein embolization may be considered to optimize the volume of the remnant liver.&lt;/p&gt;</code></p><p><code>2892</code><code>&lt;p id="_443" tabindex="-1"&gt;</code></p><p><code>2893</code><code>Partial liver resection or partial hepatectomy to achieve negative margins is a procedure with curative intent for patients with intrahepatic cholangiocarcinoma.[&lt;a href="#cit/section_5.1"&gt;</code></p><p><code>2894</code><code>1&lt;/a&gt;</code></p><p><code>2895</code><code>]  The extent of liver resection necessary depends on the extent of hepatic parenchymal involvement and the proximity of the tumor to major blood vessels in this region.&lt;/p&gt;</code></p><p><code>2896</code><code>&lt;p id="_466" tabindex="-1"&gt;</code></p><p><code>2897</code><code>The role of routine portal lymphadenectomy has not been well established because of  the risk of common bile duct devascularization. &lt;/p&gt;</code></p><p><code>2898</code><code>&lt;/section&gt;</code></p><p><code>2899</code><code>&lt;section id="_467"&gt;</code></p><p><code>2900</code><code>&lt;h5 id="_467_toc"&gt;</code></p><p><code>2901</code><code>Perihilar bile duct cancer&lt;/h5&gt;</code></p><p><code>2902</code><code>&lt;p id="_468" tabindex="-1"&gt;</code></p><p><code>2903</code><code>For perihilar cholangiocarcinomas (Klatskin tumors), bile duct resection alone leads to high local recurrence rates resulting from the  early confluence of the hepatic ducts and the caudate lobe.  The addition of partial hepatectomy that includes the caudate lobe has improved long-term outcomes, but it may be associated with increased postoperative complications.[&lt;a href="#cit/section_5.2"&gt;</code></p><p><code>2904</code><code>2&lt;/a&gt;</code></p><p><code>2905</code><code>]  With this aggressive surgical approach, 5-year survival rates of 20% to 50% have been reported.[&lt;a href="#cit/section_5.3"&gt;</code></p><p><code>2906</code><code>3&lt;/a&gt;</code></p><p><code>2907</code><code>]  An understanding of both the normal and varied vascular and ductal anatomy of the porta hepatis has increased the number of hepatic duct bifurcation tumors that can be resected.&lt;/p&gt;</code></p><p><code>2908</code><code>&lt;p id="_469" tabindex="-1"&gt;</code></p><p><code>2909</code><code>The primary site of relapse after surgical resection is local; however, distant recurrence is also frequently reported.[&lt;a href="#cit/section_5.4"&gt;</code></p><p><code>2910</code><code>4&lt;/a&gt;</code></p><p><code>2911</code><code>]&lt;/p&gt;</code></p><p><code>2912</code><code>&lt;p id="_470" tabindex="-1"&gt;</code></p><p><code>2913</code><code>The optimal surgical procedure for carcinoma of the perihilar bile duct varies according to the location of the tumor along the biliary tree, the extent of hepatic parenchymal involvement, and the proximity of the tumor to major blood vessels in this region. The state of the regional lymph nodes is assessed at the time of surgery because of  their prognostic significance. Operations for bile duct cancer are usually extensive. A historical cohort reported an operative mortality rate of approximately 10%, along with a roughly 40% risk of disease recurrence.[&lt;a href="#cit/section_5.5"&gt;</code></p><p><code>2914</code><code>5&lt;/a&gt;</code></p><p><code>2915</code><code>]&lt;/p&gt;</code></p><p><code>2916</code><code>&lt;p id="_471" tabindex="-1"&gt;</code></p><p><code>2917</code><code>In jaundiced patients, the role of percutaneous transhepatic catheter drainage or endoscopic placement of a stent for relief of biliary obstruction is controversial because of inconsistent findings of significant clinical benefit and concerns of increased risk of postoperative complications.[&lt;a href="#cit/section_5.6"&gt;</code></p><p><code>2918</code><code>6&lt;/a&gt;</code></p><p><code>2919</code><code>]  However, percutaneous transhepatic catheter drainage or endoscopic placement of a stent for relief of biliary obstruction may be considered before surgery, particularly if jaundice is severe or an element of azotemia is present.[&lt;a href="#cit/section_5.7"&gt;</code></p><p><code>2920</code><code>7&lt;/a&gt;</code></p><p><code>2921</code><code>,&lt;a href="#cit/section_5.8"&gt;</code></p><p><code>2922</code><code>8&lt;/a&gt;</code></p><p><code>2923</code><code>]&lt;/p&gt;</code></p><p><code>2924</code><code>&lt;/section&gt;</code></p><p><code>2925</code><code>&lt;section id="_472"&gt;</code></p><p><code>2926</code><code>&lt;h5 id="_472_toc"&gt;</code></p><p><code>2927</code><code>Distal bile duct cancer&lt;/h5&gt;</code></p><p><code>2928</code><code>&lt;p id="_473" tabindex="-1"&gt;</code></p><p><code>2929</code><code>Complete surgical resection with negative surgical margins offers the only chance of cure for distal bile duct cancers.  Bile duct tumors can be difficult to resect because of their proximity to major blood vessels and diffuse infiltration of adjacent bile ducts.  Total resection is possible in 25% to 30% of lesions that originate in the distal bile duct; the resectability rate is lower for lesions that occur in more proximal sites.[&lt;a href="#cit/section_5.9"&gt;</code></p><p><code>2930</code><code>9&lt;/a&gt;</code></p><p><code>2931</code><code>]&lt;/p&gt;</code></p><p><code>2932</code><code>&lt;p id="_474" tabindex="-1"&gt;</code></p><p><code>2933</code><code>The optimum surgical procedure for carcinoma of the distal bile duct will vary according to the location of the tumor along the biliary tree, the</code></p><p><code>2934</code><code>extent of hepatic parenchymal involvement, and the proximity of the tumor to</code></p><p><code>2935</code><code>major blood vessels in this region.  The regional lymph nodes are  assessed at the time of surgery because  they have prognostic significance.  Patients with cancer of the</code></p><p><code>2936</code><code>lower end of the duct and regional lymph node involvement may warrant an</code></p><p><code>2937</code><code>extensive resection (Whipple procedure). The 5-year survival outcomes range between 20% and 50%.[&lt;a href="#cit/section_5.10"&gt;</code></p><p><code>2938</code><code>10&lt;/a&gt;</code></p><p><code>2939</code><code>,&lt;a href="#cit/section_5.11"&gt;</code></p><p><code>2940</code><code>11&lt;/a&gt;</code></p><p><code>2941</code><code>] Bypass operations or endoluminal</code></p><p><code>2942</code><code>stents are alternatives if intraoperatively the tumor is found to be unresectable.[&lt;a href="#cit/section_5.10"&gt;</code></p><p><code>2943</code><code>10&lt;/a&gt;</code></p><p><code>2944</code><code>,&lt;a href="#cit/section_5.11"&gt;</code></p><p><code>2945</code><code>11&lt;/a&gt;</code></p><p><code>2946</code><code>]&lt;/p&gt;</code></p><p><code>2947</code><code>&lt;p id="_475" tabindex="-1"&gt;</code></p><p><code>2948</code><code>In jaundiced patients, the role of percutaneous transhepatic catheter drainage or endoscopic placement of a stent for relief of biliary obstruction is controversial, but these options may be considered before surgery, particularly if jaundice is severe or an element of azotemia is present.[&lt;a href="#cit/section_5.7"&gt;</code></p><p><code>2949</code><code>7&lt;/a&gt;</code></p><p><code>2950</code><code>,&lt;a href="#cit/section_5.8"&gt;</code></p><p><code>2951</code><code>8&lt;/a&gt;</code></p><p><code>2952</code><code>]&lt;/p&gt;</code></p><p><code>2953</code><code>&lt;/section&gt;</code></p><p><code>2954</code><code>&lt;/section&gt;</code></p><p><code>2955</code><code>&lt;section id="_476"&gt;</code></p><p><code>2956</code><code>&lt;h4 id="_476_toc"&gt;</code></p><p><code>2957</code><code>Adjuvant therapy&lt;/h4&gt;</code></p><p><code>2958</code><code>&lt;section id="_477"&gt;</code></p><p><code>2959</code><code>&lt;h5 id="_477_toc"&gt;</code></p><p><code>2960</code><code>Chemotherapy&lt;/h5&gt;</code></p><p><code>2961</code><code>&lt;p id="_478" tabindex="-1"&gt;</code></p><p><code>2962</code><code>Numerous retrospective series have suggested that adjuvant chemotherapy after complete surgical resection may be beneficial.[&lt;a href="#cit/section_5.12"&gt;</code></p><p><code>2963</code><code>12&lt;/a&gt;</code></p><p><code>2964</code><code>,&lt;a href="#cit/section_5.13"&gt;</code></p><p><code>2965</code><code>13&lt;/a&gt;</code></p><p><code>2966</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2967</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>2968</code><code>]  However, prospective randomized trials have failed to consistently show a significant benefit in overall survival (OS).  &lt;/p&gt;</code></p><p><code>2969</code><code>&lt;p id="_492" tabindex="-1"&gt;</code></p><p><code>2970</code><code>Evidence (chemotherapy):&lt;/p&gt;</code></p><p><code>2971</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>2972</code><code>&lt;ol id="_479"&gt;</code></p><p><code>2973</code><code>&lt;li&gt;</code></p><p><code>2974</code><code>A multicenter phase III study in the United Kingdom (BILCAP) included 447 patients with cholangiocarcinoma or muscle-invasive gallbladder cancer who underwent a macroscopically complete resection with curative intent. Patients were randomly assigned to receive eight cycles of capecitabine  (1,250 mg/m&lt;span class="sup"&gt;</code></p><p><code>2975</code><code>2&lt;/span&gt;</code></p><p><code>2976</code><code> twice a day on days 1&amp;#8722;14 of a 21-day cycle) or observation.[&lt;a href="#cit/section_5.13"&gt;</code></p><p><code>2977</code><code>13&lt;/a&gt;</code></p><p><code>2978</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810025&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810025&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2979</code><code>Level of evidence B1&lt;/a&gt;</code></p><p><code>2980</code><code>] At a median follow-up of 106 months, the following results were observed:&lt;div class="pdq-content-list"&gt;</code></p><p><code>2981</code><code>&lt;ul id="_480"&gt;</code></p><p><code>2982</code><code>&lt;li&gt;</code></p><p><code>2983</code><code>	There was no statistically significant difference in OS in the intention-to-treat analysis (median OS, 49.6 months in the capecitabine group vs. 36.1 months in the observation group; adjusted hazard ratio [HR], 0.84; 95% confidence interval [CI], 0.67&amp;#8722;1.06; &lt;em&gt;</code></p><p><code>2984</code><code>P&lt;/em&gt;</code></p><p><code>2985</code><code> &amp;gt; .05).&lt;/li&gt;</code></p><p><code>2986</code><code>&lt;li&gt;</code></p><p><code>2987</code><code>	In the intention-to-treat analysis, median recurrence-free survival (RFS) was 24.3 months (95% CI, 18.6&amp;#8211;34.6) in the capecitabine group and 17.4 months (95% CI, 11.8&amp;#8211;23) in the observation group. An adjusted Cox proportional hazards model suggested potential improvement in RFS in the first 24 months from randomization (HR, 0.74; 95% CI, 0.57&amp;#8211;0.96), but with no significant difference in the period after 24 months (HR, 1.57; 95% CI, 0.90&amp;#8211;2.74).&lt;/li&gt;</code></p><p><code>2988</code><code>&lt;/ul&gt;</code></p><p><code>2989</code><code>&lt;/div&gt;</code></p><p><code>2990</code><code>&lt;/li&gt;</code></p><p><code>2991</code><code>&lt;li&gt;</code></p><p><code>2992</code><code>	The open-label, randomized, phase II &lt;a href="/clinicaltrials/NCT03079427"&gt;</code></p><p><code>2993</code><code>STAMP&lt;/a&gt;</code></p><p><code>2994</code><code> study (NCT03079427), presented in abstract form, included 101 patients with perihilar or distal bile duct cancer, at least one regional lymph node metastasis (N1 or greater), and complete macroscopic (R0 or R1) resection within 12 weeks. Patients were assigned to receive either eight cycles of capecitabine (1,250 mg/m&lt;span class="sup"&gt;</code></p><p><code>2995</code><code>2&lt;/span&gt;</code></p><p><code>2996</code><code>) twice a day on days 1&amp;#8211;14 of a 21-day cycle (based on the BILCAP trial) or eight cycles of cisplatin (25 mg/m&lt;span class="sup"&gt;</code></p><p><code>2997</code><code>2&lt;/span&gt;</code></p><p><code>2998</code><code>) and gemcitabine (1,000 mg/m&lt;span class="sup"&gt;</code></p><p><code>2999</code><code>2&lt;/span&gt;</code></p><p><code>3000</code><code>) on days 1 and 8 of a 21-day cycle.[&lt;a href="#cit/section_5.14"&gt;</code></p><p><code>3001</code><code>14&lt;/a&gt;</code></p><p><code>3002</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810025&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810025&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3003</code><code>Level of evidence B1&lt;/a&gt;</code></p><p><code>3004</code><code>] At a median follow-up of 28.7 months, the following results were observed:&lt;div class="pdq-content-list"&gt;</code></p><p><code>3005</code><code>&lt;ul id="_578"&gt;</code></p><p><code>3006</code><code>&lt;li&gt;</code></p><p><code>3007</code><code>The median disease-free survival (DFS), the primary end point, was 14.3 months (1-sided 90% CI, 10.7&amp;#8211;16.5) in the cisplatin-and-gemcitabine group and 11.1 months in the capecitabine group (1-sided 90% CI, 8.4&amp;#8211;12.7).&lt;/li&gt;</code></p><p><code>3008</code><code>&lt;li&gt;</code></p><p><code>3009</code><code>	The median OS was 35.7 months (1-sided 90% CI, 29.5&amp;#8211;not estimated) in the cisplatin-and-gemcitabine group and 35.7 months (1-sided 90% CI, 30.9&amp;#8211;not estimated) in the capecitabine group.&lt;/li&gt;</code></p><p><code>3010</code><code>&lt;li&gt;</code></p><p><code>3011</code><code>	The gemcitabine-and-cisplatin group had increased rates of toxicity. Grade 3 to 4 adverse events occurred in 84% of patients who received gemcitabine and cisplatin (most commonly neutropenia) and in 16% of patients who received capecitabine (most commonly hand-foot syndrome).&lt;/li&gt;</code></p><p><code>3012</code><code>&lt;li&gt;</code></p><p><code>3013</code><code>	Given the lack of significant difference in DFS and OS and the higher toxicity rate in the cisplatin-and-gemcitabine group, capecitabine remains the current reference standard for adjuvant therapy.&lt;/li&gt;</code></p><p><code>3014</code><code>&lt;/ul&gt;</code></p><p><code>3015</code><code>&lt;/div&gt;</code></p><p><code>3016</code><code>&lt;/li&gt;</code></p><p><code>3017</code><code>&lt;li&gt;</code></p><p><code>3018</code><code>A French multicenter phase III study (PRODIGE 12-ACCORD 18-UNICANCER GI) randomly assigned 196 patients with R0 or R1 resection of localized biliary tract cancer to 12 cycles of adjuvant gemcitabine plus oxaliplatin (GEMOX) or surveillance.[&lt;a href="#cit/section_5.15"&gt;</code></p><p><code>3019</code><code>15&lt;/a&gt;</code></p><p><code>3020</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810025&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810025&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3021</code><code>Level of evidence B1&lt;/a&gt;</code></p><p><code>3022</code><code>] After a median follow-up of 46.5 months the following results were observed:&lt;div class="pdq-content-list"&gt;</code></p><p><code>3023</code><code>&lt;ul id="_481"&gt;</code></p><p><code>3024</code><code>&lt;li&gt;</code></p><p><code>3025</code><code>	There was no statistically significant difference in the primary outcome of RFS (median, 30.4 months with GEMOX vs. 18.5 months with observation; HR, 0.88; 95% CI, 0.62&amp;#8211;1.25,  &lt;em&gt;</code></p><p><code>3026</code><code>P&lt;/em&gt;</code></p><p><code>3027</code><code> = .48).&lt;/li&gt;</code></p><p><code>3028</code><code>&lt;li&gt;</code></p><p><code>3029</code><code>	There was also no statistically significant difference in the secondary outcome of OS (75.8 months with GEMOX vs. 50.8 months with observation; HR, 1.08; 95% CI, 0.7&amp;#8211;1.66; &lt;em&gt;</code></p><p><code>3030</code><code>P&lt;/em&gt;</code></p><p><code>3031</code><code> = .74).&lt;/li&gt;</code></p><p><code>3032</code><code>&lt;/ul&gt;</code></p><p><code>3033</code><code>&lt;/div&gt;</code></p><p><code>3034</code><code>&lt;/li&gt;</code></p><p><code>3035</code><code>&lt;li&gt;</code></p><p><code>3036</code><code>The Bile Duct Cancer Adjuvant Trial (BCAT), a Japanese multicenter phase III study, randomly assigned 225 patients with resected bile duct cancer to six cycles of adjuvant gemcitabine or observation.[&lt;a href="#cit/section_5.16"&gt;</code></p><p><code>3037</code><code>16&lt;/a&gt;</code></p><p><code>3038</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810025&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810025&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3039</code><code>Level of evidence B1&lt;/a&gt;</code></p><p><code>3040</code><code>]&lt;div class="pdq-content-list"&gt;</code></p><p><code>3041</code><code>&lt;ul id="_482"&gt;</code></p><p><code>3042</code><code>&lt;li&gt;</code></p><p><code>3043</code><code>	There was no significant difference in the primary outcome of OS (median, 62.3 months with gemcitabine vs. 63.8 months with observation; HR, 1.01; 95% CI, 0.7&amp;#8211;1.45; &lt;em&gt;</code></p><p><code>3044</code><code>P&lt;/em&gt;</code></p><p><code>3045</code><code> = .964).&lt;/li&gt;</code></p><p><code>3046</code><code>&lt;li&gt;</code></p><p><code>3047</code><code>	No OS differences were observed, even in subgroups stratified by lymph node status and surgical margin status.&lt;/li&gt;</code></p><p><code>3048</code><code>&lt;li&gt;</code></p><p><code>3049</code><code>	There was also no significant difference in the secondary outcome of RFS (median, 36 months with gemcitabine vs. 39.9 months with observation; HR, 0.93;  &lt;em&gt;</code></p><p><code>3050</code><code>P&lt;/em&gt;</code></p><p><code>3051</code><code> = .693).&lt;/li&gt;</code></p><p><code>3052</code><code>&lt;/ul&gt;</code></p><p><code>3053</code><code>&lt;/div&gt;</code></p><p><code>3054</code><code>&lt;/li&gt;</code></p><p><code>3055</code><code>&lt;li&gt;</code></p><p><code>3056</code><code>The European Study Group for Pancreatic Cancer (&lt;a href="/clinicaltrials/NCT00058201"&gt;</code></p><p><code>3057</code><code>ESPAC-3&lt;/a&gt;</code></p><p><code>3058</code><code> trial [NCT00058201]) randomly assigned 428 patients with periampullary cancer,  which included 96 patients with bile duct cancers, to observation, 6 months of fluorouracil (5-FU)/leucovorin, or 6 months of gemcitabine.[&lt;a href="#cit/section_5.17"&gt;</code></p><p><code>3059</code><code>17&lt;/a&gt;</code></p><p><code>3060</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810025&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810025&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3061</code><code>Level of evidence B1&lt;/a&gt;</code></p><p><code>3062</code><code>]   &lt;div class="pdq-content-list"&gt;</code></p><p><code>3063</code><code>&lt;ul id="_483"&gt;</code></p><p><code>3064</code><code>&lt;li&gt;</code></p><p><code>3065</code><code>Among all patients, adjuvant chemotherapy, compared with observation, was not associated with significant OS benefit.  However, after adjusting for prognostic variables by multivariable analysis, a statistically significant OS benefit was associated with adjuvant chemotherapy (HR, 0.75; 95% CI, 0.57&amp;#8211;0.98; &lt;em&gt;</code></p><p><code>3066</code><code>P&lt;/em&gt;</code></p><p><code>3067</code><code> = .03).&lt;/li&gt;</code></p><p><code>3068</code><code>&lt;li&gt;</code></p><p><code>3069</code><code>In a preplanned subgroup analysis of the 96 patients with bile duct cancer,  no benefit was seen among patients treated with chemotherapy.  Limitations of this subgroup analysis include limited statistical power and difficulty in differentiating ampullary versus distal common bile duct tumors as the pathological site of origin. &lt;/li&gt;</code></p><p><code>3070</code><code>&lt;li&gt;</code></p><p><code>3071</code><code>The median survival was 27 months for the observation-alone group, 18 months for the 5-FU/leucovorin group, and 20 months for the gemcitabine-alone group.[&lt;a href="#cit/section_5.17"&gt;</code></p><p><code>3072</code><code>17&lt;/a&gt;</code></p><p><code>3073</code><code>]&lt;/li&gt;</code></p><p><code>3074</code><code>&lt;/ul&gt;</code></p><p><code>3075</code><code>&lt;/div&gt;</code></p><p><code>3076</code><code>&lt;/li&gt;</code></p><p><code>3077</code><code>&lt;li&gt;</code></p><p><code>3078</code><code>A multi-institutional Japanese study compared surgery alone with mitomycin and infusional 5-FU followed by 5-FU until disease progression.[&lt;a href="#cit/section_5.18"&gt;</code></p><p><code>3079</code><code>18&lt;/a&gt;</code></p><p><code>3080</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810025&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810025&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3081</code><code>Level of evidence B1&lt;/a&gt;</code></p><p><code>3082</code><code>]&lt;div class="pdq-content-list"&gt;</code></p><p><code>3083</code><code>&lt;ul id="_484"&gt;</code></p><p><code>3084</code><code>&lt;li&gt;</code></p><p><code>3085</code><code>Among the subset of patients with bile duct cancer (n = 139), no survival benefit was seen.&lt;/li&gt;</code></p><p><code>3086</code><code>&lt;/ul&gt;</code></p><p><code>3087</code><code>&lt;/div&gt;</code></p><p><code>3088</code><code>&lt;/li&gt;</code></p><p><code>3089</code><code>&lt;/ol&gt;</code></p><p><code>3090</code><code>&lt;/div&gt;</code></p><p><code>3091</code><code>&lt;p id="_486" tabindex="-1"&gt;</code></p><p><code>3092</code><code>For a list of chemotherapy regimens with potential activity, see the  &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_501"&gt;</code></p><p><code>3093</code><code>Treatment of Unresectable (Including Metastatic and Recurrent) Bile Duct Cancer&lt;/a&gt;</code></p><p><code>3094</code><code> section.&lt;/p&gt;</code></p><p><code>3095</code><code>&lt;/section&gt;</code></p><p><code>3096</code><code>&lt;section id="_487"&gt;</code></p><p><code>3097</code><code>&lt;h5 id="_487_toc"&gt;</code></p><p><code>3098</code><code>External beam radiation therapy (EBRT)&lt;/h5&gt;</code></p><p><code>3099</code><code>&lt;p id="_488" tabindex="-1"&gt;</code></p><p><code>3100</code><code>Numerous retrospective studies have suggested that adding  EBRT after complete surgical resection may be beneficial.[&lt;a href="#cit/section_5.19"&gt;</code></p><p><code>3101</code><code>19&lt;/a&gt;</code></p><p><code>3102</code><code>,&lt;a href="#cit/section_5.20"&gt;</code></p><p><code>3103</code><code>20&lt;/a&gt;</code></p><p><code>3104</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3105</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>3106</code><code>]  However,  no prospective randomized trials have demonstrated an OS benefit.&lt;/p&gt;</code></p><p><code>3107</code><code>&lt;p id="_493" tabindex="-1"&gt;</code></p><p><code>3108</code><code>Evidence (EBRT):&lt;/p&gt;</code></p><p><code>3109</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3110</code><code>&lt;ol id="_489"&gt;</code></p><p><code>3111</code><code>&lt;li&gt;</code></p><p><code>3112</code><code>One small randomized trial of 207 patients with pancreatic and periampullary cancers demonstrated no survival benefit of adding chemoradiation therapy after surgery.  This study is limited, however, because only a few patients had a diagnosis of bile duct cancer, and 20% of the patients randomly assigned  to receive chemoradiation therapy did not receive treatment.[&lt;a href="#cit/section_5.21"&gt;</code></p><p><code>3113</code><code>21&lt;/a&gt;</code></p><p><code>3114</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810039&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810039&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3115</code><code>Level of evidence C3&lt;/a&gt;</code></p><p><code>3116</code><code>]&lt;/li&gt;</code></p><p><code>3117</code><code>&lt;li&gt;</code></p><p><code>3118</code><code>A phase II cooperative group trial, &lt;a href="/clinicaltrials/NCT00789958"&gt;</code></p><p><code>3119</code><code>SWOG S0809&lt;/a&gt;</code></p><p><code>3120</code><code> (NCT00789958), evaluated adjuvant capecitabine and gemcitabine followed by chemoradiation therapy for resected extrahepatic cholangiocarcinoma and gallbladder cancer.  In total, 79 eligible patients with pT2 to pT4 disease, node-positive disease, or positive-margin resection were enrolled (extrahepatic bile duct cancer, n = 54; gallbladder cancer, n = 25).[&lt;a href="#cit/section_5.22"&gt;</code></p><p><code>3121</code><code>22&lt;/a&gt;</code></p><p><code>3122</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3123</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>3124</code><code>]   &lt;div class="pdq-content-list"&gt;</code></p><p><code>3125</code><code>&lt;ul id="_490"&gt;</code></p><p><code>3126</code><code>&lt;li&gt;</code></p><p><code>3127</code><code>The 2-year survival rate of 65% was significantly higher than expected, based on historical controls.[&lt;a href="#cit/section_5.22"&gt;</code></p><p><code>3128</code><code>22&lt;/a&gt;</code></p><p><code>3129</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3130</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>3131</code><code>]&lt;/li&gt;</code></p><p><code>3132</code><code>&lt;li&gt;</code></p><p><code>3133</code><code>Grade 3 toxicity was observed in 52% of patients, and grade 4 toxicity was observed in 11% of patients.&lt;/li&gt;</code></p><p><code>3134</code><code>&lt;li&gt;</code></p><p><code>3135</code><code>On the basis of these results, this regimen was observed to be well tolerated, but it needs to be tested in a randomized controlled trial.&lt;/li&gt;</code></p><p><code>3136</code><code>&lt;/ul&gt;</code></p><p><code>3137</code><code>&lt;/div&gt;</code></p><p><code>3138</code><code>&lt;/li&gt;</code></p><p><code>3139</code><code>&lt;/ol&gt;</code></p><p><code>3140</code><code>&lt;/div&gt;</code></p><p><code>3141</code><code>&lt;p id="_491" tabindex="-1"&gt;</code></p><p><code>3142</code><code>All patients are encouraged to enroll in clinical trials for adjuvant therapies.  Information about ongoing clinical trials is available from the &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials"&gt;</code></p><p><code>3143</code><code>NCI website&lt;/a&gt;</code></p><p><code>3144</code><code>.&lt;/p&gt;</code></p><p><code>3145</code><code>&lt;/section&gt;</code></p><p><code>3146</code><code>&lt;/section&gt;</code></p><p><code>3147</code><code>&lt;/section&gt;</code></p><p><code>3148</code><code>&lt;section id="_TrialSearch_500_sid_5"&gt;</code></p><p><code>3149</code><code>&lt;h3 id="_TrialSearch_500_sid_5_toc"&gt;</code></p><p><code>3150</code><code>Current Clinical Trials&lt;/h3&gt;</code></p><p><code>3151</code><code>&lt;p id="_TrialSearch_500_22" tabindex="-1"&gt;</code></p><p><code>3152</code><code>Use our &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/advanced" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/advanced"&gt;</code></p><p><code>3153</code><code>advanced clinical trial search&lt;/a&gt;</code></p><p><code>3154</code><code> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/"&gt;</code></p><p><code>3155</code><code>General information&lt;/a&gt;</code></p><p><code>3156</code><code> about clinical trials is also available.&lt;/p&gt;</code></p><p><code>3157</code><code>&lt;/section&gt;</code></p><p><code>3158</code><code>&lt;h6 do-not-show="toc"&gt;</code></p><p><code>3159</code><code>References&lt;/h6&gt;</code></p><p><code>3160</code><code>&lt;ol&gt;</code></p><p><code>3161</code><code>&lt;li id="section_5.1"&gt;</code></p><p><code>3162</code><code>Dodson RM, Weiss MJ, Cosgrove D, et al.: Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg 217 (4): 736-750.e4, 2013.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=23890842&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=23890842&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3163</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3164</code><code>&lt;/li&gt;</code></p><p><code>3165</code><code>&lt;li id="section_5.2"&gt;</code></p><p><code>3166</code><code>Burke EC, Jarnagin WR, Hochwald SN, et al.: Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 228 (3): 385-94, 1998.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9742921&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9742921&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3167</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3168</code><code>&lt;/li&gt;</code></p><p><code>3169</code><code>&lt;li id="section_5.3"&gt;</code></p><p><code>3170</code><code>Nakeeb A, Tran KQ, Black MJ, et al.: Improved survival in resected biliary malignancies. Surgery 132 (4): 555-63; discussion 563-4, 2002.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=12407338&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=12407338&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3171</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3172</code><code>&lt;/li&gt;</code></p><p><code>3173</code><code>&lt;li id="section_5.4"&gt;</code></p><p><code>3174</code><code>Hasegawa S, Ikai I, Fujii H, et al.: Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg 31 (6): 1256-63, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17453285&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17453285&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3175</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3176</code><code>&lt;/li&gt;</code></p><p><code>3177</code><code>&lt;li id="section_5.5"&gt;</code></p><p><code>3178</code><code>Loehrer AP, House MG, Nakeeb A, et al.: Cholangiocarcinoma: are North American surgical outcomes optimal? J Am Coll Surg 216 (2): 192-200, 2013.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=23266423&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=23266423&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3179</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3180</code><code>&lt;/li&gt;</code></p><p><code>3181</code><code>&lt;li id="section_5.6"&gt;</code></p><p><code>3182</code><code>Liu F, Li Y, Wei Y, et al.: Preoperative biliary drainage before resection for hilar cholangiocarcinoma: whether or not? A systematic review. Dig Dis Sci 56 (3): 663-72, 2011.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20635143&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20635143&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3183</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3184</code><code>&lt;/li&gt;</code></p><p><code>3185</code><code>&lt;li id="section_5.7"&gt;</code></p><p><code>3186</code><code>Nimura Y: Preoperative biliary drainage before resection for cholangiocarcinoma (Pro). HPB (Oxford) 10 (2): 130-3, 2008.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18773090&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18773090&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3187</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3188</code><code>&lt;/li&gt;</code></p><p><code>3189</code><code>&lt;li id="section_5.8"&gt;</code></p><p><code>3190</code><code>Laurent A, Tayar C, Cherqui D: Cholangiocarcinoma: preoperative biliary drainage (Con). HPB (Oxford) 10 (2): 126-9, 2008.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18773089&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18773089&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3191</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3192</code><code>&lt;/li&gt;</code></p><p><code>3193</code><code>&lt;li id="section_5.9"&gt;</code></p><p><code>3194</code><code>Stain SC, Baer HU, Dennison AR, et al.: Current management of hilar cholangiocarcinoma. Surg Gynecol Obstet 175 (6): 579-88, 1992.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=1280374&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=1280374&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3195</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3196</code><code>&lt;/li&gt;</code></p><p><code>3197</code><code>&lt;li id="section_5.10"&gt;</code></p><p><code>3198</code><code>Fong Y, Blumgart LH, Lin E, et al.: Outcome of treatment for distal bile duct cancer. Br J Surg 83 (12): 1712-5, 1996.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9038548&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9038548&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3199</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3200</code><code>&lt;/li&gt;</code></p><p><code>3201</code><code>&lt;li id="section_5.11"&gt;</code></p><p><code>3202</code><code>Bortolasi L, Burgart LJ, Tsiotos GG, et al.: Adenocarcinoma of the distal bile duct. A clinicopathologic outcome analysis after curative resection. Dig Surg 17 (1): 36-41, 2000.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10720830&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10720830&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3203</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3204</code><code>&lt;/li&gt;</code></p><p><code>3205</code><code>&lt;li id="section_5.12"&gt;</code></p><p><code>3206</code><code>Murakami Y, Uemura K, Sudo T, et al.: Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg 250 (6): 950-6, 2009.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19953713&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19953713&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3207</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3208</code><code>&lt;/li&gt;</code></p><p><code>3209</code><code>&lt;li id="section_5.13"&gt;</code></p><p><code>3210</code><code>Bridgewater J, Fletcher P, Palmer DH, et al.: Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. J Clin Oncol 40 (18): 2048-2057, 2022.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=35316080&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=35316080&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3211</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3212</code><code>&lt;/li&gt;</code></p><p><code>3213</code><code>&lt;li id="section_5.14"&gt;</code></p><p><code>3214</code><code>Yoo C, Jeong H, Kim K, et al.: Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in patients (pts) with resected lymph node (LN)-positive extrahepatic cholangiocarcinoma (CCA): A multicenter, open-label, randomized, phase 2 study (STAMP). [Abstract] J Clin Oncol  40 (Suppl 16): A-4019, 2022.&lt;/li&gt;</code></p><p><code>3215</code><code>&lt;li id="section_5.15"&gt;</code></p><p><code>3216</code><code>Edeline J, Benabdelghani M, Bertaut A, et al.: Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study. J Clin Oncol 37 (8): 658-667, 2019.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=30707660&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=30707660&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3217</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3218</code><code>&lt;/li&gt;</code></p><p><code>3219</code><code>&lt;li id="section_5.16"&gt;</code></p><p><code>3220</code><code>Ebata T, Hirano S, Konishi M, et al.: Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg 105 (3): 192-202, 2018.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=29405274&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=29405274&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3221</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3222</code><code>&lt;/li&gt;</code></p><p><code>3223</code><code>&lt;li id="section_5.17"&gt;</code></p><p><code>3224</code><code>Neoptolemos JP, Moore MJ, Cox TF, et al.: Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 308 (2): 147-56, 2012.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=22782416&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=22782416&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3225</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3226</code><code>&lt;/li&gt;</code></p><p><code>3227</code><code>&lt;li id="section_5.18"&gt;</code></p><p><code>3228</code><code>Takada T, Amano H, Yasuda H, et al.: Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95 (8): 1685-95, 2002.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=12365016&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=12365016&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3229</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3230</code><code>&lt;/li&gt;</code></p><p><code>3231</code><code>&lt;li id="section_5.19"&gt;</code></p><p><code>3232</code><code>Kim TH, Han SS, Park SJ, et al.: Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer. Int J Radiat Oncol Biol Phys 81 (5): e853-9, 2011.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21497455&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21497455&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3233</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3234</code><code>&lt;/li&gt;</code></p><p><code>3235</code><code>&lt;li id="section_5.20"&gt;</code></p><p><code>3236</code><code>Hughes MA, Frassica DA, Yeo CJ, et al.: Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys 68 (1): 178-82, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17276614&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17276614&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3237</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3238</code><code>&lt;/li&gt;</code></p><p><code>3239</code><code>&lt;li id="section_5.21"&gt;</code></p><p><code>3240</code><code>Klinkenbijl JH, Jeekel J, Sahmoud T, et al.: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230 (6): 776-82; discussion 782-4, 1999.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10615932&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10615932&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3241</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3242</code><code>&lt;/li&gt;</code></p><p><code>3243</code><code>&lt;li id="section_5.22"&gt;</code></p><p><code>3244</code><code>Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al.: SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. J Clin Oncol 33 (24): 2617-22, 2015.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=25964250&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=25964250&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3245</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3246</code><code>&lt;/li&gt;</code></p><p><code>3247</code><code>&lt;/ol&gt;</code></p><p><code>3248</code><code>&lt;/div&gt;</code></p><p><code>3249</code><code>          </code></p><p><code>3250</code><code>    &lt;/section&gt;</code></p><p><code>3251</code><code>          </code></p><p><code>3252</code><code>          </code></p><p><code>3253</code><code>          </code></p><p><code>3254</code><code>    &lt;section id="_501"&gt;</code></p><p><code>3255</code><code>          </code></p><p><code>3256</code><code>        &lt;h2&gt;</code></p><p><code>3257</code><code>Treatment of Unresectable  (Including Metastatic and Recurrent) Bile Duct Cancer&lt;/h2&gt;</code></p><p><code>3258</code><code>          </code></p><p><code>3259</code><code>        &lt;div id="_section_501" class="pdq-sections"&gt;</code></p><p><code>3260</code><code>&lt;nav class="in-this-section" role="navigation"&gt;</code></p><p><code>3261</code><code>&lt;h6&gt;</code></p><p><code>3262</code><code>In This Section&lt;/h6&gt;</code></p><p><code>3263</code><code>&lt;ul&gt;</code></p><p><code>3264</code><code>&lt;li&gt;</code></p><p><code>3265</code><code>&lt;a href="#_539_toc"&gt;</code></p><p><code>3266</code><code>Treatment Options for Unresectable (Including Metastatic and Recurrent) Bile Duct Cancer &lt;ul&gt;</code></p><p><code>3267</code><code>&lt;li&gt;</code></p><p><code>3268</code><code>&lt;a href="#_542_toc"&gt;</code></p><p><code>3269</code><code>Palliative therapy&lt;/a&gt;</code></p><p><code>3270</code><code>&lt;/li&gt;</code></p><p><code>3271</code><code>&lt;li&gt;</code></p><p><code>3272</code><code>&lt;a href="#_546_toc"&gt;</code></p><p><code>3273</code><code>Chemotherapy&lt;/a&gt;</code></p><p><code>3274</code><code>&lt;/li&gt;</code></p><p><code>3275</code><code>&lt;li&gt;</code></p><p><code>3276</code><code>&lt;a href="#_558_toc"&gt;</code></p><p><code>3277</code><code>Immunotherapy&lt;/a&gt;</code></p><p><code>3278</code><code>&lt;/li&gt;</code></p><p><code>3279</code><code>&lt;li&gt;</code></p><p><code>3280</code><code>&lt;a href="#_564_toc"&gt;</code></p><p><code>3281</code><code>Targeted therapy&lt;/a&gt;</code></p><p><code>3282</code><code>&lt;/li&gt;</code></p><p><code>3283</code><code>&lt;/ul&gt;</code></p><p><code>3284</code><code>&lt;/a&gt;</code></p><p><code>3285</code><code>&lt;/li&gt;</code></p><p><code>3286</code><code>&lt;li&gt;</code></p><p><code>3287</code><code>&lt;a href="#_TrialSearch_501_sid_6_toc"&gt;</code></p><p><code>3288</code><code>Current Clinical Trials&lt;/a&gt;</code></p><p><code>3289</code><code>&lt;/li&gt;</code></p><p><code>3290</code><code>&lt;/ul&gt;</code></p><p><code>3291</code><code>&lt;/nav&gt;</code></p><p><code>3292</code><code>&lt;section id="_539"&gt;</code></p><p><code>3293</code><code>&lt;h3 id="_539_toc"&gt;</code></p><p><code>3294</code><code>Treatment Options for Unresectable (Including Metastatic and Recurrent) Bile Duct Cancer &lt;/h3&gt;</code></p><p><code>3295</code><code>&lt;p id="_540" tabindex="-1"&gt;</code></p><p><code>3296</code><code>Treatment options for unresectable (including metastatic and recurrent) bile duct cancer include the following:&lt;/p&gt;</code></p><p><code>3297</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3298</code><code>&lt;ol id="_541"&gt;</code></p><p><code>3299</code><code>&lt;li&gt;</code></p><p><code>3300</code><code>&lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_542"&gt;</code></p><p><code>3301</code><code>Palliative therapy&lt;/a&gt;</code></p><p><code>3302</code><code>.&lt;/li&gt;</code></p><p><code>3303</code><code>&lt;li&gt;</code></p><p><code>3304</code><code>&lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_546"&gt;</code></p><p><code>3305</code><code>Chemotherapy&lt;/a&gt;</code></p><p><code>3306</code><code>.&lt;/li&gt;</code></p><p><code>3307</code><code>&lt;li&gt;</code></p><p><code>3308</code><code>&lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_558"&gt;</code></p><p><code>3309</code><code>Immunotherapy&lt;/a&gt;</code></p><p><code>3310</code><code>.&lt;/li&gt;</code></p><p><code>3311</code><code>&lt;li&gt;</code></p><p><code>3312</code><code>&lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_564"&gt;</code></p><p><code>3313</code><code>Targeted therapy&lt;/a&gt;</code></p><p><code>3314</code><code>.&lt;/li&gt;</code></p><p><code>3315</code><code>&lt;/ol&gt;</code></p><p><code>3316</code><code>&lt;/div&gt;</code></p><p><code>3317</code><code>&lt;section id="_542"&gt;</code></p><p><code>3318</code><code>&lt;h4 id="_542_toc"&gt;</code></p><p><code>3319</code><code>Palliative therapy&lt;/h4&gt;</code></p><p><code>3320</code><code>&lt;p id="_544" tabindex="-1"&gt;</code></p><p><code>3321</code><code>Relief of biliary obstruction is warranted when symptoms such as pruritus and hepatic dysfunction outweigh other symptoms of the cancer. When possible, such palliation can be achieved with  the placement of bile duct stents by operative, endoscopic, or percutaneous techniques.[&lt;a href="#cit/section_6.1"&gt;</code></p><p><code>3322</code><code>1&lt;/a&gt;</code></p><p><code>3323</code><code>,&lt;a href="#cit/section_6.2"&gt;</code></p><p><code>3324</code><code>2&lt;/a&gt;</code></p><p><code>3325</code><code>]&lt;/p&gt;</code></p><p><code>3326</code><code>&lt;p id="_545" tabindex="-1"&gt;</code></p><p><code>3327</code><code>Palliative radiation therapy may be beneficial, and patients may be candidates for stereotactic body radiation therapy  [&lt;a href="#cit/section_6.3"&gt;</code></p><p><code>3328</code><code>3&lt;/a&gt;</code></p><p><code>3329</code><code>] and intra-arterial embolization.[&lt;a href="#cit/section_6.4"&gt;</code></p><p><code>3330</code><code>4&lt;/a&gt;</code></p><p><code>3331</code><code>]&lt;/p&gt;</code></p><p><code>3332</code><code>&lt;/section&gt;</code></p><p><code>3333</code><code>&lt;section id="_546"&gt;</code></p><p><code>3334</code><code>&lt;h4 id="_546_toc"&gt;</code></p><p><code>3335</code><code>Chemotherapy&lt;/h4&gt;</code></p><p><code>3336</code><code>&lt;p id="_547" tabindex="-1"&gt;</code></p><p><code>3337</code><code>Systemic chemotherapy is appropriate for selected patients with adequate performance status and intact organ function. The following agents have been reported to produce transient partial remissions in a minority of patients:&lt;/p&gt;</code></p><p><code>3338</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3339</code><code>&lt;ul id="_548"&gt;</code></p><p><code>3340</code><code>&lt;li&gt;</code></p><p><code>3341</code><code>Fluoropyrimidines (gemcitabine).&lt;/li&gt;</code></p><p><code>3342</code><code>&lt;li&gt;</code></p><p><code>3343</code><code>Platinum agents.&lt;/li&gt;</code></p><p><code>3344</code><code>&lt;li&gt;</code></p><p><code>3345</code><code>Docetaxel.&lt;/li&gt;</code></p><p><code>3346</code><code>&lt;/ul&gt;</code></p><p><code>3347</code><code>&lt;/div&gt;</code></p><p><code>3348</code><code>&lt;p id="_549" tabindex="-1"&gt;</code></p><p><code>3349</code><code>Evidence (chemotherapy):&lt;/p&gt;</code></p><p><code>3350</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3351</code><code>&lt;ol id="_550"&gt;</code></p><p><code>3352</code><code>&lt;li&gt;</code></p><p><code>3353</code><code>A phase III study (&lt;a href="/clinicaltrials/NCT00262769"&gt;</code></p><p><code>3354</code><code>NCT00262769&lt;/a&gt;</code></p><p><code>3355</code><code>) randomly assigned 410 patients with unresectable, recurrent, or metastatic biliary tract carcinoma to receive cisplatin followed by gemcitabine or to receive gemcitabine alone for up to 6 months. The following results were observed:[&lt;a href="#cit/section_6.5"&gt;</code></p><p><code>3356</code><code>5&lt;/a&gt;</code></p><p><code>3357</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3358</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>3359</code><code>]&lt;div class="pdq-content-list"&gt;</code></p><p><code>3360</code><code>&lt;ul id="_551"&gt;</code></p><p><code>3361</code><code>&lt;li&gt;</code></p><p><code>3362</code><code>Median   overall survival (OS) improved among patients treated with cisplatin and gemcitabine therapy (11.7 months) versus patients treated with gemcitabine alone (8.1 months) (hazard ratio [HR], 0.64; 95% confidence interval [CI], 0.52&amp;#8722;0.80; &lt;em&gt;</code></p><p><code>3363</code><code>P&lt;/em&gt;</code></p><p><code>3364</code><code> &amp;lt; .001).[&lt;a href="#cit/section_6.5"&gt;</code></p><p><code>3365</code><code>5&lt;/a&gt;</code></p><p><code>3366</code><code>]&lt;/li&gt;</code></p><p><code>3367</code><code>&lt;li&gt;</code></p><p><code>3368</code><code>A similar median OS benefit was demonstrated in all subgroups, including 73 patients with extrahepatic bile duct cancer and 57 patients with hilar tumors.&lt;/li&gt;</code></p><p><code>3369</code><code>&lt;li&gt;</code></p><p><code>3370</code><code>Grades 3 and 4 toxicities occurred with similar frequency in both study arms, with the exception of increased hematologic toxicity in patients randomly assigned to the gemcitabine/cisplatin arm and increased hepatic toxicity in patients randomly assigned to the single-agent gemcitabine arm.&lt;/li&gt;</code></p><p><code>3371</code><code>&lt;/ul&gt;</code></p><p><code>3372</code><code>&lt;/div&gt;</code></p><p><code>3373</code><code>&lt;/li&gt;</code></p><p><code>3374</code><code>&lt;li&gt;</code></p><p><code>3375</code><code>A phase III noninferiority study (&lt;a href="/clinicaltrials/NCT01470443"&gt;</code></p><p><code>3376</code><code>NCT01470443&lt;/a&gt;</code></p><p><code>3377</code><code>) enrolled 114 patients with metastatic biliary tract cancers, including 30 (26%) with primary gallbladder cancer. Patients were randomly assigned to receive capecitabine plus oxaliplatin (XELOX) or gemcitabine plus oxaliplatin (GEMOX).[&lt;a href="#cit/section_6.6"&gt;</code></p><p><code>3378</code><code>6&lt;/a&gt;</code></p><p><code>3379</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810025&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810025&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3380</code><code>Level of evidence B1&lt;/a&gt;</code></p><p><code>3381</code><code>]&lt;div class="pdq-content-list"&gt;</code></p><p><code>3382</code><code>&lt;ul id="_552"&gt;</code></p><p><code>3383</code><code>&lt;li&gt;</code></p><p><code>3384</code><code>	OS was not significantly different, with 10.4 months (95% CI, 8.0&amp;#8722;12.6) in the GEMOX group, compared with 10.6 months (95% CI, 7.3&amp;#8722;15.5) in the XELOX group (&lt;em&gt;</code></p><p><code>3385</code><code>P&lt;/em&gt;</code></p><p><code>3386</code><code> = .131).&lt;/li&gt;</code></p><p><code>3387</code><code>&lt;li&gt;</code></p><p><code>3388</code><code>	The primary end point of 6-month progression-free survival (PFS) was 44.6% for the GEMOX group and 46.7% for the XELOX group (95% CI of difference in 6-month PFS rate, -12% to 16%, meeting criteria for noninferiority). &lt;/li&gt;</code></p><p><code>3389</code><code>&lt;li&gt;</code></p><p><code>3390</code><code>A predefined subgroup analysis based on primary site of disease did not reveal a difference in objective response rate between the two arms in patients with gallbladder cancer (&lt;em&gt;</code></p><p><code>3391</code><code>P&lt;/em&gt;</code></p><p><code>3392</code><code> = .598). &lt;/li&gt;</code></p><p><code>3393</code><code>&lt;/ul&gt;</code></p><p><code>3394</code><code>&lt;/div&gt;</code></p><p><code>3395</code><code>&lt;/li&gt;</code></p><p><code>3396</code><code>&lt;/ol&gt;</code></p><p><code>3397</code><code>&lt;/div&gt;</code></p><p><code>3398</code><code>&lt;p id="_553" tabindex="-1"&gt;</code></p><p><code>3399</code><code>Pending further clinical trials, cisplatin plus gemcitabine is considered the reference standard first-line agent for patients with unresectable, metastatic, or recurrent bile duct cancer. The results of the TOPAZ-1 trial suggest that a checkpoint inhibitor, durvalumab, will become a standard-of-care addition to first-line therapy in combination with cisplatin and gemcitabine (for more information, see the &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_558"&gt;</code></p><p><code>3400</code><code>Immunotherapy&lt;/a&gt;</code></p><p><code>3401</code><code> section). Potential alternatives include gemcitabine plus capecitabine, GEMOX, and XELOX. Clinical trials should be considered for all patients.&lt;/p&gt;</code></p><p><code>3402</code><code>&lt;p id="_554" tabindex="-1"&gt;</code></p><p><code>3403</code><code>There is limited high-quality evidence to guide selection of a second-line regimen in refractory disease:&lt;/p&gt;</code></p><p><code>3404</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3405</code><code>&lt;ol id="_555"&gt;</code></p><p><code>3406</code><code>&lt;li&gt;</code></p><p><code>3407</code><code>A multicenter phase III trial in the United Kingdom (&lt;a href="/clinicaltrials/NCT01926236"&gt;</code></p><p><code>3408</code><code>ABC-06&lt;/a&gt;</code></p><p><code>3409</code><code> [NCT01926236]) randomly assigned 162 patients with locally advanced or metastatic biliary tract cancer and documented radiological disease progression on first-line cisplatin and gemcitabine to receive either FOLFOX (folinic acid, fluorouracil [5-FU], and oxaliplatin) with active symptom control (ASC) or ASC alone. The following was observed after a median follow-up of 21.7 months:[&lt;a href="#cit/section_6.7"&gt;</code></p><p><code>3410</code><code>7&lt;/a&gt;</code></p><p><code>3411</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3412</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>3413</code><code>]&lt;div class="pdq-content-list"&gt;</code></p><p><code>3414</code><code>&lt;ul id="_556"&gt;</code></p><p><code>3415</code><code>&lt;li&gt;</code></p><p><code>3416</code><code>	The median OS was significantly longer in the FOLFOX group (6.2 months) than in the group who received ASC alone (5.3 months) (adjusted HR, 0.69; 95% CI, 0.50&amp;#8722;0.97; &lt;em&gt;</code></p><p><code>3417</code><code>P&lt;/em&gt;</code></p><p><code>3418</code><code> = .031).	In the FOLFOX group, the OS rate was 50.6% at 6 months and 25.9% at 12 months, compared with 35.5% at 6 months and 11.4% at 12 months in the group who received ASC alone.&lt;/li&gt;</code></p><p><code>3419</code><code>&lt;li&gt;</code></p><p><code>3420</code><code>	Grade 3 to 5 adverse events were reported in 56 (69%) patients in the FOLFOX group, compared with 42 (52%) in the ASC alone group. The most frequently reported grade 3 to 5 FOLFOX-related adverse events were neutropenia (12%), fatigue/lethargy (11%), and infection (10%). There were three chemotherapy-related deaths, one each due to infection, acute kidney injury, and febrile neutropenia.&lt;/li&gt;</code></p><p><code>3421</code><code>&lt;/ul&gt;</code></p><p><code>3422</code><code>&lt;/div&gt;</code></p><p><code>3423</code><code>&lt;/li&gt;</code></p><p><code>3424</code><code>&lt;li&gt;</code></p><p><code>3425</code><code>A multicenter phase IIb trial in South Korea (&lt;a href="/clinicaltrials/NCT03524508"&gt;</code></p><p><code>3426</code><code>NIFTY&lt;/a&gt;</code></p><p><code>3427</code><code> [NCT03524508]) randomly assigned 174 patients with metastatic biliary tract cancer that had progressed on first-line cisplatin and gemcitabine to receive 5-FU and leucovorin with or without liposomal irinotecan. The following was observed after a median follow-up of 11.8 months:[&lt;a href="#cit/section_6.8"&gt;</code></p><p><code>3428</code><code>8&lt;/a&gt;</code></p><p><code>3429</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3430</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>3431</code><code>]&lt;div class="pdq-content-list"&gt;</code></p><p><code>3432</code><code>&lt;ul id="_557"&gt;</code></p><p><code>3433</code><code>&lt;li&gt;</code></p><p><code>3434</code><code>	The primary end point of  median PFS was significantly longer in the group who received liposomal irinotecan (7.1 months) compared with the group who received 5-FU plus leucovorin alone (1.4 months) (HR, 0.56; 95% CI, 0.39&amp;#8211;0.81; &lt;em&gt;</code></p><p><code>3435</code><code>P&lt;/em&gt;</code></p><p><code>3436</code><code> = .0019). A secondary end point of median OS was also significantly longer in the group who received liposomal irinotecan (8.6 months) compared with the group who received 5-FU plus leucovorin alone (5.5 months) (HR, 0.68; 95% CI, 0.48&amp;#8211;0.98; &lt;em&gt;</code></p><p><code>3437</code><code>P&lt;/em&gt;</code></p><p><code>3438</code><code> = .035).&lt;/li&gt;</code></p><p><code>3439</code><code>&lt;li&gt;</code></p><p><code>3440</code><code>	The OS rate at 6 months was 60.7% in the liposomal irinotecan group compared with 45.9% in the 5-FU plus leucovorin alone group.&lt;/li&gt;</code></p><p><code>3441</code><code>&lt;/ul&gt;</code></p><p><code>3442</code><code>&lt;/div&gt;</code></p><p><code>3443</code><code>&lt;/li&gt;</code></p><p><code>3444</code><code>&lt;/ol&gt;</code></p><p><code>3445</code><code>&lt;/div&gt;</code></p><p><code>3446</code><code>&lt;/section&gt;</code></p><p><code>3447</code><code>&lt;section id="_558"&gt;</code></p><p><code>3448</code><code>&lt;h4 id="_558_toc"&gt;</code></p><p><code>3449</code><code>Immunotherapy&lt;/h4&gt;</code></p><p><code>3450</code><code>&lt;p id="_559" tabindex="-1"&gt;</code></p><p><code>3451</code><code>Based on results from the TOPAZ-1 trial, all patients with unresectable, metastatic, or recurrent disease should be considered for treatment with the checkpoint inhibitor durvalumab combined with cisplatin and gemcitabine (the previous standard-of-care doublet) in the first-line setting.&lt;/p&gt;</code></p><p><code>3452</code><code>&lt;p id="_560" tabindex="-1"&gt;</code></p><p><code>3453</code><code>Evidence (immunotherapy):&lt;/p&gt;</code></p><p><code>3454</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3455</code><code>&lt;ol id="_561"&gt;</code></p><p><code>3456</code><code>&lt;li&gt;</code></p><p><code>3457</code><code>An international, multicenter, phase III study (&lt;a href="/clinicaltrials/NCT03875235"&gt;</code></p><p><code>3458</code><code>TOPAZ-1&lt;/a&gt;</code></p><p><code>3459</code><code> [NCT03875235]), published in abstract form, included 685 patients with locally advanced, recurrent, or metastatic biliary tract cancer that was unresectable and previously untreated. Patients were randomly assigned to receive either durvalumab or placebo with cisplatin plus gemcitabine for up to eight cycles, followed by durvalumab or placebo maintenance until disease progression or unacceptable toxicity occurred. After a median follow-up of 13.7 months for patients in the durvalumab arm, the following was observed:[&lt;a href="#cit/section_6.9"&gt;</code></p><p><code>3460</code><code>9&lt;/a&gt;</code></p><p><code>3461</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3462</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>3463</code><code>]&lt;div class="pdq-content-list"&gt;</code></p><p><code>3464</code><code>&lt;ul id="_562"&gt;</code></p><p><code>3465</code><code>&lt;li&gt;</code></p><p><code>3466</code><code>	The primary end point of median OS was significantly improved in the durvalumab group (12.8 months) compared with the placebo group (11.5 months) (HR, 0.80; 95% CI, 0.66&amp;#8211;0.97; &lt;em&gt;</code></p><p><code>3467</code><code>P&lt;/em&gt;</code></p><p><code>3468</code><code> = .021).	In the durvalumab group, the OS rate was 35.1% at 18 months and 24.9% at 24 months, compared with 25.5% at 18 months and 10.4% at 24 months in the placebo group.&lt;/li&gt;</code></p><p><code>3469</code><code>&lt;li&gt;</code></p><p><code>3470</code><code>	There was no significant difference between groups in the number of grade 3 or 4 treatment-related adverse events or the number of events leading to discontinuation of a study medication.&lt;/li&gt;</code></p><p><code>3471</code><code>&lt;/ul&gt;</code></p><p><code>3472</code><code>&lt;/div&gt;</code></p><p><code>3473</code><code>&lt;/li&gt;</code></p><p><code>3474</code><code>&lt;/ol&gt;</code></p><p><code>3475</code><code>&lt;/div&gt;</code></p><p><code>3476</code><code>&lt;p id="_563" tabindex="-1"&gt;</code></p><p><code>3477</code><code>All patients with unresectable, metastatic, or recurrent disease who have not already received a checkpoint inhibitor should have molecular testing for deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) tumors. Extrapolating from a subgroup of patients with gastrointestinal and hepatopancreatobiliary tumors in the &lt;a href="/clinicaltrials/NCT02534675"&gt;</code></p><p><code>3478</code><code>I-PREDICT&lt;/a&gt;</code></p><p><code>3479</code><code> (NCT02534675) and &lt;a href="/clinicaltrials/NCT02628067"&gt;</code></p><p><code>3480</code><code>KEYNOTE-158&lt;/a&gt;</code></p><p><code>3481</code><code> (NCT02628067) studies, patients with either dMMR or MSI-H tumors can be considered for treatment with pembrolizumab.[&lt;a href="#cit/section_6.10"&gt;</code></p><p><code>3482</code><code>10&lt;/a&gt;</code></p><p><code>3483</code><code>,&lt;a href="#cit/section_6.11"&gt;</code></p><p><code>3484</code><code>11&lt;/a&gt;</code></p><p><code>3485</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810039&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810039&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3486</code><code>Level of evidence C3&lt;/a&gt;</code></p><p><code>3487</code><code>]&lt;/p&gt;</code></p><p><code>3488</code><code>&lt;/section&gt;</code></p><p><code>3489</code><code>&lt;section id="_564"&gt;</code></p><p><code>3490</code><code>&lt;h4 id="_564_toc"&gt;</code></p><p><code>3491</code><code>Targeted therapy&lt;/h4&gt;</code></p><p><code>3492</code><code>&lt;p id="_565" tabindex="-1"&gt;</code></p><p><code>3493</code><code>Clinical trials of investigational therapies should be considered for patients with targetable mutations.&lt;/p&gt;</code></p><p><code>3494</code><code>&lt;section id="_584"&gt;</code></p><p><code>3495</code><code>&lt;h5 id="_584_toc"&gt;</code></p><p><code>3496</code><code>IDH1 inhibitors&lt;/h5&gt;</code></p><p><code>3497</code><code>&lt;p id="_585" tabindex="-1"&gt;</code></p><p><code>3498</code><code>Up to 15% of bile duct cancers express a mutation in the &lt;em class="gene-name"&gt;</code></p><p><code>3499</code><code>IDH1&lt;/em&gt;</code></p><p><code>3500</code><code> gene. &lt;/p&gt;</code></p><p><code>3501</code><code>&lt;p id="_586" tabindex="-1"&gt;</code></p><p><code>3502</code><code>Evidence (IDH1 inhibitors):&lt;/p&gt;</code></p><p><code>3503</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3504</code><code>&lt;ol id="_587"&gt;</code></p><p><code>3505</code><code>&lt;li&gt;</code></p><p><code>3506</code><code>The phase III &lt;a href="/clinicaltrials/NCT02989857"&gt;</code></p><p><code>3507</code><code>ClarIDHy&lt;/a&gt;</code></p><p><code>3508</code><code> trial (NCT02989857) included 187 patients with &lt;em class="gene-name"&gt;</code></p><p><code>3509</code><code>IDH1&lt;/em&gt;</code></p><p><code>3510</code><code>-mutated cholangiocarcinoma that had progressed during previous systemic therapy. Patients were randomly assigned to receive either the IDH1 inhibitor ivosidenib or placebo. The following results were observed:[&lt;a href="#cit/section_6.12"&gt;</code></p><p><code>3511</code><code>12&lt;/a&gt;</code></p><p><code>3512</code><code>,&lt;a href="#cit/section_6.13"&gt;</code></p><p><code>3513</code><code>13&lt;/a&gt;</code></p><p><code>3514</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810025&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810025&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3515</code><code>Level of evidence B1&lt;/a&gt;</code></p><p><code>3516</code><code>] &lt;div class="pdq-content-list"&gt;</code></p><p><code>3517</code><code>&lt;ul id="_588"&gt;</code></p><p><code>3518</code><code>&lt;li&gt;</code></p><p><code>3519</code><code>The primary end point of median PFS was improved among patients treated with ivosidenib (2.7 months) compared with placebo (1.4 months) (HR, 0.37; 95% CI, 0.25&amp;#8722;0.54; &lt;em&gt;</code></p><p><code>3520</code><code>P&lt;/em&gt;</code></p><p><code>3521</code><code> &amp;lt; .001). PFS rates at 6 months and 12 months were 32% and 21.9%, respectively, in the ivosidenib arm. No patients in the placebo group were progression free at 6 months.&lt;/li&gt;</code></p><p><code>3522</code><code>&lt;li&gt;</code></p><p><code>3523</code><code>	In the intention-to-treat analysis, median OS was 10.3 months in the ivosidenib group compared with 7.5 months for the placebo group (HR, 0.79; one-sided &lt;em&gt;</code></p><p><code>3524</code><code>P&lt;/em&gt;</code></p><p><code>3525</code><code> = .09), despite crossover of 57% of placebo patients to ivosidenib. When adjusted for crossover, median OS for the placebo group was 5.1 months.&lt;/li&gt;</code></p><p><code>3526</code><code>&lt;li&gt;</code></p><p><code>3527</code><code>	Grades 3 and 4 toxicities occurred in 46% of patients in the ivosidenib group compared with 36% in the placebo group.  &lt;/li&gt;</code></p><p><code>3528</code><code>&lt;/ul&gt;</code></p><p><code>3529</code><code>&lt;/div&gt;</code></p><p><code>3530</code><code>&lt;/li&gt;</code></p><p><code>3531</code><code>&lt;/ol&gt;</code></p><p><code>3532</code><code>&lt;/div&gt;</code></p><p><code>3533</code><code>&lt;/section&gt;</code></p><p><code>3534</code><code>&lt;section id="_589"&gt;</code></p><p><code>3535</code><code>&lt;h5 id="_589_toc"&gt;</code></p><p><code>3536</code><code>Fibroblast growth factor receptor 2 (FGFR) inhibitors&lt;/h5&gt;</code></p><p><code>3537</code><code>&lt;p id="_590" tabindex="-1"&gt;</code></p><p><code>3538</code><code>&lt;em class="gene-name"&gt;</code></p><p><code>3539</code><code>FGFR2&lt;/em&gt;</code></p><p><code>3540</code><code> fusions are present in approximately 15% of intrahepatic cholangiocarcinomas. Multiple phase II trials, some reported in abstract form, have suggested activity of FGFR inhibitors in patients with cholangiocarcinoma and &lt;em class="gene-name"&gt;</code></p><p><code>3541</code><code>FGFR2&lt;/em&gt;</code></p><p><code>3542</code><code> fusions whose disease progressed after or who were ineligible for first-line chemotherapy.[&lt;a href="#cit/section_6.14"&gt;</code></p><p><code>3543</code><code>14&lt;/a&gt;</code></p><p><code>3544</code><code>-&lt;a href="#cit/section_6.16"&gt;</code></p><p><code>3545</code><code>16&lt;/a&gt;</code></p><p><code>3546</code><code>]&lt;/p&gt;</code></p><p><code>3547</code><code>&lt;p id="_591" tabindex="-1"&gt;</code></p><p><code>3548</code><code>Evidence (FGFR inhibitors):&lt;/p&gt;</code></p><p><code>3549</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3550</code><code>&lt;ol id="_592"&gt;</code></p><p><code>3551</code><code>&lt;li&gt;</code></p><p><code>3552</code><code>The multicenter, open-label, single-arm phase II &lt;a href="/clinicaltrials/NCT02924376"&gt;</code></p><p><code>3553</code><code>FIGHT-202&lt;/a&gt;</code></p><p><code>3554</code><code> trial 	(NCT02924376), reported in abstract form,  enrolled 107 patients with disease progression on or after at least one previous therapy. All patients received pemigatinib 13.5 mg orally once daily for 14 consecutive days, 	followed by 7 days off therapy.[&lt;a href="#cit/section_6.15"&gt;</code></p><p><code>3555</code><code>15&lt;/a&gt;</code></p><p><code>3556</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810039&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810039&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3557</code><code>Level of evidence C3&lt;/a&gt;</code></p><p><code>3558</code><code>]&lt;div class="pdq-content-list"&gt;</code></p><p><code>3559</code><code>&lt;ul id="_593"&gt;</code></p><p><code>3560</code><code>&lt;li&gt;</code></p><p><code>3561</code><code>	The overall response rate was 36% (95% CI, 27%&amp;#8722;45%), including three complete responses.&lt;/li&gt;</code></p><p><code>3562</code><code>&lt;li&gt;</code></p><p><code>3563</code><code>Of the 38 patients who achieved a response, 24 had responses lasting at least 6 months, and 7 had responses lasting at least 12 months, with a median duration of response of 9.1 months.</code></p><p><code>3564</code><code>&lt;/li&gt;</code></p><p><code>3565</code><code>&lt;li&gt;</code></p><p><code>3566</code><code>	The median PFS was 6.9 months (95% CI, 6.2&amp;#8211;9.6), and the median OS was 21.1 months (95% CI, 14.8&amp;#8211;not reached [NR]).  Given the single-arm study design, the relative effect of pemigatinib on PFS and OS has not yet been established.&lt;/li&gt;</code></p><p><code>3567</code><code>&lt;li&gt;</code></p><p><code>3568</code><code>The most common adverse effect was hyperphosphatemia, occurring in 60% of patients, although no adverse effect was grade 3 or higher.  Adverse events led to dose reduction in 14% of patients, while 42% of patients required dose interruptions.&lt;/li&gt;</code></p><p><code>3569</code><code>&lt;/ul&gt;</code></p><p><code>3570</code><code>&lt;/div&gt;</code></p><p><code>3571</code><code>&lt;p id="_594" tabindex="-1"&gt;</code></p><p><code>3572</code><code>In April 2020, the FDA granted accelerated approval of pemigatinib for the treatment of adults 	with previously treated unresectable or metastatic cholangiocarcinoma with &lt;em class="gene-name"&gt;</code></p><p><code>3573</code><code>FGFR2&lt;/em&gt;</code></p><p><code>3574</code><code> fusion or 	other rearrangement. &lt;/p&gt;</code></p><p><code>3575</code><code>&lt;/li&gt;</code></p><p><code>3576</code><code>&lt;li&gt;</code></p><p><code>3577</code><code>The multicenter, open-label, single-arm phase II &lt;a href="/clinicaltrials/NCT02150967"&gt;</code></p><p><code>3578</code><code>CBGJ398X2204&lt;/a&gt;</code></p><p><code>3579</code><code> trial (NCT02150967), reported in abstract form, enrolled 108 patients with disease progression on or after at least one prior line of systemic therapy. All patients received infigratinib 125 mg orally once daily for 21 consecutive days, followed by 7 days off therapy.[&lt;a href="#cit/section_6.17"&gt;</code></p><p><code>3580</code><code>17&lt;/a&gt;</code></p><p><code>3581</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810039&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810039&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3582</code><code>Level of evidence C3&lt;/a&gt;</code></p><p><code>3583</code><code>]&lt;div class="pdq-content-list"&gt;</code></p><p><code>3584</code><code>&lt;ul id="_595"&gt;</code></p><p><code>3585</code><code>&lt;li&gt;</code></p><p><code>3586</code><code>	The overall response rate was 23.1% (95% CI, 15.6%&amp;#8722;32.2%), including one complete response.&lt;/li&gt;</code></p><p><code>3587</code><code>&lt;li&gt;</code></p><p><code>3588</code><code>	Of the 25 patients who achieved a response, 8 had responses lasting at least 6 months. The median PFS was 7.3 months (95% CI, 5.6&amp;#8722;7.6). &lt;/li&gt;</code></p><p><code>3589</code><code>&lt;li&gt;</code></p><p><code>3590</code><code>	The median PFS was 7.3 months (95% CI, 5.6&amp;#8211;7.6) and the median OS was 12.2 months (95% CI, 10.7&amp;#8211;14.9).	Given the single-arm study design, the relative effect of infigratinib on PFS and OS has not yet been established.&lt;/li&gt;</code></p><p><code>3591</code><code>&lt;li&gt;</code></p><p><code>3592</code><code>	The most common adverse effect was hyperphosphatemia, which occurred in 76.9% of patients, including 13 grade 3 events and one grade 4 event. Other common adverse effects included eye disorders (67.6%), stomatitis (54.6%), and fatigue (39.8%). Central serous retinopathy/retinal pigment epithelium detachment occurred in 16.7% of patients, including one grade 3 event.&lt;/li&gt;</code></p><p><code>3593</code><code>&lt;/ul&gt;</code></p><p><code>3594</code><code>&lt;/div&gt;</code></p><p><code>3595</code><code>&lt;p id="_596" tabindex="-1"&gt;</code></p><p><code>3596</code><code>In May 2021, the FDA also granted accelerated approval of infigratinib in patients with previously treated unresectable or metastatic cholangiocarcinoma harboring an &lt;em class="gene-name"&gt;</code></p><p><code>3597</code><code>FGFR2&lt;/em&gt;</code></p><p><code>3598</code><code> gene fusion or rearrangement. &lt;/p&gt;</code></p><p><code>3599</code><code>&lt;/li&gt;</code></p><p><code>3600</code><code>&lt;li&gt;</code></p><p><code>3601</code><code>Futibatinib is an irreversible noncompetitive inhibitor of FGFR1&amp;#8211;4. Preclinical &lt;em&gt;</code></p><p><code>3602</code><code>in vitro&lt;/em&gt;</code></p><p><code>3603</code><code> studies showed that futibatinib was less susceptible to on-target resistance mutations than pemigatinib and infigratinib. However, there are no head-to-head clinical trial data comparing outcomes for the various FGFR inhibitors. The multinational, open-label, single-group, phase II &lt;a href="/clinicaltrials/NCT02052778"&gt;</code></p><p><code>3604</code><code>FOENIX-CCA2&lt;/a&gt;</code></p><p><code>3605</code><code> trial (NCT02052778) evaluated futibatinib in patients with previously treated intrahepatic cholangiocarcinoma and an &lt;em class="gene-name"&gt;</code></p><p><code>3606</code><code>FGFR2&lt;/em&gt;</code></p><p><code>3607</code><code> fusion or rearrangement.  The study enrolled 103 patients with disease progression after at least one previous line of systemic therapy. All patients received futibatinib at a continuous dose of 20 mg once daily.[&lt;a href="#cit/section_6.18"&gt;</code></p><p><code>3608</code><code>18&lt;/a&gt;</code></p><p><code>3609</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810039&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810039&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3610</code><code>Level of evidence C3&lt;/a&gt;</code></p><p><code>3611</code><code>]&lt;div class="pdq-content-list"&gt;</code></p><p><code>3612</code><code>&lt;ul id="_597"&gt;</code></p><p><code>3613</code><code>&lt;li&gt;</code></p><p><code>3614</code><code>	The overall response rate was 42% (95% CI, 31.1%&amp;#8211;50.4%), including one complete response. Of the patients who had a response, the median duration of response was 9.7 months. &lt;/li&gt;</code></p><p><code>3615</code><code>&lt;li&gt;</code></p><p><code>3616</code><code>	The median PFS was 9 months (95% CI, 6.9&amp;#8211;13.1) and the median OS was 21.7 months (95% CI 14.5&amp;#8211;NR). Given the single-arm study design, the relative effect of futibatinib on PFS and OS has not yet been established.&lt;/li&gt;</code></p><p><code>3617</code><code>&lt;li&gt;</code></p><p><code>3618</code><code>	The most common adverse effect of any grade was hyperphosphatemia, which occurred in 85% of patients and was grade 3 in 30% of patients. Other common adverse effects included alopecia (33%), dry mouth (30%), dry skin (27%), and fatigue (25%). Other notable grade 3 toxicities included aspartate aminotransferase elevation (7%) and stomatitis (6%). Treatment-related adverse events led to dose interruptions in 50% of patients, dose reductions in 54% of patients, and permanent drug discontinuation in 2% of patients.&lt;/li&gt;</code></p><p><code>3619</code><code>&lt;/ul&gt;</code></p><p><code>3620</code><code>&lt;/div&gt;</code></p><p><code>3621</code><code> &lt;/li&gt;</code></p><p><code>3622</code><code>&lt;/ol&gt;</code></p><p><code>3623</code><code>&lt;/div&gt;</code></p><p><code>3624</code><code>&lt;p id="_598" tabindex="-1"&gt;</code></p><p><code>3625</code><code>Patients with &lt;em class="gene-name"&gt;</code></p><p><code>3626</code><code>FGFR2&lt;/em&gt;</code></p><p><code>3627</code><code> fusion&amp;#8722;positive disease should be encouraged to enroll in a clinical trial.&lt;/p&gt;</code></p><p><code>3628</code><code>&lt;/section&gt;</code></p><p><code>3629</code><code>&lt;p id="_575" tabindex="-1"&gt;</code></p><p><code>3630</code><code>All patients are encouraged to enroll in clinical trials for adjuvant therapies.  Information about ongoing clinical trials is available from the &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials"&gt;</code></p><p><code>3631</code><code>NCI website&lt;/a&gt;</code></p><p><code>3632</code><code>.&lt;/p&gt;</code></p><p><code>3633</code><code>&lt;/section&gt;</code></p><p><code>3634</code><code>&lt;/section&gt;</code></p><p><code>3635</code><code>&lt;section id="_TrialSearch_501_sid_6"&gt;</code></p><p><code>3636</code><code>&lt;h3 id="_TrialSearch_501_sid_6_toc"&gt;</code></p><p><code>3637</code><code>Current Clinical Trials&lt;/h3&gt;</code></p><p><code>3638</code><code>&lt;p id="_TrialSearch_501_22" tabindex="-1"&gt;</code></p><p><code>3639</code><code>Use our &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/advanced" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/advanced"&gt;</code></p><p><code>3640</code><code>advanced clinical trial search&lt;/a&gt;</code></p><p><code>3641</code><code> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/"&gt;</code></p><p><code>3642</code><code>General information&lt;/a&gt;</code></p><p><code>3643</code><code> about clinical trials is also available.&lt;/p&gt;</code></p><p><code>3644</code><code>&lt;/section&gt;</code></p><p><code>3645</code><code>&lt;h6 do-not-show="toc"&gt;</code></p><p><code>3646</code><code>References&lt;/h6&gt;</code></p><p><code>3647</code><code>&lt;ol&gt;</code></p><p><code>3648</code><code>&lt;li id="section_6.1"&gt;</code></p><p><code>3649</code><code>Nordback IH, Pitt HA, Coleman J, et al.: Unresectable hilar cholangiocarcinoma: percutaneous versus operative palliation. Surgery 115 (5): 597-603, 1994.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=7513906&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=7513906&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3650</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3651</code><code>&lt;/li&gt;</code></p><p><code>3652</code><code>&lt;li id="section_6.2"&gt;</code></p><p><code>3653</code><code>Levy MJ, Baron TH, Gostout CJ, et al.: Palliation of malignant extrahepatic biliary obstruction with plastic versus expandable metal stents: An evidence-based approach. Clin Gastroenterol Hepatol 2 (4): 273-85, 2004.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15067620&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15067620&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3654</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3655</code><code>&lt;/li&gt;</code></p><p><code>3656</code><code>&lt;li id="section_6.3"&gt;</code></p><p><code>3657</code><code>Barney BM, Olivier KR, Miller RC, et al.: Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol 7: 67, 2012.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=22553982&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=22553982&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3658</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3659</code><code>&lt;/li&gt;</code></p><p><code>3660</code><code>&lt;li id="section_6.4"&gt;</code></p><p><code>3661</code><code>Hyder O, Marsh JW, Salem R, et al.: Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol 20 (12): 3779-86, 2013.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=23846786&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=23846786&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3662</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3663</code><code>&lt;/li&gt;</code></p><p><code>3664</code><code>&lt;li id="section_6.5"&gt;</code></p><p><code>3665</code><code>Valle J, Wasan H, Palmer DH, et al.: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362 (14): 1273-81, 2010.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20375404&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20375404&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3666</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3667</code><code>&lt;/li&gt;</code></p><p><code>3668</code><code>&lt;li id="section_6.6"&gt;</code></p><p><code>3669</code><code>Kim ST, Kang JH, Lee J, et al.: Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Ann Oncol 30 (5): 788-795, 2019.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=30785198&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=30785198&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3670</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3671</code><code>&lt;/li&gt;</code></p><p><code>3672</code><code>&lt;li id="section_6.7"&gt;</code></p><p><code>3673</code><code>Lamarca A, Palmer DH, Wasan HS, et al.: Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 22 (5): 690-701, 2021.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=33798493&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=33798493&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3674</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3675</code><code>&lt;/li&gt;</code></p><p><code>3676</code><code>&lt;li id="section_6.8"&gt;</code></p><p><code>3677</code><code>Yoo C, Kim KP, Jeong JH, et al.: Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol 22 (11): 1560-1572, 2021.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=34656226&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=34656226&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3678</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3679</code><code>&lt;/li&gt;</code></p><p><code>3680</code><code>&lt;li id="section_6.9"&gt;</code></p><p><code>3681</code><code>Oh D, He AR, Qin S: A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. [Abstract] J Clin Oncol  40 (4 suppl): A-378, 2022.&lt;/li&gt;</code></p><p><code>3682</code><code>&lt;li id="section_6.10"&gt;</code></p><p><code>3683</code><code>Sicklick JK, Kato S, Okamura R, et al.: Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med 25 (5): 744-750, 2019.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=31011206&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=31011206&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3684</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3685</code><code>&lt;/li&gt;</code></p><p><code>3686</code><code>&lt;li id="section_6.11"&gt;</code></p><p><code>3687</code><code>Marabelle A, Le DT, Ascierto PA, et al.: Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 38 (1): 1-10, 2020.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=31682550&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=31682550&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3688</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3689</code><code>&lt;/li&gt;</code></p><p><code>3690</code><code>&lt;li id="section_6.12"&gt;</code></p><p><code>3691</code><code>Abou-Alfa GK, Macarulla T, Javle MM, et al.: Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21 (6): 796-807, 2020.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=32416072&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=32416072&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3692</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3693</code><code>&lt;/li&gt;</code></p><p><code>3694</code><code>&lt;li id="section_6.13"&gt;</code></p><p><code>3695</code><code>Zhu AX, Macarulla T, Javle MM, et al.: Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol 7 (11): 1669-1677, 2021.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=34554208&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=34554208&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3696</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3697</code><code>&lt;/li&gt;</code></p><p><code>3698</code><code>&lt;li id="section_6.14"&gt;</code></p><p><code>3699</code><code>Mazzaferro V, El-Rayes BF, Droz Dit Busset M, et al.: Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer 120 (2): 165-171, 2019.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=30420614&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=30420614&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3700</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3701</code><code>&lt;/li&gt;</code></p><p><code>3702</code><code>&lt;li id="section_6.15"&gt;</code></p><p><code>3703</code><code>Vogel A, Sahai V, Hollebecque A, et al.: FIGHT-202: a phase II study of pemigatinib in patients (pts) with previously locally advanced or metastatic cholangiocarcinoma (CCA). [Abstract] Ann Oncol  30 (Suppl 5): A-LBA40, 2019.&lt;/li&gt;</code></p><p><code>3704</code><code>&lt;li id="section_6.16"&gt;</code></p><p><code>3705</code><code>Droz Dit Busset M, Braun S, El-Rayes B, et al.: Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (ICCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications. [Abstract] Ann Oncol  30 (Suppl 5): A-721P, 2019.&lt;/li&gt;</code></p><p><code>3706</code><code>&lt;li id="section_6.17"&gt;</code></p><p><code>3707</code><code>Javle M, Roychowdhury S, Kelley RK, et al.: Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. [Abstract] J Clin Oncol  39 (3) (suppl): A-265, 2021. &lt;a href="https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.265" title="https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.265"&gt;</code></p><p><code>3708</code><code>Available online&lt;/a&gt;</code></p><p><code>3709</code><code>. Last accessed February 24, 2023.&lt;/li&gt;</code></p><p><code>3710</code><code>&lt;li id="section_6.18"&gt;</code></p><p><code>3711</code><code>Goyal L, Meric-Bernstam F, Hollebecque A, et al.: Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. N Engl J Med 388 (3): 228-239, 2023.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=36652354&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=36652354&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3712</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3713</code><code>&lt;/li&gt;</code></p><p><code>3714</code><code>&lt;/ol&gt;</code></p><p><code>3715</code><code>&lt;/div&gt;</code></p><p><code>3716</code><code>          </code></p><p><code>3717</code><code>    &lt;/section&gt;</code></p><p><code>3718</code><code>          </code></p><p><code>3719</code><code>          </code></p><p><code>3720</code><code>          </code></p><p><code>3721</code><code>    &lt;section id="_71"&gt;</code></p><p><code>3722</code><code>          </code></p><p><code>3723</code><code>        &lt;h2&gt;</code></p><p><code>3724</code><code>Changes to This Summary (02/24/2023)&lt;/h2&gt;</code></p><p><code>3725</code><code>          </code></p><p><code>3726</code><code>        &lt;div id="_section_71" class="pdq-sections"&gt;</code></p><p><code>3727</code><code>&lt;p id="_72" tabindex="-1"&gt;</code></p><p><code>3728</code><code>The PDQ cancer information summaries are reviewed regularly and updated as</code></p><p><code>3729</code><code>new information becomes available.  This section describes the latest</code></p><p><code>3730</code><code>changes made to this summary as of the date above.&lt;/p&gt;</code></p><p><code>3731</code><code>&lt;p id="_599" tabindex="-1"&gt;</code></p><p><code>3732</code><code>&lt;strong&gt;</code></p><p><code>3733</code><code>&lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_500"&gt;</code></p><p><code>3734</code><code>Treatment of Resectable (Localized) Bile Duct Cancer&lt;/a&gt;</code></p><p><code>3735</code><code>&lt;/strong&gt;</code></p><p><code>3736</code><code>&lt;/p&gt;</code></p><p><code>3737</code><code>&lt;p id="_600" tabindex="-1"&gt;</code></p><p><code>3738</code><code>Added Bridgewater et al. as &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_478"&gt;</code></p><p><code>3739</code><code>reference 13&lt;/a&gt;</code></p><p><code>3740</code><code>.&lt;/p&gt;</code></p><p><code>3741</code><code>&lt;p id="_601" tabindex="-1"&gt;</code></p><p><code>3742</code><code>Revised &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_479"&gt;</code></p><p><code>3743</code><code>text&lt;/a&gt;</code></p><p><code>3744</code><code> about the BILCAP trial to include results after a median follow-up of 106 months.&lt;/p&gt;</code></p><p><code>3745</code><code>&lt;p id="_602" tabindex="-1"&gt;</code></p><p><code>3746</code><code>Added &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_480"&gt;</code></p><p><code>3747</code><code>text&lt;/a&gt;</code></p><p><code>3748</code><code> about the results of the STAMP study, which included 101 patients with perihilar or distal bile duct cancer, at least one regional lymph node metastasis, and complete macroscopic resection within 12 weeks. Patients were assigned to receive either eight cycles of capecitabine or eight cycles of cisplatin and gemcitabine (cited Yoo et al. as reference 14 and level of evidence B1).&lt;/p&gt;</code></p><p><code>3749</code><code>&lt;p id="_605" tabindex="-1"&gt;</code></p><p><code>3750</code><code>&lt;strong&gt;</code></p><p><code>3751</code><code>&lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_501"&gt;</code></p><p><code>3752</code><code>Treatment of Unresectable (Including Metastatic and Recurrent) Bile Duct Cancer&lt;/a&gt;</code></p><p><code>3753</code><code>&lt;/strong&gt;</code></p><p><code>3754</code><code>&lt;/p&gt;</code></p><p><code>3755</code><code>&lt;p id="_603" tabindex="-1"&gt;</code></p><p><code>3756</code><code>Revised &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_592"&gt;</code></p><p><code>3757</code><code>text&lt;/a&gt;</code></p><p><code>3758</code><code> about the FIGHT-202 trial to state that the median progression-free survival (PFS) was 6.9 months and the median overall survival (OS) was 21.1 months.&lt;/p&gt;</code></p><p><code>3759</code><code>&lt;p id="_604" tabindex="-1"&gt;</code></p><p><code>3760</code><code>Revised &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_593"&gt;</code></p><p><code>3761</code><code>text&lt;/a&gt;</code></p><p><code>3762</code><code> about the CBGJ398X2204 trial to state that the median PFS was 7.3 months and the median OS was 12.2 months.&lt;/p&gt;</code></p><p><code>3763</code><code>&lt;p id="_606" tabindex="-1"&gt;</code></p><p><code>3764</code><code>Added &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_592"&gt;</code></p><p><code>3765</code><code>text&lt;/a&gt;</code></p><p><code>3766</code><code> about the results of the FOENIX-CCA2, which evaluated futibatinib in 103 patients with previously treated intrahepatic cholangiocarcinoma and an &lt;em class="gene-name"&gt;</code></p><p><code>3767</code><code>FGFR2&lt;/em&gt;</code></p><p><code>3768</code><code> fusion or rearrangement (cited Goyal et al. as reference 18 and level of evidence C3).&lt;/p&gt;</code></p><p><code>3769</code><code>&lt;p id="_disclaimerHP_3" tabindex="-1"&gt;</code></p><p><code>3770</code><code>This summary is written and maintained by the &lt;a href="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment" title="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment"&gt;</code></p><p><code>3771</code><code>PDQ Adult Treatment Editorial Board&lt;/a&gt;</code></p><p><code>3772</code><code>, which is</code></p><p><code>3773</code><code>editorially independent of NCI.  The summary reflects an independent review of</code></p><p><code>3774</code><code>the literature and does not represent a policy statement of NCI or NIH.  More</code></p><p><code>3775</code><code>information about summary policies and the role of the PDQ Editorial Boards  in</code></p><p><code>3776</code><code>maintaining the PDQ summaries can be found on the &lt;a href="/types/liver/hp/bile-duct-treatment-pdq#_AboutThis_1"&gt;</code></p><p><code>3777</code><code>About This PDQ Summary&lt;/a&gt;</code></p><p><code>3778</code><code> and &lt;a href="https://www.cancer.gov/publications/pdq" title="https://www.cancer.gov/publications/pdq"&gt;</code></p><p><code>3779</code><code>PDQ&amp;#174; Cancer Information for Health Professionals&lt;/a&gt;</code></p><p><code>3780</code><code> pages.</code></p><p><code>3781</code><code>&lt;/p&gt;</code></p><p><code>3782</code><code>&lt;/div&gt;</code></p><p><code>3783</code><code>          </code></p><p><code>3784</code><code>    &lt;/section&gt;</code></p><p><code>3785</code><code>          </code></p><p><code>3786</code><code>          </code></p><p><code>3787</code><code>          </code></p><p><code>3788</code><code>    &lt;section id="_AboutThis_1"&gt;</code></p><p><code>3789</code><code>          </code></p><p><code>3790</code><code>        &lt;h2&gt;</code></p><p><code>3791</code><code>About This PDQ Summary&lt;/h2&gt;</code></p><p><code>3792</code><code>          </code></p><p><code>3793</code><code>        &lt;div id="_section_AboutThis_1" class="pdq-sections"&gt;</code></p><p><code>3794</code><code>&lt;section id="_AboutThis_2"&gt;</code></p><p><code>3795</code><code>&lt;h3 id="_AboutThis_2_toc"&gt;</code></p><p><code>3796</code><code>Purpose of This Summary&lt;/h3&gt;</code></p><p><code>3797</code><code>&lt;p id="_AboutThis_3" tabindex="-1"&gt;</code></p><p><code>3798</code><code>This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of bile duct cancer. It is intended as a resource to inform and assist clinicians in the care of their patients.  It does not provide formal guidelines or recommendations for making health care decisions.&lt;/p&gt;</code></p><p><code>3799</code><code>&lt;/section&gt;</code></p><p><code>3800</code><code>&lt;section id="_AboutThis_4"&gt;</code></p><p><code>3801</code><code>&lt;h3 id="_AboutThis_4_toc"&gt;</code></p><p><code>3802</code><code>Reviewers and Updates&lt;/h3&gt;</code></p><p><code>3803</code><code>&lt;p id="_AboutThis_5" tabindex="-1"&gt;</code></p><p><code>3804</code><code>This summary is reviewed regularly and updated as necessary by the &lt;a href="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment" title="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment"&gt;</code></p><p><code>3805</code><code>PDQ Adult Treatment Editorial Board&lt;/a&gt;</code></p><p><code>3806</code><code>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).&lt;/p&gt;</code></p><p><code>3807</code><code>&lt;p id="_AboutThis_22" tabindex="-1"&gt;</code></p><p><code>3808</code><code> Board members review recently published articles each month to determine whether an article should:&lt;/p&gt;</code></p><p><code>3809</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3810</code><code>&lt;ul id="_AboutThis_6"&gt;</code></p><p><code>3811</code><code>&lt;li&gt;</code></p><p><code>3812</code><code>be discussed at a meeting,&lt;/li&gt;</code></p><p><code>3813</code><code>&lt;li&gt;</code></p><p><code>3814</code><code>be cited with text, or&lt;/li&gt;</code></p><p><code>3815</code><code>&lt;li&gt;</code></p><p><code>3816</code><code>replace or update an existing article that is already cited.&lt;/li&gt;</code></p><p><code>3817</code><code>&lt;/ul&gt;</code></p><p><code>3818</code><code>&lt;/div&gt;</code></p><p><code>3819</code><code>&lt;p id="_AboutThis_7" tabindex="-1"&gt;</code></p><p><code>3820</code><code>Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.&lt;/p&gt;</code></p><p><code>3821</code><code>&lt;p id="" tabindex="-1"&gt;</code></p><p><code>3822</code><code>The lead reviewers for Bile Duct Cancer (Cholangiocarcinoma) Treatment are:&lt;/p&gt;</code></p><p><code>3823</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3824</code><code>&lt;ul id=""&gt;</code></p><p><code>3825</code><code>&lt;li&gt;</code></p><p><code>3826</code><code>Valerie Lee, MD (Johns Hopkins University)&lt;/li&gt;</code></p><p><code>3827</code><code>&lt;li&gt;</code></p><p><code>3828</code><code>Ari Seifter, MD (University of Illinois at Chicago)&lt;/li&gt;</code></p><p><code>3829</code><code>&lt;/ul&gt;</code></p><p><code>3830</code><code>&lt;/div&gt;</code></p><p><code>3831</code><code>&lt;p id="_AboutThis_9" tabindex="-1"&gt;</code></p><p><code>3832</code><code>Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's &lt;a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us"&gt;</code></p><p><code>3833</code><code>Email Us&lt;/a&gt;</code></p><p><code>3834</code><code>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.&lt;/p&gt;</code></p><p><code>3835</code><code>&lt;/section&gt;</code></p><p><code>3836</code><code>&lt;section id="_AboutThis_10"&gt;</code></p><p><code>3837</code><code>&lt;h3 id="_AboutThis_10_toc"&gt;</code></p><p><code>3838</code><code>Levels of Evidence&lt;/h3&gt;</code></p><p><code>3839</code><code>&lt;p id="_AboutThis_11" tabindex="-1"&gt;</code></p><p><code>3840</code><code>Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a &lt;a href="/publications/pdq/levels-evidence/treatment"&gt;</code></p><p><code>3841</code><code>formal evidence ranking system&lt;/a&gt;</code></p><p><code>3842</code><code> in developing its level-of-evidence designations.&lt;/p&gt;</code></p><p><code>3843</code><code>&lt;/section&gt;</code></p><p><code>3844</code><code>&lt;section id="_AboutThis_12"&gt;</code></p><p><code>3845</code><code>&lt;h3 id="_AboutThis_12_toc"&gt;</code></p><p><code>3846</code><code>Permission to Use This Summary&lt;/h3&gt;</code></p><p><code>3847</code><code>&lt;p id="_AboutThis_13" tabindex="-1"&gt;</code></p><p><code>3848</code><code>PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as &amp;#8220;NCI&amp;#8217;s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].&amp;#8221;&lt;/p&gt;</code></p><p><code>3849</code><code>&lt;p id="_AboutThis_14" tabindex="-1"&gt;</code></p><p><code>3850</code><code>The preferred citation for this PDQ summary is:&lt;/p&gt;</code></p><p><code>3851</code><code>&lt;p id="_AboutThis_15" tabindex="-1"&gt;</code></p><p><code>3852</code><code>PDQ&amp;#174; Adult Treatment Editorial Board. PDQ Bile Duct Cancer (Cholangiocarcinoma) Treatment. Bethesda, MD: National Cancer Institute. Updated  &amp;lt;MM/DD/YYYY&amp;gt;. Available at: &lt;a href="https://www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq" title="https://www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq"&gt;</code></p><p><code>3853</code><code>https://www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq&lt;/a&gt;</code></p><p><code>3854</code><code>.  Accessed &amp;lt;MM/DD/YYYY&amp;gt;. [PMID: 26389308]&lt;/p&gt;</code></p><p><code>3855</code><code>&lt;p id="_AboutThis_16" tabindex="-1"&gt;</code></p><p><code>3856</code><code>Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in &lt;a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/"&gt;</code></p><p><code>3857</code><code>Visuals Online&lt;/a&gt;</code></p><p><code>3858</code><code>, a collection of over 2,000 scientific images.</code></p><p><code>3859</code><code>          </code></p><p><code>3860</code><code>&lt;/p&gt;</code></p><p><code>3861</code><code>&lt;/section&gt;</code></p><p><code>3862</code><code>&lt;section id="_AboutThis_17"&gt;</code></p><p><code>3863</code><code>&lt;h3 id="_AboutThis_17_toc"&gt;</code></p><p><code>3864</code><code>Disclaimer&lt;/h3&gt;</code></p><p><code>3865</code><code>&lt;p id="_AboutThis_18" tabindex="-1"&gt;</code></p><p><code>3866</code><code>Based on the strength of the available evidence, treatment options may be described as either &amp;#8220;standard&amp;#8221; or &amp;#8220;under clinical evaluation.&amp;#8221; These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the &lt;a href="https://www.cancer.gov/about-cancer/managing-care" title="https://www.cancer.gov/about-cancer/managing-care"&gt;</code></p><p><code>3867</code><code>Managing Cancer Care&lt;/a&gt;</code></p><p><code>3868</code><code> page.&lt;/p&gt;</code></p><p><code>3869</code><code>&lt;/section&gt;</code></p><p><code>3870</code><code>&lt;section id="_AboutThis_20"&gt;</code></p><p><code>3871</code><code>&lt;h3 id="_AboutThis_20_toc"&gt;</code></p><p><code>3872</code><code>Contact Us&lt;/h3&gt;</code></p><p><code>3873</code><code>&lt;p id="_AboutThis_21" tabindex="-1"&gt;</code></p><p><code>3874</code><code>More information about contacting us or receiving help with the Cancer.gov website can be found on our &lt;a href="https://www.cancer.gov/contact" title="https://www.cancer.gov/contact"&gt;</code></p><p><code>3875</code><code>Contact Us for Help&lt;/a&gt;</code></p><p><code>3876</code><code> page. Questions can also be submitted to Cancer.gov through the website&amp;#8217;s &lt;a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us"&gt;</code></p><p><code>3877</code><code>Email Us&lt;/a&gt;</code></p><p><code>3878</code><code>.&lt;/p&gt;</code></p><p><code>3879</code><code>&lt;/section&gt;</code></p><p><code>3880</code><code>&lt;/div&gt;</code></p><p><code>3881</code><code>          </code></p><p><code>3882</code><code>    &lt;/section&gt;</code></p><p><code>3883</code><code>          </code></p><p><code>3884</code><code>          </code></p><p><code>3885</code><code>        &lt;/div&gt;</code></p><p><code>3886</code><code>          </code></p><p><code>3887</code><code>      &lt;/div&gt;</code></p><p><code>3888</code><code>          </code></p><p><code>3889</code><code>    &lt;/div&gt;</code></p><p><code>3890</code><code>          </code></p><p><code>3891</code><code>  &lt;/div&gt;</code></p><p><code>3892</code><code>          </code></p><p><code>3893</code><code>          </code></p><p><code>3894</code><code>    &lt;footer class="article-footer"&gt;</code></p><p><code>3895</code><code>                    </code></p><p><code>3896</code><code>            &lt;div class="document-dates horizontal"&gt;</code></p><p><code>3897</code><code>          </code></p><p><code>3898</code><code>                &lt;ul class="clearfix"&gt;</code></p><p><code>3899</code><code>          </code></p><p><code>3900</code><code>                                                                &lt;li&gt;</code></p><p><code>3901</code><code>          </code></p><p><code>3902</code><code>                            &lt;strong&gt;</code></p><p><code>3903</code><code>Updated:&lt;/strong&gt;</code></p><p><code>3904</code><code>          </code></p><p><code>3905</code><code>                            &lt;time datetime="2023-02-24T12:00:00Z"&gt;</code></p><p><code>3906</code><code>February 24, 2023&lt;/time&gt;</code></p><p><code>3907</code><code>          </code></p><p><code>3908</code><code>          </code></p><p><code>3909</code><code>                        &lt;/li&gt;</code></p><p><code>3910</code><code>          </code></p><p><code>3911</code><code>                                                        &lt;/ul&gt;</code></p><p><code>3912</code><code>          </code></p><p><code>3913</code><code>            &lt;/div&gt;</code></p><p><code>3914</code><code>          </code></p><p><code>3915</code><code>                  &lt;div id="nvcgSlPublicUse"&gt;</code></p><p><code>3916</code><code>          </code></p><p><code>3917</code><code>  &lt;div class="slot-item only-SI"&gt;</code></p><p><code>3918</code><code>          </code></p><p><code>3919</code><code>    &lt;div class="public-use"&gt;</code></p><p><code>3920</code><code>          </code></p><p><code>3921</code><code>      &lt;div id="block-ncids-trans-public-use"&gt;</code></p><p><code>3922</code><code>          </code></p><p><code>3923</code><code>  </code></p><p><code>3924</code><code>    </code></p><p><code>3925</code><code>      &lt;p&gt;</code></p><p><code>3926</code><code>&lt;em&gt;</code></p><p><code>3927</code><code>If you would like to reproduce some or all of this content, see &lt;a href="/policies/copyright-reuse"&gt;</code></p><p><code>3928</code><code>Reuse of NCI Information&lt;/a&gt;</code></p><p><code>3929</code><code> for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version was originally published by the National Cancer Institute.”&lt;/em&gt;</code></p><p><code>3930</code><code>&lt;/p&gt;</code></p><p><code>3931</code><code>          </code></p><p><code>3932</code><code>          </code></p><p><code>3933</code><code>  &lt;/div&gt;</code></p><p><code>3934</code><code>          </code></p><p><code>3935</code><code>          </code></p><p><code>3936</code><code>    &lt;/div&gt;</code></p><p><code>3937</code><code>          </code></p><p><code>3938</code><code>  &lt;/div&gt;</code></p><p><code>3939</code><code>          </code></p><p><code>3940</code><code>&lt;/div&gt;</code></p><p><code>3941</code><code>          </code></p><p><code>3942</code><code>          </code></p><p><code>3943</code><code>                &lt;div id="block-ncids-trans-syndication-message"&gt;</code></p><p><code>3944</code><code>          </code></p><p><code>3945</code><code>  </code></p><p><code>3946</code><code>    </code></p><p><code>3947</code><code>        &lt;div class="syndication"&gt;</code></p><p><code>3948</code><code>          </code></p><p><code>3949</code><code>    &lt;div&gt;</code></p><p><code>3950</code><code>          </code></p><p><code>3951</code><code>      &lt;p&gt;</code></p><p><code>3952</code><code>Want to use this content on your website or other digital platform? Our &lt;a href="/syndication"&gt;</code></p><p><code>3953</code><code>syndication services page&lt;/a&gt;</code></p><p><code>3954</code><code> shows you how.&lt;/p&gt;</code></p><p><code>3955</code><code>          </code></p><p><code>3956</code><code>    &lt;/div&gt;</code></p><p><code>3957</code><code>          </code></p><p><code>3958</code><code>  &lt;/div&gt;</code></p><p><code>3959</code><code>          </code></p><p><code>3960</code><code>          </code></p><p><code>3961</code><code>  &lt;/div&gt;</code></p><p><code>3962</code><code>          </code></p><p><code>3963</code><code>          </code></p><p><code>3964</code><code>          </code></p><p><code>3965</code><code>      &lt;/footer&gt;</code></p><p><code>3966</code><code>          </code></p><p><code>3967</code><code>&lt;/article&gt;</code></p><p><code>3968</code><code>          </code></p><p><code>3969</code><code>          </code></p><p><code>3970</code><code>          </code></p><p><code>3971</code><code>        &lt;/main&gt;</code></p><p><code>3972</code><code>          </code></p><p><code>3973</code><code>      &lt;/div&gt;</code></p><p><code>3974</code><code>          </code></p><p><code>3975</code><code>    &lt;/div&gt;</code></p><p><code>3976</code><code>          </code></p><p><code>3977</code><code>    &lt;div class="desktop:grid-col-9 desktop:grid-offset-3"&gt;</code></p><p><code>3978</code><code>          </code></p><p><code>3979</code><code>      </code></p><p><code>3980</code><code>          </code></p><p><code>3981</code><code>      </code></p><p><code>3982</code><code>          </code></p><p><code>3983</code><code>          </code></p><p><code>3984</code><code>&lt;section  class="cgdp-page-options cgdp-page-options--bottom" aria-label="Page options bottom"&gt;</code></p><p><code>3985</code><code>          </code></p><p><code>3986</code><code>  &lt;button class="usa-button usa-button--unstyled" onclick="window.print()"&gt;</code></p><p><code>3987</code><code>          </code></p><p><code>3988</code><code>    &lt;svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"&gt;</code></p><p><code>3989</code><code>          </code></p><p><code>3990</code><code>      &lt;path d="M0 0h24v24H0z" fill="none"/&gt;</code></p><p><code>3991</code><code>          </code></p><p><code>3992</code><code>      &lt;path d="M19 8H5c-1.66 0-3 1.34-3 3v6h4v4h12v-4h4v-6c0-1.66-1.34-3-3-3zm-3 11H8v-5h8v5zm3-7c-.55 0-1-.45-1-1s.45-1 1-1 1 .45 1 1-.45 1-1 1zm-1-9H6v4h12V3z"/&gt;</code></p><p><code>3993</code><code>          </code></p><p><code>3994</code><code>    &lt;/svg&gt;</code></p><p><code>3995</code><code>          </code></p><p><code>3996</code><code>    &lt;span class="usa-sr-only"&gt;</code></p><p><code>3997</code><code>          </code></p><p><code>3998</code><code>      Print    &lt;/span&gt;</code></p><p><code>3999</code><code>          </code></p><p><code>4000</code><code>  &lt;/button&gt;</code></p><p><code>4001</code><code>          </code></p><p><code>4002</code><code>  &lt;a class="usa-button usa-button--unstyled" href="mailto:?subject=Information from the National Cancer Institute Web Site &amp;body=I found this information on www.cancer.gov and I'd like to share it with you: https://www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq %0D%0A%0D%0A NCI's Web site, www.cancer.gov, provides accurate, up-to-date, comprehensive cancer information from the U.S. government's principal agency for cancer research. If you have questions or need additional information, we invite you to contact NCI's LiveHelp instant messaging service at https://livehelp.cancer.gov, or call the NCI's Contact Center 1-800-4-CANCER (1-800-422-6237) (toll-free from the United States)."&gt;</code></p><p><code>4003</code><code>          </code></p><p><code>4004</code><code>    &lt;svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"&gt;</code></p><p><code>4005</code><code>          </code></p><p><code>4006</code><code>        &lt;path d="M0 0h24v24H0z" fill="none"/&gt;</code></p><p><code>4007</code><code>          </code></p><p><code>4008</code><code>        &lt;path d="M20 4H4c-1.1 0-1.99.9-1.99 2L2 18c0 1.1.9 2 2 2h16c1.1 0 2-.9 2-2V6c0-1.1-.9-2-2-2zm0 14H4V8l8 5 8-5v10zm-8-7L4 6h16l-8 5z"/&gt;</code></p><p><code>4009</code><code>          </code></p><p><code>4010</code><code>    &lt;/svg&gt;</code></p><p><code>4011</code><code>          </code></p><p><code>4012</code><code>    &lt;span class="usa-sr-only"&gt;</code></p><p><code>4013</code><code>          </code></p><p><code>4014</code><code>      Email    &lt;/span&gt;</code></p><p><code>4015</code><code>          </code></p><p><code>4016</code><code>  &lt;/a&gt;</code></p><p><code>4017</code><code>          </code></p><p><code>4018</code><code>&lt;/section&gt;</code></p><p><code>4019</code><code>          </code></p><p><code>4020</code><code>          </code></p><p><code>4021</code><code>    &lt;/div&gt;</code></p><p><code>4022</code><code>          </code></p><p><code>4023</code><code>  &lt;/div&gt;</code></p><p><code>4024</code><code>          </code></p><p><code>4025</code><code>&lt;/div&gt;</code></p><p><code>4026</code><code>          </code></p><p><code>4027</code><code>          </code></p><p><code>4028</code><code>  &lt;div id="block-ncidsfooterenglish"&gt;</code></p><p><code>4029</code><code>          </code></p><p><code>4030</code><code>  </code></p><p><code>4031</code><code>    </code></p><p><code>4032</code><code>      &lt;footer</code></p><p><code>4033</code><code>  class="usa-footer usa-footer--nci-big"</code></p><p><code>4034</code><code>  id="nci-footer"</code></p><p><code>4035</code><code>  aria-label="Footer"</code></p><p><code>4036</code><code>&gt;</code></p><p><code>4037</code><code>          </code></p><p><code>4038</code><code>  &lt;div class="grid-container usa-footer__return-to-top"&gt;</code></p><p><code>4039</code><code>          </code></p><p><code>4040</code><code>    &lt;a href="#top" aria-label="Back To Top"&gt;</code></p><p><code>4041</code><code>&lt;span&gt;</code></p><p><code>4042</code><code>Back To Top&lt;/span&gt;</code></p><p><code>4043</code><code>&lt;/a&gt;</code></p><p><code>4044</code><code>          </code></p><p><code>4045</code><code>  &lt;/div&gt;</code></p><p><code>4046</code><code>          </code></p><p><code>4047</code><code>  &lt;div class="usa-footer__primary-section"&gt;</code></p><p><code>4048</code><code>          </code></p><p><code>4049</code><code>    &lt;div class="grid-container"&gt;</code></p><p><code>4050</code><code>          </code></p><p><code>4051</code><code>      &lt;div class="grid-row grid-gap"&gt;</code></p><p><code>4052</code><code>          </code></p><p><code>4053</code><code>        &lt;div class="tablet:grid-col-8"&gt;</code></p><p><code>4054</code><code>          </code></p><p><code>4055</code><code>          &lt;nav class="usa-footer__nav" aria-label="Footer navigation"&gt;</code></p><p><code>4056</code><code>          </code></p><p><code>4057</code><code>            &lt;div class="grid-row grid-gap-4"&gt;</code></p><p><code>4058</code><code>          </code></p><p><code>4059</code><code>              &lt;div class="mobile-lg:grid-col-6 desktop:grid-col-4"&gt;</code></p><p><code>4060</code><code>          </code></p><p><code>4061</code><code>                &lt;section</code></p><p><code>4062</code><code>                  class="usa-footer__primary-content usa-footer__primary-content--collapsible"</code></p><p><code>4063</code><code>                &gt;</code></p><p><code>4064</code><code>          </code></p><p><code>4065</code><code>                  &lt;div class="usa-footer__primary-link"&gt;</code></p><p><code>4066</code><code>About&lt;/div&gt;</code></p><p><code>4067</code><code>          </code></p><p><code>4068</code><code>                  &lt;ul class="usa-list usa-list--unstyled"&gt;</code></p><p><code>4069</code><code>          </code></p><p><code>4070</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4071</code><code>          </code></p><p><code>4072</code><code>                      &lt;a href="/about-website"&gt;</code></p><p><code>4073</code><code>About This Website&lt;/a&gt;</code></p><p><code>4074</code><code>          </code></p><p><code>4075</code><code>                    &lt;/li&gt;</code></p><p><code>4076</code><code>          </code></p><p><code>4077</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4078</code><code>          </code></p><p><code>4079</code><code>                      &lt;a href="/espanol"&gt;</code></p><p><code>4080</code><code>en Español&lt;/a&gt;</code></p><p><code>4081</code><code>          </code></p><p><code>4082</code><code>                    &lt;/li&gt;</code></p><p><code>4083</code><code>          </code></p><p><code>4084</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4085</code><code>          </code></p><p><code>4086</code><code>                      &lt;a href="/policies/copyright-reuse"&gt;</code></p><p><code>4087</code><code>Reuse &amp;amp; Copyright&lt;/a&gt;</code></p><p><code>4088</code><code>          </code></p><p><code>4089</code><code>                    &lt;/li&gt;</code></p><p><code>4090</code><code>          </code></p><p><code>4091</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4092</code><code>          </code></p><p><code>4093</code><code>                      &lt;a href="/social-media"&gt;</code></p><p><code>4094</code><code>Social Media&lt;/a&gt;</code></p><p><code>4095</code><code>          </code></p><p><code>4096</code><code>                    &lt;/li&gt;</code></p><p><code>4097</code><code>          </code></p><p><code>4098</code><code>                  &lt;/ul&gt;</code></p><p><code>4099</code><code>          </code></p><p><code>4100</code><code>                &lt;/section&gt;</code></p><p><code>4101</code><code>          </code></p><p><code>4102</code><code>              &lt;/div&gt;</code></p><p><code>4103</code><code>          </code></p><p><code>4104</code><code>              &lt;div class="mobile-lg:grid-col-6 desktop:grid-col-4"&gt;</code></p><p><code>4105</code><code>          </code></p><p><code>4106</code><code>                &lt;section</code></p><p><code>4107</code><code>                  class="usa-footer__primary-content usa-footer__primary-content--collapsible"</code></p><p><code>4108</code><code>                &gt;</code></p><p><code>4109</code><code>          </code></p><p><code>4110</code><code>                  &lt;div class="usa-footer__primary-link"&gt;</code></p><p><code>4111</code><code>Resources&lt;/div&gt;</code></p><p><code>4112</code><code>          </code></p><p><code>4113</code><code>                  &lt;ul class="usa-list usa-list--unstyled"&gt;</code></p><p><code>4114</code><code>          </code></p><p><code>4115</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4116</code><code>          </code></p><p><code>4117</code><code>                      &lt;a href="/contact"&gt;</code></p><p><code>4118</code><code>Contact Us&lt;/a&gt;</code></p><p><code>4119</code><code>          </code></p><p><code>4120</code><code>                    &lt;/li&gt;</code></p><p><code>4121</code><code>          </code></p><p><code>4122</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4123</code><code>          </code></p><p><code>4124</code><code>                      &lt;a href="/publications"&gt;</code></p><p><code>4125</code><code>Publications&lt;/a&gt;</code></p><p><code>4126</code><code>          </code></p><p><code>4127</code><code>                    &lt;/li&gt;</code></p><p><code>4128</code><code>          </code></p><p><code>4129</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4130</code><code>          </code></p><p><code>4131</code><code>                      &lt;a href="/publications/dictionaries/cancer-terms"</code></p><p><code>4132</code><code>                        &gt;</code></p><p><code>4133</code><code>Dictionary of Cancer Terms&lt;/a</code></p><p><code>4134</code><code>                      &gt;</code></p><p><code>4135</code><code>          </code></p><p><code>4136</code><code>                    &lt;/li&gt;</code></p><p><code>4137</code><code>          </code></p><p><code>4138</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4139</code><code>          </code></p><p><code>4140</code><code>                      &lt;a href="/research/participate/clinical-trials-search"</code></p><p><code>4141</code><code>                        &gt;</code></p><p><code>4142</code><code>Find a Clinical Trial&lt;/a</code></p><p><code>4143</code><code>                      &gt;</code></p><p><code>4144</code><code>          </code></p><p><code>4145</code><code>                    &lt;/li&gt;</code></p><p><code>4146</code><code>          </code></p><p><code>4147</code><code>                  &lt;/ul&gt;</code></p><p><code>4148</code><code>          </code></p><p><code>4149</code><code>                &lt;/section&gt;</code></p><p><code>4150</code><code>          </code></p><p><code>4151</code><code>              &lt;/div&gt;</code></p><p><code>4152</code><code>          </code></p><p><code>4153</code><code>              &lt;div class="mobile-lg:grid-col-6 desktop:grid-col-4"&gt;</code></p><p><code>4154</code><code>          </code></p><p><code>4155</code><code>                &lt;section</code></p><p><code>4156</code><code>                  class="usa-footer__primary-content usa-footer__primary-content--collapsible"</code></p><p><code>4157</code><code>                &gt;</code></p><p><code>4158</code><code>          </code></p><p><code>4159</code><code>                  &lt;div class="usa-footer__primary-link"&gt;</code></p><p><code>4160</code><code>Policies&lt;/div&gt;</code></p><p><code>4161</code><code>          </code></p><p><code>4162</code><code>                  &lt;ul class="usa-list usa-list--unstyled"&gt;</code></p><p><code>4163</code><code>          </code></p><p><code>4164</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4165</code><code>          </code></p><p><code>4166</code><code>                      &lt;a href="/policies/accessibility"&gt;</code></p><p><code>4167</code><code>Accessibility&lt;/a&gt;</code></p><p><code>4168</code><code>          </code></p><p><code>4169</code><code>                    &lt;/li&gt;</code></p><p><code>4170</code><code>          </code></p><p><code>4171</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4172</code><code>          </code></p><p><code>4173</code><code>                      &lt;a href="/policies/foia"&gt;</code></p><p><code>4174</code><code>FOIA&lt;/a&gt;</code></p><p><code>4175</code><code>          </code></p><p><code>4176</code><code>                    &lt;/li&gt;</code></p><p><code>4177</code><code>          </code></p><p><code>4178</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4179</code><code>          </code></p><p><code>4180</code><code>                      &lt;a href="/policies/privacy-security"</code></p><p><code>4181</code><code>                        &gt;</code></p><p><code>4182</code><code>Privacy &amp;amp; Security&lt;/a</code></p><p><code>4183</code><code>                      &gt;</code></p><p><code>4184</code><code>          </code></p><p><code>4185</code><code>                    &lt;/li&gt;</code></p><p><code>4186</code><code>          </code></p><p><code>4187</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4188</code><code>          </code></p><p><code>4189</code><code>                      &lt;a href="/policies/disclaimer"&gt;</code></p><p><code>4190</code><code>Disclaimers&lt;/a&gt;</code></p><p><code>4191</code><code>          </code></p><p><code>4192</code><code>                    &lt;/li&gt;</code></p><p><code>4193</code><code>          </code></p><p><code>4194</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4195</code><code>          </code></p><p><code>4196</code><code>                      &lt;a</code></p><p><code>4197</code><code>                        href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html"</code></p><p><code>4198</code><code>                        &gt;</code></p><p><code>4199</code><code>Vulnerability Disclosure&lt;/a</code></p><p><code>4200</code><code>                      &gt;</code></p><p><code>4201</code><code>          </code></p><p><code>4202</code><code>                    &lt;/li&gt;</code></p><p><code>4203</code><code>          </code></p><p><code>4204</code><code>                  &lt;/ul&gt;</code></p><p><code>4205</code><code>          </code></p><p><code>4206</code><code>                &lt;/section&gt;</code></p><p><code>4207</code><code>          </code></p><p><code>4208</code><code>              &lt;/div&gt;</code></p><p><code>4209</code><code>          </code></p><p><code>4210</code><code>            &lt;/div&gt;</code></p><p><code>4211</code><code>          </code></p><p><code>4212</code><code>          &lt;/nav&gt;</code></p><p><code>4213</code><code>          </code></p><p><code>4214</code><code>        &lt;/div&gt;</code></p><p><code>4215</code><code>          </code></p><p><code>4216</code><code>        &lt;div class="tablet:grid-col-4"&gt;</code></p><p><code>4217</code><code>          </code></p><p><code>4218</code><code>          &lt;div class="usa-sign-up"&gt;</code></p><p><code>4219</code><code>          </code></p><p><code>4220</code><code>            &lt;div class="usa-sign-up__heading"&gt;</code></p><p><code>4221</code><code>Sign up for email updates&lt;/div&gt;</code></p><p><code>4222</code><code>          </code></p><p><code>4223</code><code>            &lt;form</code></p><p><code>4224</code><code>              action="https://public.govdelivery.com/accounts/USNIHNCI/subscribers/qualify"</code></p><p><code>4225</code><code>              aria-label="Footer subscribe"</code></p><p><code>4226</code><code>              class="usa-form"</code></p><p><code>4227</code><code>              accept-charset="UTF-8"</code></p><p><code>4228</code><code>              method="post"</code></p><p><code>4229</code><code>              novalidate</code></p><p><code>4230</code><code>              target="_blank"</code></p><p><code>4231</code><code>              id="signup"</code></p><p><code>4232</code><code>            &gt;</code></p><p><code>4233</code><code>          </code></p><p><code>4234</code><code>              &lt;input</code></p><p><code>4235</code><code>                type="hidden"</code></p><p><code>4236</code><code>                name="category_id"</code></p><p><code>4237</code><code>                id="category_id"</code></p><p><code>4238</code><code>                value=""</code></p><p><code>4239</code><code>              /&gt;</code></p><p><code>4240</code><code>          </code></p><p><code>4241</code><code>              &lt;div class="usa-form-group"&gt;</code></p><p><code>4242</code><code>          </code></p><p><code>4243</code><code>                &lt;label class="usa-label" for="email"&gt;</code></p><p><code>4244</code><code>          </code></p><p><code>4245</code><code>                  Enter your email address</code></p><p><code>4246</code><code>                &lt;/label&gt;</code></p><p><code>4247</code><code>          </code></p><p><code>4248</code><code>                &lt;input</code></p><p><code>4249</code><code>                  class="usa-input width-full"</code></p><p><code>4250</code><code>                  id="email"</code></p><p><code>4251</code><code>                  name="email"</code></p><p><code>4252</code><code>                  type="email"</code></p><p><code>4253</code><code>                  value=""</code></p><p><code>4254</code><code>                /&gt;</code></p><p><code>4255</code><code>          </code></p><p><code>4256</code><code>              &lt;/div&gt;</code></p><p><code>4257</code><code>          </code></p><p><code>4258</code><code>              &lt;button class="usa-button usa-button--accent-warm" type="submit"&gt;</code></p><p><code>4259</code><code>          </code></p><p><code>4260</code><code>                Sign up</code></p><p><code>4261</code><code>              &lt;/button&gt;</code></p><p><code>4262</code><code>          </code></p><p><code>4263</code><code>            &lt;/form&gt;</code></p><p><code>4264</code><code>          </code></p><p><code>4265</code><code>          &lt;/div&gt;</code></p><p><code>4266</code><code>          </code></p><p><code>4267</code><code>        &lt;/div&gt;</code></p><p><code>4268</code><code>          </code></p><p><code>4269</code><code>      &lt;/div&gt;</code></p><p><code>4270</code><code>          </code></p><p><code>4271</code><code>    &lt;/div&gt;</code></p><p><code>4272</code><code>          </code></p><p><code>4273</code><code>  &lt;/div&gt;</code></p><p><code>4274</code><code>          </code></p><p><code>4275</code><code>  &lt;div class="usa-footer__secondary-section"&gt;</code></p><p><code>4276</code><code>          </code></p><p><code>4277</code><code>    &lt;div class="grid-container"&gt;</code></p><p><code>4278</code><code>          </code></p><p><code>4279</code><code>      &lt;div class="grid-row grid-gap"&gt;</code></p><p><code>4280</code><code>          </code></p><p><code>4281</code><code>        &lt;div class="usa-footer__logo grid-row desktop:grid-col-5"&gt;</code></p><p><code>4282</code><code>          </code></p><p><code>4283</code><code>          &lt;div class="mobile-lg:grid-col-auto desktop:margin-bottom-3"&gt;</code></p><p><code>4284</code><code>          </code></p><p><code>4285</code><code>            &lt;p class="usa-footer__logo-heading"&gt;</code></p><p><code>4286</code><code>          </code></p><p><code>4287</code><code>              &lt;span class="logo__agency-name"&gt;</code></p><p><code>4288</code><code>National Cancer Institute &lt;/span&gt;</code></p><p><code>4289</code><code>          </code></p><p><code>4290</code><code>              &lt;span class="logo__parent-organization"</code></p><p><code>4291</code><code>                &gt;</code></p><p><code>4292</code><code>at the National Institutes of Health&lt;/span</code></p><p><code>4293</code><code>              &gt;</code></p><p><code>4294</code><code>          </code></p><p><code>4295</code><code>            &lt;/p&gt;</code></p><p><code>4296</code><code>          </code></p><p><code>4297</code><code>          &lt;/div&gt;</code></p><p><code>4298</code><code>          </code></p><p><code>4299</code><code>        &lt;/div&gt;</code></p><p><code>4300</code><code>          </code></p><p><code>4301</code><code>        &lt;div class="usa-footer__contact-links mobile-lg:grid-col-7"&gt;</code></p><p><code>4302</code><code>          </code></p><p><code>4303</code><code>          &lt;div class="usa-footer__contact-heading"&gt;</code></p><p><code>4304</code><code>Contact Us&lt;/div&gt;</code></p><p><code>4305</code><code>          </code></p><p><code>4306</code><code>          &lt;div class="usa-footer__address"&gt;</code></p><p><code>4307</code><code>          </code></p><p><code>4308</code><code>            &lt;div class="usa-footer__contact-info grid-row grid-gap"&gt;</code></p><p><code>4309</code><code>          </code></p><p><code>4310</code><code>              &lt;div class="tablet:grid-col-auto"&gt;</code></p><p><code>4311</code><code>          </code></p><p><code>4312</code><code>                &lt;a href="https://livehelp.cancer.gov/"&gt;</code></p><p><code>4313</code><code>Live Chat&lt;/a&gt;</code></p><p><code>4314</code><code>          </code></p><p><code>4315</code><code>              &lt;/div&gt;</code></p><p><code>4316</code><code>          </code></p><p><code>4317</code><code>              &lt;div class="tablet:grid-col-auto"&gt;</code></p><p><code>4318</code><code>          </code></p><p><code>4319</code><code>                &lt;a href="tel:1-800-4-CANCER"&gt;</code></p><p><code>4320</code><code>1-800-4-CANCER&lt;/a&gt;</code></p><p><code>4321</code><code>          </code></p><p><code>4322</code><code>              &lt;/div&gt;</code></p><p><code>4323</code><code>          </code></p><p><code>4324</code><code>              &lt;div class="tablet:grid-col-auto"&gt;</code></p><p><code>4325</code><code>          </code></p><p><code>4326</code><code>                &lt;a href="mailto:NCIinfo@nih.gov"&gt;</code></p><p><code>4327</code><code>NCIinfo@nih.gov&lt;/a&gt;</code></p><p><code>4328</code><code>          </code></p><p><code>4329</code><code>              &lt;/div&gt;</code></p><p><code>4330</code><code>          </code></p><p><code>4331</code><code>              &lt;div class="tablet:grid-col-auto"&gt;</code></p><p><code>4332</code><code>          </code></p><p><code>4333</code><code>                &lt;a</code></p><p><code>4334</code><code>                  class="no-exit-notification"</code></p><p><code>4335</code><code>                  href="https://nci.az1.qualtrics.com/jfe/form/SV_aeLLobt6ZeGVn5I"</code></p><p><code>4336</code><code>                  target="_blank"</code></p><p><code>4337</code><code>                  &gt;</code></p><p><code>4338</code><code>Site Feedback&lt;/a</code></p><p><code>4339</code><code>                &gt;</code></p><p><code>4340</code><code>          </code></p><p><code>4341</code><code>              &lt;/div&gt;</code></p><p><code>4342</code><code>          </code></p><p><code>4343</code><code>            &lt;/div&gt;</code></p><p><code>4344</code><code>          </code></p><p><code>4345</code><code>          &lt;/div&gt;</code></p><p><code>4346</code><code>          </code></p><p><code>4347</code><code>        &lt;/div&gt;</code></p><p><code>4348</code><code>          </code></p><p><code>4349</code><code>      &lt;/div&gt;</code></p><p><code>4350</code><code>          </code></p><p><code>4351</code><code>      &lt;div class="grid-row grid-gap"&gt;</code></p><p><code>4352</code><code>          </code></p><p><code>4353</code><code>        &lt;div class="usa-footer__social-links desktop:grid-col-5"&gt;</code></p><p><code>4354</code><code>          </code></p><p><code>4355</code><code>          &lt;div class="usa-footer__social-heading"&gt;</code></p><p><code>4356</code><code>Follow us&lt;/div&gt;</code></p><p><code>4357</code><code>          </code></p><p><code>4358</code><code>          &lt;div class="grid-row grid-gap-1 nci-big__social"&gt;</code></p><p><code>4359</code><code>          </code></p><p><code>4360</code><code>            &lt;div class="grid-col-auto"&gt;</code></p><p><code>4361</code><code>          </code></p><p><code>4362</code><code>              &lt;a</code></p><p><code>4363</code><code>                class="usa-social-link usa-social-link--facebook no-exit-notification"</code></p><p><code>4364</code><code>                href="https://www.facebook.com/cancer.gov"</code></p><p><code>4365</code><code>              &gt;</code></p><p><code>4366</code><code>          </code></p><p><code>4367</code><code>                &lt;svg</code></p><p><code>4368</code><code>                  xmlns="http://www.w3.org/2000/svg"</code></p><p><code>4369</code><code>                  viewBox="0 0 24 24"</code></p><p><code>4370</code><code>                  width="24"</code></p><p><code>4371</code><code>                  class="usa-icon"</code></p><p><code>4372</code><code>                  role="img"</code></p><p><code>4373</code><code>                  aria-labelledby="facebook-title"</code></p><p><code>4374</code><code>                &gt;</code></p><p><code>4375</code><code>          </code></p><p><code>4376</code><code>                  &lt;title id="facebook-title"&gt;</code></p><p><code>4377</code><code>Facebook&lt;/title&gt;</code></p><p><code>4378</code><code>          </code></p><p><code>4379</code><code>                  &lt;rect fill="none" height="24" width="24" /&gt;</code></p><p><code>4380</code><code>          </code></p><p><code>4381</code><code>                  &lt;path</code></p><p><code>4382</code><code>                    d="M22,12c0-5.52-4.48-10-10-10S2,6.48,2,12c0,4.84,3.44,8.87,8,9.8V15H8v-3h2V9.5C10,7.57,11.57,6,13.5,6H16v3h-2 c-0.55,0-1,0.45-1,1v2h3v3h-3v6.95C18.05,21.45,22,17.19,22,12z"</code></p><p><code>4383</code><code>                  /&gt;</code></p><p><code>4384</code><code>          </code></p><p><code>4385</code><code>                &lt;/svg&gt;</code></p><p><code>4386</code><code>          </code></p><p><code>4387</code><code>              &lt;/a&gt;</code></p><p><code>4388</code><code>          </code></p><p><code>4389</code><code>            &lt;/div&gt;</code></p><p><code>4390</code><code>          </code></p><p><code>4391</code><code>            &lt;div class="grid-col-auto"&gt;</code></p><p><code>4392</code><code>          </code></p><p><code>4393</code><code>              &lt;a</code></p><p><code>4394</code><code>                class="usa-social-link usa-social-link--twitter no-exit-notification"</code></p><p><code>4395</code><code>                href="https://twitter.com/thenci"</code></p><p><code>4396</code><code>              &gt;</code></p><p><code>4397</code><code>          </code></p><p><code>4398</code><code>                &lt;svg</code></p><p><code>4399</code><code>                  xmlns="http://www.w3.org/2000/svg"</code></p><p><code>4400</code><code>                  viewBox="0 0 24 24"</code></p><p><code>4401</code><code>                  class="usa-icon"</code></p><p><code>4402</code><code>                  role="img"</code></p><p><code>4403</code><code>                  aria-labelledby="twitter-title"</code></p><p><code>4404</code><code>                &gt;</code></p><p><code>4405</code><code>          </code></p><p><code>4406</code><code>                  &lt;title id="twitter-title"&gt;</code></p><p><code>4407</code><code>Twitter&lt;/title&gt;</code></p><p><code>4408</code><code>          </code></p><p><code>4409</code><code>                  &lt;path</code></p><p><code>4410</code><code>                    id="Twitter"</code></p><p><code>4411</code><code>                    d="M12,2A10,10,0,1,0,22,12,10,10,0,0,0,12,2Zm5,8.1c0,.1,0,.21,0,.31a6.81,6.81,0,0,1-6.86,6.86,6.74,6.74,0,0,1-3.69-1.08,5.63,5.63,0,0,0,.58,0,4.79,4.79,0,0,0,3-1A2.41,2.41,0,0,1,7.8,13.51a1.75,1.75,0,0,0,.46.05,2.59,2.59,0,0,0,.63-.08A2.42,2.42,0,0,1,7,11.11v0a2.33,2.33,0,0,0,1.09.3A2.43,2.43,0,0,1,7.3,8.16a6.84,6.84,0,0,0,5,2.53,2.59,2.59,0,0,1-.07-.55,2.41,2.41,0,0,1,2.41-2.41,2.38,2.38,0,0,1,1.77.76A4.67,4.67,0,0,0,17.9,7.9a2.39,2.39,0,0,1-1.06,1.34,4.55,4.55,0,0,0,1.39-.39A5,5,0,0,1,17,10.1Z"</code></p><p><code>4412</code><code>                  /&gt;</code></p><p><code>4413</code><code>          </code></p><p><code>4414</code><code>                &lt;/svg&gt;</code></p><p><code>4415</code><code>          </code></p><p><code>4416</code><code>              &lt;/a&gt;</code></p><p><code>4417</code><code>          </code></p><p><code>4418</code><code>            &lt;/div&gt;</code></p><p><code>4419</code><code>          </code></p><p><code>4420</code><code>            &lt;div class="grid-col-auto"&gt;</code></p><p><code>4421</code><code>          </code></p><p><code>4422</code><code>              &lt;a</code></p><p><code>4423</code><code>                class="usa-social-link usa-social-link--instagram no-exit-notification"</code></p><p><code>4424</code><code>                href="https://www.instagram.com/nationalcancerinstitute/"</code></p><p><code>4425</code><code>              &gt;</code></p><p><code>4426</code><code>          </code></p><p><code>4427</code><code>                &lt;svg</code></p><p><code>4428</code><code>                  xmlns="http://www.w3.org/2000/svg"</code></p><p><code>4429</code><code>                  viewBox="0 0 24 24"</code></p><p><code>4430</code><code>                  class="usa-icon"</code></p><p><code>4431</code><code>                  role="img"</code></p><p><code>4432</code><code>                  aria-labelledby="instagram-title"</code></p><p><code>4433</code><code>                &gt;</code></p><p><code>4434</code><code>          </code></p><p><code>4435</code><code>                  &lt;title id="instagram-title"&gt;</code></p><p><code>4436</code><code>Instagram&lt;/title&gt;</code></p><p><code>4437</code><code>          </code></p><p><code>4438</code><code>                  &lt;g id="Instagram"&gt;</code></p><p><code>4439</code><code>          </code></p><p><code>4440</code><code>                    &lt;path d="M12,10a2,2,0,1,0,2,2A2,2,0,0,0,12,10Z" /&gt;</code></p><p><code>4441</code><code>          </code></p><p><code>4442</code><code>                    &lt;path</code></p><p><code>4443</code><code>                      d="M12,2A10,10,0,1,0,22,12,10,10,0,0,0,12,2Zm6,12.69A3.32,3.32,0,0,1,14.69,18H9.31A3.32,3.32,0,0,1,6,14.69V9.31A3.32,3.32,0,0,1,9.31,6h5.38A3.32,3.32,0,0,1,18,9.31Z"</code></p><p><code>4444</code><code>                    /&gt;</code></p><p><code>4445</code><code>          </code></p><p><code>4446</code><code>                    &lt;path</code></p><p><code>4447</code><code>                      d="M16.94,9.31a2.25,2.25,0,0,0-2.25-2.25H9.31A2.25,2.25,0,0,0,7.06,9.31v5.38a2.25,2.25,0,0,0,2.25,2.25h5.38a2.25,2.25,0,0,0,2.25-2.25h0ZM12,15.09A3.09,3.09,0,1,1,15.09,12,3.09,3.09,0,0,1,12,15.09Zm3.77-5.75a.79.79,0,0,1-.55.23.83.83,0,0,1-.55-.23.78.78,0,0,1,0-1.11A.82.82,0,0,1,15.22,8a.78.78,0,0,1,.55,1.33Z"</code></p><p><code>4448</code><code>                    /&gt;</code></p><p><code>4449</code><code>          </code></p><p><code>4450</code><code>                  &lt;/g&gt;</code></p><p><code>4451</code><code>          </code></p><p><code>4452</code><code>                &lt;/svg&gt;</code></p><p><code>4453</code><code>          </code></p><p><code>4454</code><code>              &lt;/a&gt;</code></p><p><code>4455</code><code>          </code></p><p><code>4456</code><code>            &lt;/div&gt;</code></p><p><code>4457</code><code>          </code></p><p><code>4458</code><code>            &lt;div class="grid-col-auto"&gt;</code></p><p><code>4459</code><code>          </code></p><p><code>4460</code><code>              &lt;a</code></p><p><code>4461</code><code>                class="usa-social-link usa-social-link--youtube no-exit-notification"</code></p><p><code>4462</code><code>                href="https://www.youtube.com/NCIgov"</code></p><p><code>4463</code><code>              &gt;</code></p><p><code>4464</code><code>          </code></p><p><code>4465</code><code>                &lt;svg</code></p><p><code>4466</code><code>                  xmlns="http://www.w3.org/2000/svg"</code></p><p><code>4467</code><code>                  viewBox="0 0 24 24"</code></p><p><code>4468</code><code>                  class="usa-icon"</code></p><p><code>4469</code><code>                  role="img"</code></p><p><code>4470</code><code>                  aria-labelledby="youtube-title"</code></p><p><code>4471</code><code>                &gt;</code></p><p><code>4472</code><code>          </code></p><p><code>4473</code><code>                  &lt;title id="youtube-title"&gt;</code></p><p><code>4474</code><code>Youtube&lt;/title&gt;</code></p><p><code>4475</code><code>          </code></p><p><code>4476</code><code>                  &lt;g id="YouTube"&gt;</code></p><p><code>4477</code><code>          </code></p><p><code>4478</code><code>                    &lt;path</code></p><p><code>4479</code><code>                      d="M12,2A10,10,0,1,0,22,12,10,10,0,0,0,12,2Zm5.75,12.91A1.49,1.49,0,0,1,16.69,16a34.65,34.65,0,0,1-4.69.26A34.65,34.65,0,0,1,7.31,16a1.49,1.49,0,0,1-1.06-1.06A15.88,15.88,0,0,1,6,12a15.88,15.88,0,0,1,.25-2.91A1.49,1.49,0,0,1,7.31,8,34.65,34.65,0,0,1,12,7.77,34.65,34.65,0,0,1,16.69,8a1.49,1.49,0,0,1,1.06,1.06A15.88,15.88,0,0,1,18,12,15.88,15.88,0,0,1,17.75,14.91Z"</code></p><p><code>4480</code><code>                    /&gt;</code></p><p><code>4481</code><code>          </code></p><p><code>4482</code><code>                    &lt;polygon</code></p><p><code>4483</code><code>                      points="10.77 13.78 13.91 12 10.77 10.22 10.77 13.78"</code></p><p><code>4484</code><code>                    /&gt;</code></p><p><code>4485</code><code>          </code></p><p><code>4486</code><code>                  &lt;/g&gt;</code></p><p><code>4487</code><code>          </code></p><p><code>4488</code><code>                &lt;/svg&gt;</code></p><p><code>4489</code><code>          </code></p><p><code>4490</code><code>              &lt;/a&gt;</code></p><p><code>4491</code><code>          </code></p><p><code>4492</code><code>            &lt;/div&gt;</code></p><p><code>4493</code><code>          </code></p><p><code>4494</code><code>            &lt;div class="grid-col-auto"&gt;</code></p><p><code>4495</code><code>          </code></p><p><code>4496</code><code>              &lt;a</code></p><p><code>4497</code><code>                class="usa-social-link usa-social-link--linkedin no-exit-notification"</code></p><p><code>4498</code><code>                href="https://www.linkedin.com/company/nationalcancerinstitute/"</code></p><p><code>4499</code><code>              &gt;</code></p><p><code>4500</code><code>          </code></p><p><code>4501</code><code>                &lt;svg</code></p><p><code>4502</code><code>                  xmlns="http://www.w3.org/2000/svg"</code></p><p><code>4503</code><code>                  viewBox="0 0 24 24"</code></p><p><code>4504</code><code>                  class="usa-icon"</code></p><p><code>4505</code><code>                  role="img"</code></p><p><code>4506</code><code>                  aria-labelledby="linkedin-title"</code></p><p><code>4507</code><code>                &gt;</code></p><p><code>4508</code><code>          </code></p><p><code>4509</code><code>                  &lt;title id="linkedin-title"&gt;</code></p><p><code>4510</code><code>Linkedin&lt;/title&gt;</code></p><p><code>4511</code><code>          </code></p><p><code>4512</code><code>                  &lt;g id="final"&gt;</code></p><p><code>4513</code><code>          </code></p><p><code>4514</code><code>                    &lt;path</code></p><p><code>4515</code><code>                      d="M12,2C6.48,2,2,6.48,2,12s4.48,10,10,10s10-4.48,10-10S17.52,2,12,2z M8.912001,17.584H6.584v-7.472h2.328001V17.584z</code></p><p><code>4516</code><code>                          M7.744,9.104C6.992,9.104,6.4,8.488,6.4,7.76c0-0.752,0.592-1.344,1.344-1.344c0.728,0,1.343999,0.592,1.343999,1.344</code></p><p><code>4517</code><code>                          C9.087999,8.488,8.472,9.104,7.744,9.104z M17.6,17.584h-2.328v-3.64c0-0.856-0.024001-1.967999-1.216001-1.967999</code></p><p><code>4518</code><code>                          s-1.392,0.927999-1.392,1.912v3.696H10.36v-7.472h2.224v1.008h0.024c0.464-0.752,1.296-1.216001,2.199999-1.192</code></p><p><code>4519</code><code>                          c2.352001,0,2.792,1.552001,2.792,3.544001C17.6,13.472,17.6,17.584,17.6,17.584z"</code></p><p><code>4520</code><code>                    /&gt;</code></p><p><code>4521</code><code>          </code></p><p><code>4522</code><code>                  &lt;/g&gt;</code></p><p><code>4523</code><code>          </code></p><p><code>4524</code><code>                &lt;/svg&gt;</code></p><p><code>4525</code><code>          </code></p><p><code>4526</code><code>              &lt;/a&gt;</code></p><p><code>4527</code><code>          </code></p><p><code>4528</code><code>            &lt;/div&gt;</code></p><p><code>4529</code><code>          </code></p><p><code>4530</code><code>          &lt;/div&gt;</code></p><p><code>4531</code><code>          </code></p><p><code>4532</code><code>        &lt;/div&gt;</code></p><p><code>4533</code><code>          </code></p><p><code>4534</code><code>        &lt;div class="usa-footer__contact-links desktop:grid-col-7"&gt;</code></p><p><code>4535</code><code>          </code></p><p><code>4536</code><code>          &lt;div class="usa-footer__address height-full"&gt;</code></p><p><code>4537</code><code>          </code></p><p><code>4538</code><code>            &lt;div class="usa-footer__contact-info grid-row grid-gap height-full"&gt;</code></p><p><code>4539</code><code>          </code></p><p><code>4540</code><code>              &lt;address&gt;</code></p><p><code>4541</code><code>          </code></p><p><code>4542</code><code>                &lt;a href="https://www.hhs.gov/"</code></p><p><code>4543</code><code>                  &gt;</code></p><p><code>4544</code><code>U.S. Department of Health and Human Services</code></p><p><code>4545</code><code>                &lt;/a&gt;</code></p><p><code>4546</code><code>          </code></p><p><code>4547</code><code>                &lt;a href="https://www.nih.gov/"</code></p><p><code>4548</code><code>                  &gt;</code></p><p><code>4549</code><code>National Institutes of Health</code></p><p><code>4550</code><code>                &lt;/a&gt;</code></p><p><code>4551</code><code>          </code></p><p><code>4552</code><code>                &lt;a href="https://www.cancer.gov/"&gt;</code></p><p><code>4553</code><code>National Cancer Institute &lt;/a&gt;</code></p><p><code>4554</code><code>          </code></p><p><code>4555</code><code>                &lt;a href="https://usa.gov/"&gt;</code></p><p><code>4556</code><code>USA.gov&lt;/a&gt;</code></p><p><code>4557</code><code>          </code></p><p><code>4558</code><code>              &lt;/address&gt;</code></p><p><code>4559</code><code>          </code></p><p><code>4560</code><code>            &lt;/div&gt;</code></p><p><code>4561</code><code>          </code></p><p><code>4562</code><code>          &lt;/div&gt;</code></p><p><code>4563</code><code>          </code></p><p><code>4564</code><code>        &lt;/div&gt;</code></p><p><code>4565</code><code>          </code></p><p><code>4566</code><code>      &lt;/div&gt;</code></p><p><code>4567</code><code>          </code></p><p><code>4568</code><code>    &lt;/div&gt;</code></p><p><code>4569</code><code>          </code></p><p><code>4570</code><code>  &lt;/div&gt;</code></p><p><code>4571</code><code>          </code></p><p><code>4572</code><code>&lt;/footer&gt;</code></p><p><code>4573</code><code>          </code></p><p><code>4574</code><code>          </code></p><p><code>4575</code><code>          </code></p><p><code>4576</code><code>  &lt;/div&gt;</code></p><p><code>4577</code><code>          </code></p><p><code>4578</code><code>          </code></p><p><code>4579</code><code>          </code></p><p><code>4580</code><code>          </code></p><p><code>4581</code><code>  &lt;/div&gt;</code></p><p><code>4582</code><code>          </code></p><p><code>4583</code><code>          </code></p><p><code>4584</code><code>    &lt;script src="/sites/g/files/xnrzdm211/files/js/js_gyckXKPoD2Pap4CjJRNIMCAxSADZa425IpIz5JlrgqE.js"&gt;</code></p><p><code>4585</code><code>&lt;/script&gt;</code></p><p><code>4586</code><code>          </code></p><p><code>4587</code><code>&lt;script src="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/js/ncids-common.js?s1d5be"&gt;</code></p><p><code>4588</code><code>&lt;/script&gt;</code></p><p><code>4589</code><code>          </code></p><p><code>4590</code><code>&lt;script src="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/js/pdq.js?s1d5be"&gt;</code></p><p><code>4591</code><code>&lt;/script&gt;</code></p><p><code>4592</code><code>          </code></p><p><code>4593</code><code>          </code></p><p><code>4594</code><code>    &lt;script id="cgov-adobe-bottom" type="text/javascript"&gt;</code></p><p><code>4595</code><code>_satellite.pageBottom();&lt;/script&gt;</code></p><p><code>4596</code><code>          </code></p><p><code>4597</code><code>          </code></p><p><code>4598</code><code>  &lt;script type="text/javascript"&gt;</code></p><p><code>4599</code><code>window.NREUM||(NREUM={});NREUM.info={"beacon":"gov-bam.nr-data.net","licenseKey":"bfc00e1ee3","applicationID":"355359682,336353556","transactionName":"NVVTbBMHDEQDBUVcDgwfcFsVDw1ZTSJDQBEDXG1WDgIHayEJX0ETDVxdXRM6LFgGA2dcBBVzXlYVFA1bDgNDGF8UWVRP","queueTime":58,"applicationTime":1081,"atts":"GRJQGlsdH0o=","errorBeacon":"gov-bam.nr-data.net","agent":""}&lt;/script&gt;</code></p><p><code>4600</code><code>&lt;/body&gt;</code></p><p><code>4601</code><code>          </code></p><p><code>4602</code><code>&lt;/html&gt;</code></p><p><code>4603</code><code>          </code></p><div></div></main><iframe hidden="hidden" title="Hidden frame for spell checking" src="about:blank" id="iframeSpelling"></iframe></body></html>